var title_f27_13_27856="Acute cholecystitis positive HIDA scan";
var content_f27_13_27856=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    HIDA scan in a patient with acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The hepatic iminodiacetic acid (HIDA) scan is abnormal and shows absence of filling of the gallbladder, indicating obstruction of the cystic duct. The duodenum starts to fill with radioisotope at about 20 minutes (white arrow). The radioisotope flows directly into the duodenum (white arrow) starting at 20 minutes. The gallbladder never fills during the course of the 60 minute examination. These findings are consistent with the diagnosis of acute cholecystitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27856=[""].join("\n");
var outline_f27_13_27856=null;
var title_f27_13_27857="Ultrasound of protruding tongue";
var content_f27_13_27857=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Beckwith-Wiedeman syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow points to large and protruding tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27857=[""].join("\n");
var outline_f27_13_27857=null;
var title_f27_13_27858="Patient information: Rotavirus infection (The Basics)";
var content_f27_13_27858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/3/9267\">",
"         Patient information: Viral gastroenteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/54/22371\">",
"         Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rotavirus infection (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rotavirus-infection-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H203812249\">",
"      <span class=\"h1\">",
"       What is rotavirus?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Rotavirus is a virus (germ) that can infect the intestines and cause diarrhea and vomiting. When a virus infects the intestines and causes diarrhea and vomiting, doctors call it &ldquo;viral gastroenteritis.&rdquo; In children, rotavirus is the most common cause of viral gastroenteritis.",
"     </p>",
"     <p>",
"      Children can get a rotavirus infection if they:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Touch an infected person or a surface with the virus on it, and then don&rsquo;t wash their hands.",
"       </li>",
"       <li>",
"        Eat foods or drink liquids with the virus in them. If people with a rotavirus infection don&rsquo;t wash their hands, they can spread it to food or liquid they touch.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Adults can also get a rotavirus infection, but it is much more common in children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H203812256\">",
"      <span class=\"h1\">",
"       What are the symptoms of a rotavirus infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A rotavirus infection commonly causes:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Diarrhea that is watery but not bloody",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child has vomiting or diarrhea, his or her body can lose too much water. Doctors call this &ldquo;dehydration.&rdquo; Symptoms of dehydration can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fewer wet diapers, or dark yellow or brown urine",
"       </li>",
"       <li>",
"        No tears when a child cries",
"       </li>",
"       <li>",
"        A dry mouth or cracked lips",
"       </li>",
"       <li>",
"        Eyes that look sunken in the face",
"       </li>",
"       <li>",
"        A &ldquo;sunken fontanel&rdquo; (in babies) &ndash; A fontanel is a gap between the bones in a baby&rsquo;s skull. When babies are dehydrated, the fontanel on the top of their head can look or feel caved in.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H203812263\">",
"      <span class=\"h1\">",
"       When should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your child&rsquo;s doctor or nurse if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has any symptoms of dehydration",
"       </li>",
"       <li>",
"        Has diarrhea or vomiting that lasts longer than a few days",
"       </li>",
"       <li>",
"        Vomits up blood, has bloody diarrhea, or has severe belly pain",
"       </li>",
"       <li>",
"        Is urinating much more than usual",
"       </li>",
"       <li>",
"        Hasn&rsquo;t had anything to drink in a few hours, or can&rsquo;t keep fluids down",
"       </li>",
"       <li>",
"        Hasn&rsquo;t needed to urinate in the past 6 to 8 hours (in older children), or hasn&rsquo;t had a wet diaper for 4 to 6 hours (in babies and young children)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H203812271\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The doctor or nurse should be able to tell if your child has a rotavirus infection by learning about his or her symptoms and doing an exam.",
"     </p>",
"     <p>",
"      He or she might also do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Lab tests on a sample of your child&rsquo;s bowel movement",
"       </li>",
"       <li>",
"        Blood or urine tests to check for dehydration",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H203812278\">",
"      <span class=\"h1\">",
"       How is a rotavirus infection treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most children do not need any treatment, because their symptoms will get better on their own. But it&rsquo;s important to make sure your child drinks enough fluids so that he or she doesn&rsquo;t get dehydrated. You&rsquo;ll know that you are giving your child enough fluids when his or her urine looks pale yellow or clear, or when your baby has a normal amount of wet diapers.",
"     </p>",
"     <p>",
"      To prevent dehydration, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give your baby or young child an &ldquo;oral rehydration solution,&rdquo; such as Pedialyte&reg;. You can buy this in a grocery store or pharmacy. If your child is vomiting, you can try to give him or her a few teaspoons of fluid every few minutes. Oral rehydration solution works better than juice, because juice sometimes makes diarrhea worse.",
"       </li>",
"       <li>",
"        Continue to breastfeed your baby, if he or she breastfeeds.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should NOT give your child medicines to stop diarrhea (anti-diarrhea medicines). These medicines can make the infection last longer.",
"     </p>",
"     <p>",
"      If your child has a severe infection and gets dehydrated, he or she might need to be treated in the hospital. In the hospital, the doctor might give your child fluids into his or her vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H203812285\">",
"      <span class=\"h1\">",
"       Can a rotavirus infection be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors recommend that all babies get a vaccine to prevent the rotavirus infection. Vaccines are treatments that can prevent serious infections. There are 2 main types of rotavirus vaccines. Depending on the type your baby gets, he or she will need either 2 or 3 doses of the vaccine.",
"     </p>",
"     <p>",
"      If your child has a rotavirus infection, you can prevent spreading the infection by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Washing your hands with soap after you change your child&rsquo;s diaper",
"       </li>",
"       <li>",
"        Not changing your child&rsquo;s diaper near where you prepare food",
"       </li>",
"       <li>",
"        Putting diapers in a sealed bag before you throw them out",
"       </li>",
"       <li>",
"        Cleaning the diaper changing area with alcohol or with a bleach and water mixture",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H203812335\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=see_link\">",
"       Patient information: Viral gastroenteritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/13/27858?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17044 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27858=[""].join("\n");
var outline_f27_13_27858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812249\">",
"      What is rotavirus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812256\">",
"      What are the symptoms of a rotavirus infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812263\">",
"      When should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812271\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812278\">",
"      How is a rotavirus infection treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812285\">",
"      Can a rotavirus infection be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H203812335\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_13_27859="2D TTE RV outflow tract view";
var content_f27_13_27859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64091%7ECARD%2F63066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64091%7ECARD%2F63066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the right ventricular (RV) outflow tract view showing the pulmonic valve and the pulmonary artery bifurcation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary artery (PA) bifurcation into the right (RPA) and left (LPA) pulmonary arteries can be seen in the short axis precordial view. Note that in this view the LPA is proximal to the descending aorta (dAo).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Ao: aorta; RVOT: right ventricular outflow tract; pv: pulmonic valve.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The right pulmonary artery (RPA) can be seen in the precordial long axis view as it crosses under the transverse aorta (Ao), superior to the left atrium (LA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27859=[""].join("\n");
var outline_f27_13_27859=null;
var title_f27_13_27860="Carmustine lung fibrosis Gross";
var content_f27_13_27860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung fibrosis due to carmustine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 382px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF+AZEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3Fc8jjPX6UuOBkDn0pM/nSgjHPU+tfIHSAJAAH4U7GRwaYW2k8U9GHODSCwY9sU7I9KQMCcYP49qUEHBGKEABgxIGcqOeOKcidh3oTHbp+VY3jDWv7F0d5IiBcyny4if4T3P4U2+VXY4xc3yoh8W+KrbQYDHCY59Q4xEDkRj1b/CuTj8f6jcJmB4A3oYuPrXnFzqLSzyQyj9++dx3ZyfXPvVzSbgCaVfmzHGPLz/Fnrn3GKbg+Xme51exjF8u538njLVp4RGJYgSPn2IBj6VlX/iPWWeJGvHaQgnhiAo98dTWVDcL5fnKC3O3jtRdzNDZyvBEZpAOFXqx9KwcW3qaJRj0O48O+OGgkgtNZYyBxxJjJX6nuK9Dt5YrmETW0qSxnoyHNeD6fOZLSJrhFicruaM8lTXQaHrslhc7raQBgPmXqrD3pOUoaWuiJUoz1WjPXCufT60g68nA7iq2m30WpWiXER5OAy+h9Ks5ABrZNNXRytNOzG/w5Pag+gGTinEj8Peg8989qVhDcY6dBQSAOvFL04J7U0rk9KSGNlkWOJmbdtGMlQSeTjoKHZd5QsplxnaDzj6U8Nt5BpAqJkKANx3H1JpgHO4nr6Uv/wCqgdf6Ud+eKADpjuf880gBHPUZ/KlHOCaM/l7UhjcZyKAOM8dacoB4z9KMUgGgZ6g0uOMnr7UpByD3pQOMA0wG880c/KKcMdf1ozzyc+xoEMYEc9hSEYbPWpDjPBzTTxjueuKYC4OO9GMADpSnrg7sjng/pSnA5x06YNMQ3BA5zilI49aeQPYH3pAOCOMCkkAw9B/OkcHyz5YDMOzNgE/WpRzwTTWjBOclT7d/rQ0AhGDxxQF59c9qeRx/jTD16+/TtTAAOeo6U1s9utOIOf4cdqTr9R+GaTAYybpFyCQOQM8Z/wAaVwc/ePSnHsT3560dSR36ihsEiIghfvHOaadw/jIH1qV8cccjrUePXAxQIQMwI+YnPbNMyQSSTgU709z1pOMc49qBlf8Aef8APMf99f8A1qKm+X++lFTYLlXn86fjnk8e1NH3u+P0pUORwPw9a1JF2gsOOacMYGOlIOeO55xinEAk8ce9FgAdQfbmlA4GOuOaCDkEj6U5f8n1oSAYBwNvUV5h8WdSkS9W2hwfJQHDH5dx6/0r1L5Vy75VVBYn6DNeE+I9QfUtQuCyZMzGQueQBngUmrtI6MMrNy7HFRxTBnM6+XMTuBz8tbGi3CPcXMWyQRRlV8x+DISOq+1Ur1J4rqaQnzbdiojC8YIHJJ+vaol1CGHbbkqGUfvHPTNd0o88dBqo02mdDDI8WWwVR+iHvz1+tSyXPlOJCx3EHYc8Vy97ry21uPIw8zDChj0Hqaym8QyzmH7Qn7sfeH94etQsLKWthe1S0udtZ3bXd0qShUBBO8N0qxbSnc5QnanylSMHP+cV55b6zcrqPmwsuARtY4Ax+NdVBfQjY7rw0mSVblSe+Ohoq4ZxEqqaPVPh3qk1rqIimkVrecbQvcH616e2SOP1rwrS5YUeNrWQ/uiCMdc+9e16NdLfaXDOpySuGx6iuCErScC68NFNFg845OfXtS/SlPA49aT0zWljmDPAyeaMnnI6d6Xr14GKQ46etKwxvQnIzk9KM+vPvSYyeRhewpxwOe9FgDOGBPSjn25puTind/b2oAX9M84o4OeDg84oxgDGMj1pueCO/ekMXJ6etKvX+XpSgYzgfhQOmO1AACfXpSg5644pcbgO9IPp07+tNIQgJwTz7Uingdee1OxnHr9KBw3PSnYVwXqT3pGHI559Kdg7exHFKwADEkAAZLE4AFPlC43Hf25p2CQMd65jVPHGhaeWVp3ncHB8peCfqa5m7+JM1wrHT4IraIDG+T52Y+w6U7JIahJ9D036ZP4U2WSKHBnliiH+24H8680i8V66Bm8vI41dflVYlXGfU+tc/eXkkswLZlLN8zMcn61g6yvaKudEcJJ6ydj0rUPGGl2M7oonuCDhjHjbn2zVSPx/pkjhGtbxTnk4XivOJnUxS8kbBkjHr6VXErLFtYBcEHceM1KlJ7mvsIpaHsun+KNIv5DHFdeVJnBWZSv69K2DuXGenb3r57Opb5zbGAlm7jp+fet3QvEupaSF+z3BmjHWCY7lI9PY/StveXxHPKmn8J7KcZ4zz+lBJyfWsvQNctNctTJbZjuFH72Bj8yf4itQgYI9adr7GTTi7Mb6kDr1xSFj8vAI7/SlYdM9faoudxOQV7DGKTVhDnJbr09qZu445PpQRz0prZxzzjkcYosAhbHUcUwkNHjgoRxxkYpT0600nPXn1pWGO2xf3R/3zRTdo/yKK25fJff/AMEXzIhxmlGASe4pOOvX3oLKrAMQpboD3qRIcOoFOwOPyx60gznp2pyjHv8AjRYLi479u9OPPI4pfTGelKoyQSOau3QkyvEtx9n0G7cfxLsGDjrXhev3i2UEkkhVQuTkjr7V7x4gt1utFvIj8pCFwfQivmXxzdXSQGE7WXd93A+6O9KlT566R2UpKNBvrcxL3xPLNORFGPLPAz3+tZ0MUt4pZi5dmPUE49TVa0kMSO0cYlnDKV3emea3LS/Q3tzCIHVVXzWdffjFe24KmvcRxKpzu0ihexKlsssYZ5du2Qccc1EqG7swiY81cADOKrtJ5m9Y8qrHc3vWjZ2kDW0UbytHMQZsqOVGcAmq+Fai3IVT7Km6ZMoB8wOMkVJeXk7vHucAAAqFGMD0PtUF47RrHHO3myAbXde9Ot42kWOVVLIAfvjA4ost2LVaHpHhW9W9sknlTaxJGE6A/SvZfh/qUX9nusjkKTxmvmvStZj0yOM7GZd+GUcAAmvUdB1e3urVTbTIgQ8gN614WOoSpy9pFHoYeSnF05Hukckc4JhkRvpzig9h3ryzQdcax1EsJOWY5BOQR6V6XY3sd/b+dFuHOGBHQ1y0q3PpLRixGGdLVaosqSAfbsaaAcE4FO4zk9z3pMj3zW5zDcc47/7Xekxk4AFOPU9PrSD260rAJjA44pw7AH2po6euKdxRYYo6dfrSDP1zSg/Njmk6twMGkA7pxzgUoGQTxSFeeCR6YoBGfTmmgHL0HUDP6Uo5AJz+FA7UpP05qkhCBRgjBJoAHYe9OAyCMZHQisXWvFWiaMzpd3gadRzDD8zZ9D2FPbcEnLRGnfXltp9q1xeSiOIdzyT7D1NeS+NfFl1qbtbxs9tZjpEp5YerVh+L/G0uuOXZZYrdSRHEGxtA/r6muKGpvDJNJJPI+9cHzGzgdacaM6j7I6IclNXe5Umv7y7vpInOVDAZHTGetdvpdiY7+0wiywqQxc9B+Fee6Jcw319eW02/bIAwcDoM12GkG90yaD7Pcrc2u7LIzfMBXRiocseVaCoS5pXOj1Z5VuWyFOH2gNyTz2rPNyPtDDPGcDH9azNfmk1G/wBPhZJLdmm8yUbuiJzzj1OKxpdamTUZYrcDY7ELkZJI6GuWnhbxSW50Sq+877HUv5MttNcTPJKIgSYlOSSBx071T0nV31qO48vTZrOOMKqGY5aQ9+PasC11SBo5QskkUryM8g9WxjHt0qWPVhG5+yzSqEx04ByOfrWksM0rW1Gq6fU3bpW2qH+4/wCXH/16ntbcNEjlo4gp+YngZrn4/EskhW2tbcu7DGAuVBz1FbF3DHdWjWbyqUnUqURsMD7e9ZuMoJKehLSk246m7pF1PZXi3trMUaPKkL6+/rXrnh3XIdbs2K4S5hOJo+mPcexrwOyaKxhjsWkm8tRtQscngdM1r2WsXen3EN5YTKZUIG7P319CKy5JRldbET5ZRs9z3g8dP50w4xzzms7w9rdvruni4hAjlXAliz90+3tWifYEGtLpnG04uzGHOP5Uh5ODSkfoc00jjOfyosA1vpTTwc8cU7r1zkU3qCelG4CY9v0opcCijXsGhFnpSjg9D745pMe3NKOD1P1qrCFXGeKkVT6/l3poxkcde471LGvzDecZ96aQXHAHrigLwM59c968M8aeNdeL3Nxpl/c2yRSlVjhA4QcZIxzXoHwm8Yp4t0IrcXKy6ratiXja0i9mxVxi3Hn6BOLhozU8dXBtfDF05bBdli6+pr5j8X3MdzdSxxkK6fK7Zzx6V9K/EaPf4akGAxWQN16HtmvnTxdFGmoRTyFYmcFSyqGHXqcdTWmFsq2pvZug7HExvLDcboSoZOnvWm+q3ixswnGZgEEQAATHB5HJqtcLGbq4zzudcEdAO9LeWoC+bkjdyqgcYHZq9h8rtc4kmnoV4crbE7gZC3HtVp72VY1jUBJGRUdsc4HQf1qkkYkfEYI2rnBPb2p7KSNw+5jANNpPcE+xJ5peIxFBkDBkAzz7GpdNnRYLm3mVtzDdG+7gAdRUVoyodrEZwVOeQfeolWSQ/u15bPHaiy1QndlxYpJrF5UDukZAckcDPSnWVxcWZ3WpcKOvNS6ZOUV7VpcQTHaykZGQOP51NYNE1ticpvVyir3Ye9Zy6pq6LTtZpnSeGNdLyxpdkiRjgFuhxXuvgbUhbv5MzMI5O5OcHtmvmQyxgs5C/LwFUnK+4FeneA9clmnSCRiNo+bJ7D+teLmGHdP99TWx6uFq+3i6U2fQ5PXHcetNPBOD+Jqvpk4uNMgk3Bvlx9DVgk56dfesl7yTOCS5W12DjkHqaRuRk/hQDz17d6XPXPWnYVxATj9B609fTvTF754IpR1wOn9aBjhxnjGPWlP15pATkg56enWhvr70mAo9/rQxVI2dm2IBksegFHGfUU/JAHrTsApGPUHoaEBOFx1NKBngd+3rXN+Iry5u0ey0ycQISVmuF5b3VP6mlOaguZlU4Ob5UYnxE8ZrYW82m6PMDcAETSxnlP8AZX3968Qv7ufb+6GFJyzHqa9Zl8KaTGq2/wBme4kkBZ5nlO78AOOteG6jqXlXMiMw+RyuSvGQeBWmBnHESly7o6K8FQgvMW9urqXbEMM6DLOxwAP8aS2sPOKzXcbiMHAPPzfnRYM+oTRl2BxzgfxGuysoLu4SO3n2yxRj92XHIFelOapKxwxi6jKFpoUEU8fkJcHeMqYzk5x39q3BELaIM0UahGDExDnPcf0qVFj0rBlnIJU49qzLW8Fu000uyOKQ5bPQfieleXKcq0tHoepGEaMNdytqkMttDJK5Zr65GZG3cInZB7CuWuUK2sckzeSqfdK8N+B9abqmtwX09yp1ByqbmCLwoHpu71qQz2sumo12E8hQrgIDlhj36e9d8ac6UU5HN7WFR8qMO7jhtrctFlZuoAO7j375qxpjf6QEdSI/L3Et0HfNMupPtTXEggd+dqqBjC9v6Vmm6a0jkgdMOxzjHIPp9K6EnKNupnJqMr9DbOpQwCRI4Cqg7opVfBZh049KzjfST3SiO4Z2znc/HJ749qzkkRrNXdsPuPDN1x7enWkfeI7dlgMZJys2Mgnt9BVqlH5mPtZLrodrpOpm6nFvOUmVcgSHgtjpWoZcBpLYkIuCUI+97CuGsAtvdRSXTq2B5jBT0z/WuuggnltYJ43Egfhgp5HfH5VxVqcYPyNE3U2Wp23hTW306aG8twAowsik8MD1FeyW80V3bR3Fu26GRdy/4V8/2w/cAS/IUPIJ6jsDXpHw21f/AFmmznYr5kiDN0buo+tef8MvJm04OUL9Ud1jAUAYA7e1MIOf6mpSvqD+NRnqMnvnFVY5rjG9xyOlIen8uKcfTvSEfMPxoY0NytFO5/yaKLBcjx8wx075pQMA5ORSRbypEqqrBiBtOcjPB/8ArU/vt/HirJHKO3f2rK8W6mNK0KeVWAnlHlRDqSx/wFay8g9BXm/xYvTNeW2nISFhi80leuT2/Kk9i6ceaVjzW9tpJ9KvV81lYAskuOD/ALNefeEvElz4b8S22pWj/NDJuK9mHdT7GvSLXUba2EkDShlKFSDzjPfFeceKdHXR9Qmg89Z8xiQPtxjPI4r0MI1eVOXUeIV0po+q9V1W28UfDqTVbAGOGePeFY8ow6g14L4h0439lHLbFJNg6dBnvV74U6/JZeCNWju5nNn5oVY+27Fc3DrktlfyLGrCGcEMMZ2E98VhCjP20uT7JtGUYU0pbM557Z7eWVJE2juh5OadPcSsmxoyquMYB5J4H6DtXYXuj21/dRXVmWGMl1iGWY45wO1V7nw5Bbyx3InZY9u8H+79DXasVB77mLoNarY57T7I3YuWhxtiCrtJwTnuK0jBbS6W0MUDttIy6kdu+a0W0o2yMyzbZZYyFIPUnoce1QW8S6d4dWGfLzRHJbjrS9qp6ruJ0nB26HHPsWRwMkK3GeDWta28UULTPMuGXeyBjgD0NU9Ra3juXeMuTJ8wUc9am0ySSWUEqsikEMvcg8HiuqV3G5z7MmksoRdbElMW5VPPO4n09KsTadIxVoVIbOGP901HqINu0IJUzRKPlI6e5rT0mSS6urUCIGBw29s4II7VlJu1yrrYxdRtnt5OVJlI5PUZrs/CSJZxySqQZgATuOcZ6gVh6pJHNb3OdyyIwUEfyNTaFLLDEUkzHuQ/f6MccfSsK6dSlZmlCfs6l0fRXw+1XzY2tJSFMn7xM+uOa7EnPYV88+BtZuokQZUSQEFWz3/wr3vSNQi1bToruIAZ4dP7rdxXkQi6bdOXQ6sVFN+1js/zLWOTR06HimBSisZJN2MnO3GBTuvI+lWcwvOcc59qeMge47gY5pnb5eAO9PH49O1OwCig5o6gdxSketJggx3yOmacBnBPWgDn260u7au4nCryxppdwKOszSpAIIH2SzcGQHBRO5HuegrnlVIGEcXyxoMY9vqetaM8hkna4c9emR0Fcs08mt68lpEMWlucuR39q8jE1ed3+49fCUeWP5mpqL/Z4oXRQzMMntkH3rxv4g+ArcaLdajoAu5bhJd81sxDEIerL3PPavYNb2bszyeWp4Ck+npWNL5dnaXF20pECoxBzyMd6jA4mtTq3p7GtelTnTtLc+bdE1ltLmaKaHEhG0+YpBH4V7DodyiaWt08hlVgCDjCg4rkLGCDxT4mbxRqij+yLdxDFEw3Pcuo6Y7jNabamb6+W2t4RJFCxeSOP7kX1Pr7V9NiH7WyS16+XkeRSpqGt9OhoasTNdxTHmJhuAPcetcvrPh698Q38cNtOIdOC7uvBbvkdzVvVNcigaVCQ5xtL5xj2Fafh+9iOhyCJ5EMiMPMxkqe1YQjOhHmidcmqukjkltvB+g3jwXN5LdXUbBSxjLIH9gPQ11GsWNurx4YROYi0qDkY/hP41wWj+HbqbxCr3Nv5sO/JZhhRz1rpfFplW9DCReSCy/w57EmuipG9RJTbfUyjpF3VjLvbqKCcMZHOxRgDp/+vFZE93HJLGzDcVPzFep9qfqM8l1NHCSN8jAntnjqapswt2O0jejZUD19feu6ELLXc4pS102GyiKRnCLsldujcACrDXQRTECJRjDcH5SO30rNedXfcWww6EjBJPepYpNoVSwCHk/WtXHuZXvsXYGyIoZsGFud+PmUfWt/w9dLBBIRMxmDFDz0Hr+Vc1bmRZsZLKB1UZPWtK8tWkd10dJZXIBkbb90Y/Q1hWipLlZpSbg7o9CSeS5tw6x4IAyoI5XHXNWoLt7WBpIWLbOV28nNcj4du5rYRwyyjzDFjAOWb+7WtbXVy0bvKpWJ3xHxyNvXNeVOjq49DucuWKl1PoLwprEWt6FbXaN+/VAkyHqr961WH4j0ryr4Z6h9j1xozJttNQG0q3/PQDj6V6o4IB6jBrK/Q5px5ZaDcDvwaaRg4Ix68058lfl68fhSHn/OKGiBPx/Winc+lFFhXIx1Py80uMcZGTzR75Bz2pVyeBmrsK4+MBiBnGfavAPH2rzS+JtTmZgsQlZAc/eVeBivbfEWojSdBvr3gtFEdg9WPC/rXy94jaWaZTcHYw5Az1961pw552NqWibKETGfVALfIdpN2W67e496d8U0ax1G2yRsmhBzjrxV7wzLF51tdyoSxbAxwT26VkeLLoa/qTXF07SwQthIU4EQJ6E+td0LusuyQqiXK/Mbp94LHw/ZWTrhJiZnBP8AEen6Yqe5iRpTMtwDI6hQh4z71Rv5YHkaSFNu37qkZxj0qzaGG3VvtPzsf4upz2H0ro5VFc3VmF5TfL0R02nTbLXdFIVdBk7e5qr4k1WySxgGoSu+yVZVjXhnA7EelZ2q6qmlws86jLj91GP42/wHeuPsBLq+uwi7Ys00nzn2/oKwpYdSl7R7I2qVbLkXU9FW8ka0gkSEv57b0AXpntTr3Sw0TpcrJC7YfkdfbFWvFdzJ4c8JG9tIRLOzCGNyOIQf4sd+mK5aHW9RuPGmj3VtGztdxxpJA3KsDjcMHp0zXPFOpecNFr+B0x9yKjLVlbU9Ca3RGtpBOwPz4OPpUOgQ3QuS6wSY8wBjt79cZrvtY0RpvEenpo9on2Rmb7XIGA2j1/CqV5NbWsu0XCtIGLKM8dcD6mto4lyilvc550bSfkZl3548x5EZpGOFP90Z96tJ5sTwpvjZh83ynnPfFQaz4hLNHDHBE0gX5iByB7e9Yh1h8SSNGdzDarZzs+lXGM5LVGErRejN7zIZ5pljgEkrTCMAevdvpTdQZrGH5SfmJUY56da5SO7mglMqSHfnJx2qUXcjp5plbg4HH3c+lU6Lv5BGasbmm6s1lPuXL+vPH0+te7fDDWlku41ik3W1yoRg38LjpXzhHKXRUGBk5LHPbvXqHwx1ELPHFuIYHdkf3hXBmFJRiqqWqO3DT9pek+p9HMv59hTW/GnBt6K4AwwDZ+vNByPriuY5RpHBx/8ArpwHJ54pvQ4xT8DGO/tQMUZzjFLjg5/xoA7jv707Ht+HSiwBjJGfyFZd/qCs89vD9yIYkfsW/uj6d6s6wL06bMumKhumXClm27R3OfWuQluodL0qCG7YBtuWAO4s3c+/NceLrOmuVLc7MJQ9o7/gT6jeJb6bLJKcHbnJ9awfDWoRaJaSS3KF7ycl1iHLZPQGsrVL+71G6ijhTDjmKI9E/wBpvf2rH8U6inh632WNyjakFzLcSfMAT1wK4KNKVaSjHdnrVOWhTfOdJ5d3qWovcaoRCqn7h7VQ8Q6usGyCOETQ/cKEZDDvmvLdS+IN3NKiw7n29T0ya6rw3ey6jpsV1dIVmL4BbvXpQy+rQtOpt2OCeMhVuoHP6jBcWscdlDcwabZRlmOwcpn09zUNrrOk6dZC1W7McJBUskZJYn7xJ6k+9dJ8TdHth4dL/ao4yg8w8HLN6GvKPCWmXmtahHHbWzeVBKryzsOEHpz6+le3ScK1LmeiR5rU6crvc6PUdFdLoIG/0YjeJWYHIPQmtTTNW03SYVi+0s4UFWby2KnPXpWtqWkQ32be3uiZZCOFGeAOBiqUvg60RhDfXkrsxGFjfYB9awdaE1y1GdcKcrXityG+1fSmge5+2Tug6IsZCgewrlNQ8XQCVlt7dpQ3O6UcD3ArvE+H2nPjMd15QYDMkudy+w9KxvEWgeFLbXbfRfJMFy4+Rg7dT0BOetGHrYfm5Vd/5DxFGo1e9jlDOl5GE019/lgyOHAV29Sf/rVTmllKnMePUkZP4e1dTZaJZ6JqEkaLKtzIpjBlIPB6gfX1qvNEiK9qUhkkByPMbayEnJPuPau5VYvWOqOF05L3ZHL/ACn5nGSetSr5bYldB97hckkird68hupncI3QbgmAMdgKpxiR1l2AYT72Oa3TurmUvdNK0mASSVPLjcsAeeintWtpd1/ZjBpWdY5mLbl+bcv0zWLDbGOzaWZ1WJDuJ2E8Hj+dP06bTbqdLYzu8hO2MMCoYnsDWc4KSa6Ap8r5rnTnWtPs7thZWpnhx80rKF39/wDOK1hd2gFrEJSfMy8eX4PqPzripLO7Eb+Qu1oThVkbI4PIrf0+xje7t3PIhkD4z147CuGrShGzTO2nKU07naaPeRWdpb3LJskhcMR6c/8A1698Y7jv4wwDf1r56jtlvrd7VSAznaT3617/AADbawYzgRKB9ABXBZXYqrukSE8E+tMA6buKcc+v403nOBQzBDuP+eo/Wik3D1NFaXj2/r7ydSMd80oHGVIx0FJjqRzinEDkHPTt3pIbOE+MV15Wg2NnuIFxc7mA7qo/xIrw3XZI7mbyUX9/txz2Ar074z6hv1D7JGyn7PCF54wzcn9MV5RcSCJZH+UPtGGJ5HHXNdGHV3zG692CQ3TopP7O86Nj5qodrHnac9qwkjurPTpLoPiKaUKwI5JGcZ/OrdjqP9naZdyTuZFMgaKPP3uMYPtV6WH7bZWSRpiOQi4dcfdGOAa9KN4N32ZySfNojKtLV5pbctl2C7vlBPJOa1n08vsikSRXdlGCMDPXJPcVbvUu7NI57WHaIxwAOgqpezXfyLO7yXMmc9xGCOgpKTnrEUnyaMy/HthNP4lSG3iaWQRopRRnAxwR9aZNpNxoVlbysR9rkcmVm6RIMfLn1rtIJw0wmUQQ3cihZ5Ty5wOg9M1j+JbK61myigtIypGXcNxuPb/9dYwrSVoS0SOj2cZJuO5q6N4lg8QQPYxx+a6DeVcYVh39iKuajqRW4hMcEULRqNoBGV46ZrhfBNnNpusySXrfZ12GIgEEnPX8K7vxFBYmOCVIFMXygSLkFvYeorCvSpwnZbM3w8qklbsc2/iJ4Z5Cqgnce+SQeo9q53Ub557+WXJYv2z+ldJPoq3SrNbbmUNuIXk4zWDeaQ0UrNGHUseVcfd/Guqh7P7O5liHP7XUqmV45g+0ZxhlbuKsBYnBUYUE/MpGCDU9vZ+dau6SgiJSJN4wGx/dPciqHlPKVbcz4JLZ6/jW90zm2I5m2uAq7UPJGaSJzJAsanJJyBU18qNEBFhRndjPQemam0qFGjbzXCIuXLAbuBTvpcm2okSqI8zM3mfwgnp7V3fw3LprMUqkhNuDnnIrh54yhVoySjfMpPIb3rv/AIb3KoJI2UZY5Vv6Vw49v2ErHbg1aqj6dssNY2pIx+7U/pT8DABHPWq+lzJPpdnJHtK+WBx7cGrBPTJ59681apGT0bAcE4zTh7jP0po5Hp9O1O6d+9MQ9exHX2pV65wcHvSD6mnAnJAGT0zRYCtqd2lhp81ywJ28AD1PSvJ9Snkl1F1iQyS4B3tyEr0LxhOxto7OMAmUFjxzxxXjHjzxH/wjka2tmrPcsM7z91Pf3NedWpvE11Rh0PWwc1h6TqvqP8S69D4btmigdXvpBl5Cc7c9vrXkes3s1/KWmkLnOWXOeaivL2W7leaclmYkndzz61p6bptpbaeuraw0kdm7YjhiX95OR6A9F96+hwmEhhI3esmebicVLEuy2LfgfRm1C8bFmXCjJfbwPatTXPEiWNw1vakLFAQNxGSWB6gdOK1/h/4ztdR1caNHp/2KN4nEJDAg4BJB98Vh+JPC0NvI893e20Vu3KtI23j2Hf8ACpk1Ktar8hQuqb5dLGZqPj66nh8pmLYOd2wfNWLf+LdUuYfKad1THRPlz9cdazp105ZGEd8NoOMiJufpUlra2t7OIbFb25c8ZCBAK7o0aVNXUTnlUqT0udF8OvEH9naysk4yJVKF2/h96Xx1Zatda+buBJrrTnUPGsBO5c9mHXNSWum6VpkCreSFroqSyR/Nj2LetP8A7ft7Py3s7mXzB8pUA4UfWuaUL1fa01rt/XY7KVVRhyTZ6b4GEtj4Ngh1iU+ciEgSNlkBOQp9wK4rxfplreeM7bW3ulSKMoI7cD95LIvT6DNVE8VWTZM/2hzkM2Tnmn6pcx6xbTSaZdsx8rakLkA5zkn8uK4aeGnTquo9L3v8zoniYTjyo5vxZrkt7qMo352E7iDnLH09qwfN8rJY75CMA53VHcwmOcROpUghSDTHj8iVkYjdGcZB6/Svap04wioxPLqVJSldlyylikl2ykAEfKM9+2fSmX0qxXEkUQ8sbVWQKe/U1VXLy724Y8/KK0I0KKZJYRJuQYdu3+NW1bUjVhDqd3FCsEU7eUvQHpg0scMU8StMgSRm3RtGuGU+v0FVgdpkUOVz91QOD9a3tBtbmeaO2jIIDbn4xtH1rObUFdFKPNoxlpeSyNLBcsRMh3u27Icn+L8a6bTLwLFBbXMm2OZwNwGSG7c+lPs9NgN4ySMg28bccgHpV66sV+wm0XIlUeZHIR90j1/lXBWqxbsdWHTSszThnWO5jCL5m4HLL1B9fzr3vRJ1udHspFOSYlB4718/WsoKMixmMbRuXpjjnFe8+GlK+H9PHX90MD04rgeki6vwpmkQfTik/LNKcjGe9GM4FIwE3Sf3m/76oowfT9KK09pLuTYj4I4/XoacuOCchRyTQMZyTjiqWu3H2fRNQmBwywNhvcjAqb2VxpXaR4J42vY9X1u5uc4WWchQTjODgfyrlSh82V5UUgjBBHB9OKsa/KiPG0koXbyoH8/rWDdXjWs8YtXMz3Enzc/dGOCK7aFNuOh01JcrsUI7C7v9Ou4ZCoZJfNjyedvcV38jRNtV/KjWONfkA2/wgCsVHFplmkSMEEM5Pfv+FT3LSR3DQyqW86FWiIOQwGDx+Fazm5GXs7HZSrE2jSSsoYIdr7e3Fcfq9kDHhVKzDgvnG4dQR+FdAt6iabqKtGqg7ZAvYgjrXPateC40WIvjkeWSAeMHg/rXLhuaNRpbNmuIipQUuqODu7lfNYK7nBwSD1q7p+q3cMTOLlvICMjxOxIwRgEenNZki7ZnypVunTgVbsg771QRosg2HcOxIFezKKaszzotpnQ2M6SqJJTgJGN+7jPvW7b38Vwdkg3SumxcPyhxxgdORXI62Rbarc24bzEjZUBHyggKMcVS0+4Avy+9lB7qefwrklh1NXZ2RxLjsdHaSa1o19cNY2Ul3aKN1wy/KMex65HpW3rduVug9tIEWVVdlI7dxj1rP8Mm/smuJpZUubMAtFKWw4PoRU+vCW5Q3FspWRfflRiueV1USdvX/M3japC6MTxNIkc8ZtyUiYcDOcD1rnXky7OCQclht4xV0Xvmt5c4Xy2+Xd3FVWjEJ85CDER8vOT+PvXfTjyKzOGpLndyJp5ZI1Vzkqc8+9TiRgqOgKjBV2HTNJY2pu5mG7y1xkk966PS1tUtxBMDIGbgBc4Pc/8A1qJzURRg2JpV3FPaC3vQoBUIrgDhfcf1rT8N3iaZdLDIP3gbBf2rO1bRDCi3Vmx8gZJRf4T61No13AQLea1LzltzM/DYx0rkqqNSDa1udFJunJXPp7wDeGfTHt2GCnzpz2P/ANeulPr37+1eW/CO9xLHCz53qykA5x3A/SvUSAeCK8mlpHlfTQ0xMbVG111EXrnoPyFPGDnrSexGKcO/HHtV2MR6juTRNIkELySsQq9cdTSqD6H15rjvFmrmSUWFm+WzhiR/Ks69X2UHI1oUvazURup35u4ri72jcP3aEdAK+c/H17dza5PEyZ6EY5yPb3r6HntcWkcCsQNvJ+tcTcaPDcXDJJZAPuCRvtH3c/zrzcvxfsq7lNXZ6uIoKVHlhojzfwf4OkuiLzUoSbQcpDnBlPv7VJ4rhiMwmv8A5gvyhRwkY/uqB2r1+5WzskXzsJFCAFUjg+1eRfFTWbXUZre004IYrfc0ki9Cx7fhX0FGpOvO8jx2uXSJzsuu2ekzh9DtEkuEPFxMvX6J2Fa9l4UvvEkY1bxBdPH5x3KAMsQem0dAKw9C8F6x4gnj2L9gsTybmcY3D/ZHU16P4h1kWmjXFvZybxYQeV9oK4MjgfewOgrWrUUZKFF+91KjTk/eqHB6jF4b0WYW0dus1xvwxmYuVPvjgVq6n/xK9MjlLRB5UxHFAu1FPqfXivLZCZckn5ieT3Jrv9Qid9IsI5UbFvCqZHUk10VaXK43dyKc3JOxyTyOXYMzd+c9ahDkAgDaR61p3cEcQJbIHYkVVmtwFDAEhuQ1dcZJnLKDRUQtk5H/ANepbe7ezmE8MjLIDwR2prgL8vcDH0qMxr3HA75qrJ7md2jrZHg1rSjLtBuwMkgYJP8AhXI3ULrL0OQcEH1q1pt09tIXjcJ3H/6u9b1zGmoW++OMJckZORw2axS9k/I3b9ovM52CJWjLKBuDcjPQVaYliiRAlQevatq20eOCIRXsiLK3zEbscdxVq10Rzc2awRttZ/nPUYzxmolXitTSNJvQxrTR7i8mBRMIMgseAK7fw7p0GlW8wDiSVwAxIHXrWRfvKLh9LtZRBbwq0k07nAAHUj2q14S8P6jqcMs1paz6iBIVRlBKuOxPp+Nc1aTnC8nZGkI8stDbuljaPzArJIeA3r+NK7zSyQjB2LgHP+HeiTTNQ0mNYNStpVlLZ2zrwo7Y9akt7xEnljl2Z6DAwQPpXJ001LtqWdJgW81ILu3SGTBjHYete/aapSxgXAHyDpXkXgvTVF/G0SBWc4wo65r2YAIu0YwAAKwa965NSSaSQ0g7SGHB460i9enHUU5vlXJPSkxzzk/WgyHbf9ofmaKTaf7sf50V0cj7fmLQjUisXxrMsHhe+Y4wyqvtyRWyMdxgGuQ+KM3k+FRGx3GWZV9M4yelc71VjSmvfR85+KpY11CcckjkA9BVPTYEMXnuAXB43fpirPi2LNzE4YFnGOKLcGOzVTx/CD1wa9aOlJWB6zdyg88Epn0uaYGR+nrn0B9a6G30iaHT7WNnZTGMQyMc4b0JrE0Lw9Jea1LqFxIiwQt52QPvY7HsBXa6bPDqXn3EUim1iHTdwW+lRXqKNuX5hBSe5manG0thdIXLOIsHYcdPesnRozNoEhm3MqkqM1sXTqunzKGACxMGwep9ay7S5ij8Hy4+Vllzmpp/Dp3RdRtXTMPUbCdITcRgMAgZhj7w9vcVW0qAahOmwN5KDdKw6LjmtbQLo6o1zaTg5EO2Ik4wB/Oo7dTbXMK2yli5KSIDjex4z+Vd7um4nDF3jfqRJOuralqySqnmxp56s3B6AEfyrAikCNn36elSXt3LYeJEvcbYkfy2VegToQau+K7RbTUj5ahY3AZdvIYHoaatGSXcpXcbrobukXK+TaIfmZpPwCkd/wAa35IWaFtp3O8ZZeeGrjNDv/KuIlRVBThSwzmvQtHbfFEi/MdxBGeMH+Vedik4Suj0KE1KFmeUXSgSyjB3ZO5T2PpS2hdh5a5KDkg+td34l0WI3Et1bRDdACXAHXvzXIWCK10pULycnJwAK7adZVI3RxzptSL0a5hWEAR5+Yljj8KkaYI8AiypMmcZIWosC4laQsBGCcEn73YAe+anM0YuEzt4T51IzsPtUMs0dN1J4J3R0EkJXawByM9/rUN5bzwXH9oRtlXYuGzyD0qiU2RHYSybs8k8E1oLN9mtC0qgsh2qvYqef51lypO6NJX2Z6b8Ib+M6lAyOoG9A2Rzk9T/ADr3uQYZunevmrwDJCrQXMDjesgZugK/419KCRJoklQgrIgcEHqCK8qSSqTSNa692LBd3+RxTxtVeScAZPFMzkAnr7VU1K78rbbjlnGTg/dH/wBelKSirswjFydkUL66edmLkrGnAQHHHv61x+4PrzTPk49ea3LyWSR8RqQv8zWIsZSYvJ97divCq1XKd2z3aFFRhaxvXUgWKPBxn+VUIQst15q/6uIFjU17G0tkpj42YJNULTeUnhVgDIh246nHWuOGlTmOlxTp2PNPHup3FxdyW1uxCvxxUWk+GIrCzhv7+FZZ3Obe3k+6f9ph6V08Ph43OqedKpEYbkdyBWbqeq2+peKzpUKT3M8SlWSDASIdyzHgYr6CjWlOHJT+Zw1KcKcrs4rW/EepJdlyskkRByqnt7elYb+Iy8bQC3Z0b7wdsjHoa7zxRo9pAzFb233rgEtIqk/h1pvh7wbFPcyvqESqYgPl7Ma9SnXo06d5ROGrRnUl7stDhrHw81xItzpmnHIwVLsSin1961Y9Pv7FH/tRmmSRsgYxluw+lalx8RrTS7i9s30C2vo4mMcLSzOipjgnavXmq3gXXrzxDY6imprH9mtcMkirgs5JOPwGK0nVrcvPNWX4ihQhGXKnqcfrkDjEkoC9W2Dp16VTi3NZgbTlDn8K2NdV7i/IQFhgsR7E8E1DJp7wIgjdZcg5I9f616EH7qucFW3MzDYhuWwTnOc9aiwM4QMxPOK0EtnuGkVNokUbiGHatjQ9BS5bzHJCjC7gerelXOrGmrszjSlN2Rz9has0ysyEIoJbnqB1rtRbyy3zXJieW3ERkkiRcuV7Edtw9Kin0NLKdYYrosJAMuwxgen9Kv3etmyhWKBtirGFVR3Pqa461Z1LcnU7KNHkbcuh55q8+ozTMI7K8S2VuQUIYjtuPrXS+C7a/utJuZbl5Igql7aQtglgcEMOvToagudeu1uD5jlt/qa1dNv4ZwpaMIo+Ukd6urKfJawQhBy3In025l0uKwijlvNT1iYRWyjnYARur6w8FeHU8LeGLHSLbloUBmkH8ch+8fzrwrSNam0iS3ks/LS4jRlikVRuQN1we2asX3jbWrpSs+rXEUYHIVwDn3xXnSqTqdDSrSS0T0PdfEMemGwJ15YDbryDL94H/Z715Re6H4TudTNxpuux2qnrDcRNu/AgcivOtV8XMu6NpHmdBjdJIWOfoa2NL1YSxQtIdjyKGXIGcf0rOpSmlzWsOlGMVbmPW/DN74Z0+RI01NJLo8B3iZF/DI/Wuz25xjGDXhEWLicsQPl6EcmvZfDhc6BYeY25vLxnr06VjCV3yk16fL71zQ49P0pCBjPHXNO5AHGSfXpSevTP1q7HPcMp/cH50Um7/Zoqrvt+QiIA5OefTivPfjHva30YxbiEkd1A6ZxjNeh9V45ryz4qXx/tlLQMAkMAUjHALHOf5UbGlNXkeP67btLKW2nchwx7bqgRUEEmwY3AByT3qw0pe6k/eMyhtoXGMn1zUF5HwAGycj64r0It2UWa8i3Llm6w2U1nMC1vOhSQA4JB9KS3tNO0lo4dMgaOOXhpXcs0h9DnpTZ5Ta+TcInmRfK4yOcA1zUVtdSa9JqM8rf2f5hkBVsEk9AB9acIc13exM52sdLfOkdlcMVCEpgl/wCKsnSzI3hrUI5oiYdm5HHPNR+LLz7NaC3YlXIycnJGexrU8LvG3he584FWdCQR/dxj+dXbkgpeaM5S9pOxz2jTFLqJyMPGysAOCcdRXS3ckI15JUQN5jCaNR07f/XrmYIJIrtW2gsG4Gex6CuwFqDcWMilJHiYNIpOCOORXTVlE41Fpnnk3lzajdxyfMkkrDk9s1cGoSfZF0nVOfs+Ps9wwy2zsp+lZ+p2klnfSo4K/OSCe4zmr3iErJ4a0rUYl/eJI0TkjqOozWjinYqMmmT6fbJEfNMoIVgB2rtdN1S3tIwisoJ68Z5z2ry9p54442Uld3zFgc1ZF6GjjLszNjpjvWNWh7Vas2hV5Nkez3dzbGITBYBNM6K7nq4wR+NcTLoIhmdoUfYxPA55NYtnrDRxRoz/AHGDj0FbVrryS3OyYnZLgEr/ADrmp0JUtCqlVy1Rzs6y2krxscZyASvLD2qb7Q4dQyqI2ILEjOfrXRzWxutRm0u9tih2mWxu0+7NGO31rnJIJIbx1lU4TO4ehroUlIhXLYdmRjjryKnukDWR8wNkKu0k/XgiqCTERupONgz06e5rbWGS4tkYphUA3Y53Z71nP3bM3j7+hU8N6rPY3imInYw2bR39q+sPAd4194YgDjbJAfL2k5IGMgV8l2enTi43xdug6EV9LfB2eVtFmhuTmcBWxXDjOX2kZLqaRhL2Lv0Z3oONzOQE6k+3rXFT37S3lxcyZEcp+TB/h7V12pE/2ZdYUMWjKgE4znjFcFrMyWlisOeUGK8jGczskdOBSu2zTW4UjcCDx2rLuZPNnUcZz071RsLtZIEZMMScdavogFw7tz2FeZKnbc9SLszXSby7Fww7d+9c8JW+zho9weJ2wfetaGXfE8R5AGRXNXbtaX1xF1jljLL7kdqzhHmuWnymjc3jz6bKIJPImc7WcdU46gVylyttpcfk6XAiylcOf4m7lmbuSea37MG4gSaRCkgX5uevFY2uJnT98LKJpGzvA5wOw967sLU5XyMxq076o4bxfDDeWEUl9Gk7yNtH7vEg+hrQ8H+MLWGwe31Z/wB9AqwrNuILKOBn3A6muR8TXdxezrhdnl5GAf1P4VgxafM6KVAlLsflVuR3ya+njhY1KXLU/wCGPDdeUZ3gdprmhaJqOoNevfjynOWSFhnNWri607StPXTdAhLJtYM+RyxHJPfPTmuB+ypC+Lu5gjYKSYw2Xx7gVG2p21vLH/ZjPK+QC7gouPT1NaRwuii22kFTFN6pWZZ1PW1tLvyowSANsjE9W9PoMVlvrtw773CNzwCOB9KraraXbq17OmIppDhj3NVI4XkC4YDPqe9d0YxscL0OgsNVF86xTIolGdrDhj7Zr0GK38vS7XyVZEeMEAckZ5JPvXj9qTb3UUoGTE4bHbg16/pGoG90+J4ot6Su2FQY2sT79q4sbBpJx2OzCTSepUvLR5JVYJtAwoYNlc4ziuQ1Cf8AftuAJB5x3rrPGOm6rOYIdNG1AhaQhsED+lclqunTRIkpGIiowaMLaybZVeUpXSRm7xJIgk+4pz79a6CxnQnCogQEYCnBz+Nc6sW9gDjk45NaMUyR8MMnGK65x5kcsJOJ2cF6saOCu4AAKw5OTVHVFS4dYo4y10p3BlOMCua+1OjeapI5wMdj610ekarbPaSSSJ+9hXr3Y+tcjouGqNXVUnqc9cy3LzStcbCwOXO2ug8MSXTxu4cLiQOpPIIHbHpWBdsL2eaZmVAx3lfSrOj6wbKRY4lHkb8ncefrW1SDlCyRlGfK7nsVjIk7LKkZBbgKOMCvZ9EXZo9ijLkiIcZrw7w5dxzy/NuBTpnoR7V7rpTB9Ms3HAaIECvBUeWo0zurTU6UWiz1PGPxNN56kgnnHGMClYEdeuaAPU5qzlEy1FSY/wBpvyop8j/poLldQc4wCT7mvE/ibO0viDUXRli2kRnvwBivbHO1SWYqo+YkHB45r528WTi4+2ux/eyyMwcnk5PSml76RtQ6tnEvNcQXEvmCORmOSUPAHrVHUdWaSJ5FwHBEceOMseKnuJYBblQp87GBtrMmiRRAd2WRi/sp/wAa9enBPVoipPl0R09vdgzxQmNnQoI2YnqfXFOnt7a3O+6ASC1BlWNeBKeoLfjWHoF5580k0bFEZ+c88DuKreNNTMem/ZPMLTTtlj6IOn+fao9i+eyD2i5Tmr6a61vVWW1iknmkYkKgyT/9avS9OsJ9K8OfZb8q8zJyiD7i5yM/jVj4ZeHktPB39pyIVvLuUFSRyYwcAfQmq3j68uEltrJb0QSO4WVQMbU9S1KpV9pUVKOy/QIQcYub3KI0+aWW38pkbe+0FR0NWrqc6T4mUoS7YCyK2OT0OK1vCUctvbTrOhuGyTHMMMHA5ByPSuF8cLInih7ssxgnyyqSRsP1Hp1FKEva1XTe1hyh7Onzmz4z0Ji8d0WaOOZSyCQcg91/rWHPaFtMsLaVm8h5GYkdB2FaKave6r4Ws7F28x7OdvLlkydwIyFJ71U1B55ruOWZx9hVo4yuQCrMOePzrpo86XLPdX/4By1OXeJiGJtLnexvwTbk5jkU/dP+FST6ZNF8yYeJhkN7V3F3oVlrOnSDdsuR8seWzlR04rlfDiyPetotzFvcbguT6c4qvaXTa3W4JX3M6WF4tokQqW6kjFWLQRlG8yXZ1/Cl1SZzdNEfljRuB/WordnjPmIAVX5cHpVXugtrY6Ow8STwLBHIolghOUQjlT3YHsa2rj7HqyrcxjbI42nvj6iuGj3bFk/hyQTn1rT0e9EEmxEDZG0D096wnTVrx3NISs9TZvdBEYabeuGG0R7s5pbXUV0tLLf5oiG5JLd1x5mejH09qralqEd5KbaKQRzqBskPTd/d/pmqniCFoHJZ8upCSqvIDYyP51nGDklGp1LdS0rxN221e3W4kz/q89Oh/wDr17V8J9Qjub5fLUgPGYzz1OM/0r5msbx4brem05BXEig4yOce/vXrvwh17y9YtI14YyDjp9f51xY3DcqU49Dto1/aRlTfVH0cyI+BIgZB2IrgPG+mXZNwsVpK8AXzFmXkY7g+mK9CcHewA6GgqdrBWUEjGXG4fiO49q45w5zClVdN3PDPDpdLlUZjtUZrsGwI93ryK891PX5fDniq9sfENj9mLSHbPAuEwTwQvdfpXoNsEn0uG5ilSaCQblkjOVZa4MVSnyc1tz1adSLna462ASGTe3zcYA5qO9skubeRCMv1Vh1Bq/IiQWUZbBlkYkcdqoSiXczMzLz0HTFeR7RQdnudyg56oyLidbSzWGaYM8YwzYwaoX5jbS4lABkuJQkIU5we5H0FP1e0kbPQk/Lx396W3sXfVtOmk2iC2RifQE8dK7KXK/3iY3HlVjzvxpobWEUuqoJDagjeiuRtOfvY75ry+/v7m/uxDZecA5wkatkn8q+kfEjvLG7yoq2jqVKY+Vx0x9K8+07QdH0eaVIyshfJLYw5yeFB7ADivpsDjLQ5ZK76HgYvDLm5+h59faX/AGBpQ8xt95eEozDnao5OKueFvDkt4yTTxHyypMYb+Z9q7K60aPV9SW9u7djAHAhhQcAcD5vbitTV1tNFP2y6aNZSgjCA/wAI6YFdVTF8q5PtM56eHlP30tDB1jw3cy6BfW7RgTqBJEAc5Ze2fpXl67skfdKdvevoHw/JHrth5kBGBkZPSvMfHPhie31hp7KEssxw6L/A/f8AClg8VeTpz0KxOGaSkjE8MaW2q6vb2yYxnzJG/wBkc16VpJWwlwMBEkdGJH8Wef51ieELQ6JYXzSp/pcwCFvQeg9qJ7mW3jcvIGwcjBycmniG60mugYePIjS8m4l8YXMxSa004KJbqctzcgAbYx/s1ynijxPN/a11BHBF5SHaoYZyPUV0NhqQvYnt5DJ5jodpBGM46CqEtlp93Y2v2qFiJVHzMPmjY8bSamjFRleottB1ZNq0DI0OyF/G9xklFieQRkZ5HaqFj/p1g808ZglEm1cAhXGPQ+ld1JoUFrZvDbecsNuu9zHgnkVgafFbzaVLdMsihZTGPNOSx9R7VvGupXaMZUWrXMtbVdvznap/iPf2qpJGV4Q5TsSME/hWhqM0flIiMxXPA6ZrOUFFDsSc5OPTt17V0Rb3MWlsNCu2SrA9sZpyYSZT070+a3jRHWRwZWVWUdAR61oaNDb/AGbfK376RgFyM49KHKyuRbWx6l4CjF7ZRPvw8jYJHY9K+gdOAXTrZQcqkYX644rxH4d2TWwt0jyGznPYd69vtBstYRk42DrXz7fNUkzvrLlhGKJW6DHIJ49qAQPr3NH+0eh70djximc4uD6CimZT+9RRoGpQ1eXyNJvZSMHyyB/LNfLnjW/Md40MhDDO5QOgr6N8e3X2bw3PhwplIX8OtfK/i5idSLYyrjIOMV0YSKlW16I0elK/dmbJKjYfJJPoe9U7pftQWMSeXuYA7epFMUkMSwA3d6uWqF0abYpQEpubsQOtevblMb3RoRNHZWSxbQi7eCP4VzyfrWN4f0i68W+IzI6MLJZAZXPRUHRR74p1/wDadQvodNshvnlAVsHAC+/869S8OWkGhaZb20EmbdARI4H+uc9SfasK9R0YXj8TLpRU567G5qWsWuk2SNIgisFCqoA+6o4HHpXLePNMTW7D7bpjQeZLHlWbgEd+fXFT+MVik019wM0CkYXP3lB5AHc1hW+tC11GOxkuBFLIVEYiTCqCPlDDscYripw0U4dDrTtdSIPANvrGjrOLyR1RiAls2WOT3B7cVZ12xtru/mi1JZigx5bR+o7Vszajeu7WZUs8Z+eRf4h9Oxpbe1FvLdwEu0c0TPHnruC5rT2j5nUe77CnD3eRbHPajJHbWnkW0QjtYtvlKq5YscZxjqareJrCNbmzuAFZZF8twvGMdM1n+C9WliivRuLNGhkjUjoc4/rXaWMUdxaLb3EYMiDnzFOOOuK1qSdGV+xhSipLlM7RbiKwibZNvfORkZ2msHxfFcPPDq9uogmQ/wCsh4O4d/rXaxaRpyT7IUZh3YdR/npUtvaW25rfUS32MggYXcfoaiOJjzXQSw7SODvLf+19Cg1W2iYzAlLkqDgOOrf1rEhZQUV2IUsM/T1rqLy3bwtrjW8NxKdJvSCGBKgHsSO+Oh9aytVh+z3Lu6BmdzIWCbR15wOwrqhLp0exlKL37FW/j8h1C5AxuUnjI7GtLw/avPvdFwFTcSDyD61kFt8Dqznnle4A+tdj4VgjSaO1ynl3sDo8wOPKbb8o+h9aKrcYOwoW5tTirlGiuX5ZXVuQTnn1rVuZJJtPFxKf30rBXJbhgo4z71DqcUtwIJfLIeRAjqDndInyk1XvEmtCiS7WyAcK2QM/1q/isQ9CJQu75MGvR/hBEJdehbeoVNrcjJPPavNspnKEAHHymu9+Fk62/im0UnCswBx9e1c2PTdCVux04N/vUfXzfeJHXg0HJOTyKR3VpGCMrMACRnoD0P44NB6HsTXk9RGT4g8PaR4igSHWrCG6CZEbtkOn0Yc1i6V4Li8P201rpE8s2nSNvFvMQWhb/ZPcH0rsD06DNAyD1I/xqJQUlys0hVlHY4PVJGt7+xiZD9zYTj7p9TXJeMpNVtNSs7zSpZJEWTDW4JKyL6EV6xq2mLeozwFYrnH3iOG9jWNpFtHaapay3JEQUsp8w8BzwBXjvDOjXTdmm/lqezTxcalF+SPNNY13UXubOCx0W5ikeZPOeXnCZ5Vfr6mt3VbpTfG0slDIpxn29z616VrrwRWNxNdR5CIeQBuz7V5dpuXmlMkQ3ynjIyQOa6J0Y0bRSVl6ioYj2yc3e5znxP1y20yxghCsZJFJh55X3+lY9qpu9K0+4v7WMXcw+VhxuX1rC0W0fxJ4+mk1MM1lbMzvuGQQMhVFdb441e20yOBzGxjQj5AMEr7ds16cY+zcaUdZbv8AyMKseaLb2RvWtuII2XytyggEL6YrgfFvgy61i+N81+5tsn90sfzoPTrivRPDGs2Gu6at7ZzbgCEkBGHjP+0P61HqTywxzvCI05IBY8HNckK1ShVv9rZm8IRqQ5baHB+GdROjyx6fariNTswx+b3P1rd1PTXvrl5hJ++xuZccOuO3vXmtxmTX5leRy3mEjyx05r2bRUivdGRmIeTaBuAI6V2YmDpSjUju9yYyjKMoyWiPNNeLyi3toVKx7X3c44+tZl6WjtVmCZYHIOPStrxUjW2uXKKSyGPKZ6Z71xWoX1wTFiVljySgH8NenQTnFHkVbQbaI01GVWJL4LEn5Rggmka7kZebhhGDnCsf196itkjkuRuf5SeM8Z980X4t1lUQt5m0Yyen4V2cqvsc3M7HW+HtYluiEify72NOd33ZVxyCPWs7W4J/skMwZhHKCSMngZ6Vi2d6NOlSW3UCfd8zN2rqrK7tZ5ri5Z2LXUOxl6hXz94dhxmuacPZy5orQ1hPnXK2clI25AzAg54FVnuCcgZ29DWrqAVCyD5oxkK2Mn2+lZkcS7C8mc5+prqi01cxnFp2L8qQXxhkuxkxKEQgY3DHGaiSPNw3kgquQFBboKkaKVYQj7lQc5K43H2qON1klC4yoOMDoRUryBqx7l8KbmSa0WWVslAV2nqa9wgB+zx5x90Y5r5/+D6CKbMjKyS5VQO1e92MqyWqEEHb8px2I7V4UklUkvM66+0X5FhXBPAPHFL9D81IeM8k9qR9yr8i5APIxzj296DAMr6D9aKlz/sj8zRT5V3Fc8++K1yqaZBGXAOHfn8BXzJrV6t1eMMgKp4Pc17V8Z9ZK6lNAhULCnlfQ9/514PcfI5yoyT1rswENZTfU2rO0IxIHkQAlQQB0zzU09xJI+m5RlsrVvOlbp5jZzj+QqpKAqMTwT+tWNTk+zaXBFjLOoJyegr07K6OVtmh4CZ7zX9RlK5kljZ8gfcG7oK6fVdWMGoWtlFsCgAHf0b3BrO+HNpHFpF3czqyvduIodvUhep+n+FZtzqEd54yhgvIbyGCElFVlGR7/SuOpapVa6JHXRjyQUlu2d5r2z/hGo2dA80edi56sBxXn3h3w/qmp6kNY1DENtFKHkd2AbPUYHpXU+JpVttKglndjEWyFU4OfrUej6ok2kXBtCpVSqFGHP4+tZUeeNK8OppWcVU5Z9DEvtXmvNbl/sfc168mFPYY/iANbjtHbxx/bp3W5Dr/AKQjfxdGAHTBrG063tNK8RLcy7nv1YPGjDamCOwHf2q54tmjn0WZo4BPvbeMEgxZPXA4/OuiaXuxWxyQbk2ykmjnR9Ze5s5TLZSExHjlM9M+2a6uG5ZtPmMihJQBGXPbnOR+NZvw6Mlz4bu2vtzpG48rzCRuGORn0qleaq+iaw9veFJbOUb4JsZUr/dPuPWsZr2snDrH8TVXpe90Z19vqE8MsOzZIrIQCoBzUumQtKXkv2UCVuvQZrIn1CzW2t5RcrEnJ3/UdOOn41clk2TRl5gkMqZjzzj6e9cU6b7WOqnNLZ3LniHw1Hq9i0ERSQYzGQeQa4q4s3u7kaRqMckOpx8Rb+BIB6Huf516BbXs1mVKlV24Uk+/r61DrOjR6+GmuZXeYKMSD7yEdMGnRquOkmE1rdHkWpWVzYs8c0Y254bHWm6ffTW0gMR+9wxx2rt76Jrif+zNUGb0LuSVDxcD1Ho3qK4260y4s9QEUsZKEj5gOCDXqUqvN7stzhq09OaOxc+1w3Frcyl3jmWTeinpk9cfXrWLNJJKI1baFRcDC4/OptQP+muygqv3cY/M0kFvcy2ckyRF4g4UtjgVskkrmKu9CCKLf8xUhehye9dl4ADrrkQDEHON2OlcgjEMw3Yya9A+GsKSa5ErhSwxgg85rlx0rUJPyOvBJe1jc+srVUEMcgC73jUs+OW4HU/gKsZ/+vUcShYIUA/hA/SpB/nivHWwnuJzwe9AyAPSlHPfijH44/WmIRQM5BrmfGDWl7Lb6Gg83UL5wrIpx5UXUufyrqB6dq8/8bRXXh7xNZeKoEF1b4KS25Ow/dxwfTms6sFKKUlob4dtTvF69PM2fH80cGnWtuHIG8EZP8IGBmvN7O9YX9750w/6dyvDIuOR9c1peN9YbUJ7S7kVo4ZY1dIt2duRwuR1rj4JVJkMbtICNo74J61i17SUmd1KPsqSTLukw29paRxwxH7TO4ck9c571zPxajun0ZZoIs2IkyXA3FW6EE9hmsvWfE2oDxHa21iUXymVHkjG49fm/IV1uj6q8H2s3apLbMxLQuu4SIeoIPtzXoU6EqLjVer7HPUxHtG4W0PMvhFqclp8Q9IQuwiuJDDIgPyuCDgEdxnFe4+LLl7TR7i42g+RHkDbnP4V5be6BY+GPi/4YnsVYaReyw3UILZ2BjgqD7GvVtUVb6C/g3BmDMnA6MORWGZyUqlOqtmv1OnL1ZSgz51GstHqLXII5PdQe9e1W1xJa6EtxCZI7iS33pGnHOM8+nauM8J6NpUviGRp7eITQuSu4Fl3D0XpXSeLtYXT1EgykTqfMduwHQfif5V0YiSrVI04LbUbj7CEpT1uc/NDc3cNssrp51upaQkffJP61zOv6TPG3mJGcE8Ioztq/pHiWPUdSYS4jZWGwcfP7fWt/UHGPMkYs8bbtmOXYjjp1xzxXZedKaTPKvGcWzzdQFcCQkAHsOlMlI3t5QUqe5781LfeYbpnJADMcL0xzVdD825gMHsB6dq713OR+QhmO0grGSw4JGQD71PIzxCIRuSpUElKd5UI5clmYZChc4qKbKc8Kp+UKD0p7k7E1ndmObLjcBztPOSO1a2pzwXNs9wLRbYvt2iNsrjuMdjXPxkKwILj1P1q8l3tQwgI8fBUkZx9KzlBXujSM3aw68mE0X3nLcKBnhR9Kbpdt5k2NxZVGTjpV2SwV4VdOS4ygX68gmiwXyWXy5D1I44B9RS5ly6D5dT0X4eSBdRtzAwC5XI6c45Fe+aFxHdKTlTIGH4jmvnnwPfQ296JMDczcqx6/wCFfQfhmQNZuqKMKR8w79sGvDmn7aV/L9Tur29lGxr54HIz6kUdc8dOlHrxRjg8+/FM5B+xvX/x4UUnmD+6v5UVran3/r7hanzX8RdQgutQ1G48veskzMhP1ryy6ZXkJPU8DPFdr4nu7fzXQqr4yMk4/GuNjQTT7T90dK7cHHlgbV7uVhtsgmYROM56FhnFY15LJd3mwtv+YRqAOOuK6O5sZUguGgVzKEzj29RUXhrTI4pjdXylZNpaJAOV/wBo11xmknI5pRbdjeudRTRtNkVZHiRIlSP3b0HpxmuOiuni1lpLiK4R5j+6SZvmAY8ZJHNdpodqb2OXVL6RBZwOVggdcliMDcSfxxUPjV7W/wBUt9sL5i+YMgyW6cZrlhUSm4233Z3un+7TvsQeJEu9R0v7DbxhpI1VkGevXIBPpUmiaRJoenPuu4JPNCCVs5AbrsX1PvVmSBFjW5kztCjaM9qr3lrZQHT7p3mlnB3NGzfKnPUCtIXceWOxyVmnK8uo/V9LtZZkuRdNBe27BplPzLz0NVbdZy3nRzBtmCVBxnPcD0qlaSS3mv6w16WjHMYU8bBuB/lzWleRxyFH0945SowNuRuHvVX5bRZCi3do6W1vpZ7KKFZI5WKkBUTlV9x2rA8QW8s2l3VrcQF1HzxFRzE45yPYjgisi8mFzC0TPJA+7cxiOGz06+ntW7/wkEIt5FnUbiMBl/U1j7GVN3irlqqpq0jD8HXbwPNZXMYaEgZSQZG08Hr2rvrqdAsKJbxCNFCuZOwHTp7Vx6NY3O2W1JeVGwUHBYe1a1zrUdunl3qNHIcHk5JHapxFPnkpJalUZuN4k9tPLNIHdnCknl+QPSt/Q9RYQA5K5zu561yr61AZ4Y4zKYNwZ26EZ4/KrFj4ktvNe3MeIg5aQ55PGMCsp0pSWxSkoPc6/WdKtdYtwyxrg/ddDgofWo/Cek2+sPJoOrXbWmujmwncAwXYA+43o/uK5+y12xlkSKC9NtGCQ/mDr/uj15roY57PULYWt4FfB/dTK2CpHfI6VzyU4Lln/wAMbKUZax0ZxniDQxa3Nx9tiaKaJyssLDBVh/8AXrG0+7S1hAQuAC5CZ4bcMfN6+1evXXk34/sTxg6NNNGV03XicEtjiGc9wegY14ddW0yXb2+0+YhwVAruw8/aJxkznqpLVIreUSCBjjivQvhJA03iW3G0hsgE1wBVopNpcEjjntXtnwKjgudVibyPLeOQbmPVsVOPk/Ytd9PvNMKlzuT6H0OThyvTHYUY4wRx+lITkmheOB+fevNZCHDk9ecUpyB9aTH4f0oP3uO9LYBrsI0Z8ZKqWwfYV4rrN/PfXNz9sklmMvVWY4x6D0r23aGG08ggg/SvHLuKGO+lZMNDggL7gmsqqu0jqw0rJvqRa7HEtvbAINscSrjPAGK5y5WLTvLV8r9o+6vpnua6+9iRrGFpPvtGGbd1zjtXCeI2NxfRCSQrwDGpIx75rLDxcpcvQ7qkkoJkM+m2Ph9jcFFlmVCZZSBuGfup9T/Kq2gOdXt7lo0PnvuUr6BuKwNf1iU3Uunp/wAe0BI2P1f1JrX8J6jCl0GsVwG2+aCcY969b2cow5nucDknLQtX9nHra2MTzPv0KffHF0cxkjGfYEdq7aF/JsfPmOJpyZCccAt2rz3UXnsPHz2jsRDMjNEOwz2rq9MvkvdHDOzsUASQHqp6VyY2lLlTWx04GtG7i9zk9BuFtNevVzuZ5ChJ9z61ifFPUWkMFkufLB3sf7x6f41r39hLpPiS2kSIpDPN8rEZPPpmrHi/SILzTU+0Ha+4hWXrn/Pauik4KtGpvdDxN5UpR7Hj8EhguYpU+9GwcdxkV2UfiuG4KPMzwSA7hgblz6561XOi2VpAWunYHJ2kj52P07Cqi2mmS2wzG8UnUspOAPX3r15OFTdHiWlFaM6eyWLVW3XEUTPJ9yYfcb6+9UrnQop7m7iVWt54COC2VkHqvfFY+i3UemSFRM8kDnpjGD9K7CA22s/ISwkVcoyn5s9vqK5qilSd09DenJTXK1qco6iEGNpWB6cVXt9Olu5DHEjFwM4XkADqx9quauqQmSQ8ThzHIhHRsdQPQ1krcES8F1zxkHkV0xu1dGMrXsyuxKsV59DmpYWCONw2469/09KjYDgNg56H+uKnaJUlO3HGMAd+elWyOpsWP7zTgZnAcMGVfX1NTY3FVAPTpnFZdlM6XKuwAMZwqt6elWtRuCLkZCs7KN4xwD3xWDi2zo5konb+BrGQ6zEAUVQAWZucc9K+i/DkASzZwT8zngd/evnP4ZzK19mQNvRdwPqB2r6W0Vdmlwg8lhuGfevJrJ+1dzapK9ONi5kdu3rSnnGe9A9j+VHTGD+FZmAu4ejfnRScf7P50VN2PQ+M9ZuYZJgyHcuSTmsaFkkvEQOEaR9udp4FSB/MmZpBiNc9untUUt+g2CHgA/wjnPfn0r3oQ5VYmc7u51UE8cV4qll2Km3IHXnpio7a+jmuhYWpia4uWbKgdAOxPbFV4ZE+zLI6kMFBdx1FWrVLaOePVUieO2dGZpScBwev0J9K53ZKzNox97mRb1a3a3gtrOJlZTy6jp16Cnu9iIS2GBjXLADkEHGB65rF0S/F5LfTks0EQ3R7z932qKPWbeJnMbtI/QL296fs3blF7S7bbI9X1WQPNGQBD245VRz+vSo3kDratOsgKoNx68nJOaiANxckMB+9YEr14Bz+tWrRRNf7HI8plZHDDLM3bFb2UFYw1nK7JL5kubcln8uSYDOFyW4x1qxaTywXaAQ4t9vyKB93j9ayIbxTMUZRLDFKY489sDrW3aeXJYhpJSjb+BnjHTilOPR7BTlaPmRvbPcRNNMkaFeR8vJFVbmFSFSGbfE45YpjHqK6OCJIwyyRbl69efpWZqkcFvKAAyxtyEPC1mpNOyL92Sv1GWC26om0ozqMNjrUniG3huYzMYwk3Tfu5rMuDBbTrNlvMLDCr6Y4z+NZ1xdStKwBPU5Ao9m5S50zRVIxjytGkbeaPRztI2Fsbx1wO1YXzgH5m8zP6Vea6k+yLHL8yId6ZHf8KZcwyTIJzjPr0ya1j7u5lP3/AIRlnay3bNJC25h82MdhVxNUvoXX96wKntUFrdvBCRGdkhPLKefpimxxb9jTOke47lkznj0NNq+5C00R6V4W16LU45tH1tA8JXkHH4Eeh6dK5LxfY3ejX0kbOW3n91P03oe/1rJR54Z0mR2G8/K+ccA9c132l/ZvF+iPYXhUXca5jfPQjv8AQ1xSj9Xlzr4Xv/mdUf3keXqjzzG+FTL8zliM+g+te0fACznj1QSOwKMePoAa8lsdNnstaWzvA8Qjf5w3GQO1e6fB4RprW23G1SW698issfU91RXVr8zTDQ92Te6TPaMc54FLg8Hj160wE9TxS55PeuMwHgAjgcEZoz1OM/hScnPH5ilB55GfwpDF6OD2/pXj3ivT7iLVLqzhJjkaTMeB1DHivYACCcEVgeM5La30+GaWJGulY+S56pxyayre7Hn7G2Hbc+S25wOpBIlSJuSm2Mn1wOv415r4z1cWWo+XBCC7cE4/hzxipvEHiOeO9kZJCiDIQE/xe5rlvEGrR6jZRCRSLxPvODxn0Het8FhZpqU1ozsxNSMU4p6nPX9w815LM333Ykn61o+Grp7fVETcqg8EevHQ1nGP90pVtztwQw6GtbwxpUlxPJMVwFXIc9FP+Ne1UcVBpnlQUnK6Os8Txy30en63ahnezYCRe5q54chLG9EDOI3l84hum3GeaoeGtYD6tc2DI8OVwEbnzD7/AIVa0a6eDW9R02PaxnRQpPBRScZH0rgqc3I49janFRmmyhq9ubnxTblkkFtFgjc5PI7ijxPex3jW0VrIRgs8rA/cJPA+tO1eBU1uKAXMs0gRgEYkrkHr+VcnfXE1lCH25aVd2WXPOT0qqFPncZdka4ipyRcF1My/naW8fyXYxxfKm88+5/Gq5SUsuxHyxwUzyKZFIhX593UlmAya0dPkVp2PmNLIwARs4wfevSfuo85LmM/yy+5Y1HyZyScEf41s+Gb1IbsRE5BBHI4XNZl6Ss58xNkqnBUr8pOeTVWR0MoKAJjgn1NNxU1YXNY7IzWepJeWiqPNjbB5yQf72e4rj5gUkZVyFVttaWjW6pfy3qSF4ihMi91J9ar6gF+0zvE4XaQcE+vpUxXK2kF9NStOoQxmOQsuOQRjb7VIv72PzGBCq2N3fFVpXLvklj6ZpftUv2cQE/uVbcFHqauwuYu28fmTEK23gtlz0Ap8cX2gbzsV+Tuc9gMVAg82PIYD5ck+w7UkrAoqqQ2OAvpUNFpo9T+EQSYXajBn2goD3Ud6+krOIwWcERPzJGoJ9Tjmvnb4CwNeeJY5MqUQFZFAzxjIz+VfRkrN5sYXPzP82PTBrxq/8WR0T+GKXYcBwMj3603nHH0p3HTnFJznpxWRAZX0H/fNFGz3X86KLMV0fDGru8Ehj5VvvHI6ZqO0tVcLJh3B64/h/wDr1BMZLiVi7O7seWPJNbmkExShF+aRxnaOn4/Svfk+WJEY8z0NDw9G8VxCs0W/zCG2nkED19as+PLw30EGjaYiG9ZjJOqALHCvYE9B6mtOzmitWn+Xzo4Tncq8+hAqnrNzHeJmBBCrfNgfef0zXErSmptbHTecVyLqZ88Nhp+jW2l2XmPECGurkfekbvgenYfnWbIiRpvgjAZvuA9fypj3iKPLcMOc8c02ESPK0/PzMFGe3pXRGLS1Zm2nsiawjNnIZnUecVDDJzxUCyxJqUl3h5JCCqrnCrkYzjuaGSSBNzzAyAYJAGOaryhI9sq5ZeMkjrWiSerMpS6IlFlJbxoGQmPJJIHXPetmxggkCxFzkncc9Bgen1oimjmtViBSM5AVieB/9erEUO23k3sA6Y3sCCG/KpVS+jFVp21iwa8nWOOJsb849QKkgBmSSZ0OVypB/hz9ewwaW3sfIdLpy0qgFlA6Ejrj1pLBBPdzEOVgkBHXIOTSbi4uxmoyi1c5KQmWU5bcSeGz1FTSR+TIC+Vfqecc+1Nmtzb3s0ZA+SQr196S5cszLKrFSPkP9K132L2umN0uOO0aYzS7w4yBjgn/AD3rWhuI54vIMRC9Qc8CsFPMDAKDuHHNaGntMGEIU9T/ACqZxurlUpOMjoYfDhmieYA4UZHP3hWDeWnkkgbQCciujh1CaHTlETiNV+8c8Cqt9ay3AAdCQORjrmuWnOcZe+9DtnThONobo5tZW2bGbKgg4Y1ueFtW+wXUzsTtkHLdORWFNbmGRklyDn6fnVm0JQZ2luP0roqRU42OOLcZHreh6dpPjZJxcM0esGApaTB9q+aOVVx0IPTNdD8EnD675TJsliWRXRzyhAwa8c0PU5dKudvlEHILDPK+jV9C/Diw0+81tdfsZhHctA6XlttxlmHDr9e/vXkYmHJaL26HdCpeMn5HpQAySD9acoAGcdvypAeelL/COg4rE5hR2Axil68E8Umfl4FJk5A4pWGP53AYzmvPvjDc3FtptrJarvlGflHpXfknr0z61xvxNC/YoJM4IVh/hWdd+581+Z0YTSqvn+R8y6tIxllN0WaWY7ioHIPt2rnGldpApbaQep7Vq65FItxKC7OokYg57k9aypYZIVXzMpuG4A8mvoKKSirHJXbc9Tf0rTpLaE3lwoeBkJTBySfWqJ1aaFdkNwY0Y/NtHT0FW7e+eHw80LSttkP8RyBgcBfQ1gp+9U/KF9/60ow5m3McppK0Ta07XGgvVmkUkgA+Zt+YYrQ8Z3J0Txfo2sW8yPbXKpMDGeTG3DKf14rkipUbW2naecd66OXRpdf8BTSW6776yl3Qxr1kQ8MFHt1onCMZKT2ehMW5LQ6fxmLiGayWFfJX77yfdG3sM9eRXJa7Ikzw8MIEyOB0JPaur1O43aVph1QYktrdInyd3mMABwPUetYuoXET2YCKuHAKjHp/WubC+6krHRivedzkJhmYK/yKflGP61PYSWxuJxMNkZjZUZB91scH6ZqvcSoxO1MbiWOecmoY1XA3gk46Zr0bXRwXLF8ymbDyCWQhSzjoTgcCq8alxgb84AVQOTSvxy3SiK4kV+oJxgU7aaCVuo6JnEbANtQ/e+bGf8amtlhnOx3Kvg9sgnsP581XaNXaNIwS5PJLDH0pigxndnPPQdsUWuD0HMqqxXJY9CemKaImIcggDG7GaH+9vJGHORz/ADpu4qnIOR1PtTESyRlI1Lny2JBA74qe1GZEyNp6DC8mq6zGRyZVD/LgDHTirifNEMgqy88DpUSLike3/s+xFdZmdYwqrC33ec44/rXuvOSCSQfpXjf7PUasLy4Bx+6CHI+8xP8AgDXsxwMA4x2GOleHU1qSv3Omp09BCRgcHHTBpvJbuKXnqBnvmjOM5rMgTcv+cUUn5/lRRdhofD8cm5tseBubqByPWuh0+2a3jDp8zuQQPQVSs7CKba0yYZlIVVOMY6nitOXUFsvKVRuGMg7envXr1Jc3uxNIRcdWW2uLfT1kAcCQ8lQ/JNclJe3M5lEnJZvTAAqZ5cRIluylUIBbPzMTySar3LASshXCkc+9VTpqJM6knqytEuJwz5YnsOlX5FGfKVg1v8rSNnAx6VCQjWyqV2Ro2WYfpg1FeXCOWjQYizkLu6//AF625ebUxc7aITUL2MRCC1j3ruySeP8A69T2IS8sB5ylRuIDDocdvesuVXEeY4wgIODWjorWi6HIkrFrmN2LgtwmejY7iia5VoFN80tSSVH8mFQ4XY33iOoNa2hRsN0LMMsNxXsVrEivZGgMYdUwQyg859q0tPu4re+VkVtkyY69/epaew5NW0Oh06aOC4gS6UlFJ6t0yMUpjjaEhNqG35Ur0Y+lc7d6i7N5ckXEeeQOT9TTYryf7OgyV3DkMMfrVexVjndWVzb1jTIJpEuQyeRMwywGChPFY2r6bLBg7CFUZ3ddwrQW9aO0FiwV1b53Ynv2rq9EWK5WQSlJQyZI6g9gKxqN0lzG9GXtHy9zysSNb5jMYCsd/vn1rr/C/k3mq2jPA7xrH5srA8x44z9M9qoeL9IEN+htYmEbLynXBrU8K2kdl4X1fUGuA00bfZvL4+XIzSnNThc05HTlYjvba3AvBuBt3B+Q9/UfWooJII9JsrNpJGjWYM259r+Vzxn2Ncy17cthgx2AYUdBT3cNbZlLrNnGD02+1Cou1my3WV+ZIu6lILiQrFHmMAqhznjtUdvaxW8O6dgXbjv8uaq2jOk0b7dqFuG7Vo6ndmdik0MXmRyYj8ofwYzn61dre6tjNyu79S5CbeDymSIGEkAMw5B4zn29K9f+FOuxRa4kW5lgddm4E9Og/WvFrSTdd8I4UcnJ6+ua6/wbe3CaxA0EflFWXzCo4Izx19687GQvHm7anbh3f3O59V9Sf0xSBsDp0/GmxM7QoznDlRu9zT+3Hb9K5L31Oe1gHQjGKDxyuSe/FA6gDvSZyODyKSYNDs8+hrgfi7b3E2jo9tyxUpge/au9UnPAyBVLV7FNS0+W2kA+cfKT/CairFyjpua4eoqdRSex8YX0MkUsiyghhlQDz+FUZleWcbxlmIG0jFes+P8AwvIlwiQxCKaNirEg81yl74eistHnvLpwtwAOB3J747V6mHxsKkU+vYdfCOMrrY5bVUQIv2b5o0+QnHG729apLhlUAjA45OKdPkghMkAbj2xUAX92XVencnjNehFWVjgbuyzdKfKR3iCuFGe2c9K2PB+pvaXUkMeT5ibME4CfjWdaQpdnycl7hh8rMcEDuP8A9dDo1mVYhSQSDjjB/wD11ErSXKy46O56Jrl7Fq1hbWa24jmjIBUp8yHH8qwtAhjj0nVI9RljhW1l81JHOHKnqFH8XPYUmj3s13ZfaXYm5RsbucsvcGuhla0Oqabc2yqYGBhmLjO3cvA/PvXnSvTTgv6a/wAzvg1PVnmcsKzWnmSJ9nJ/vng+mPwqmIjGT90+6nNb3jO3e1lCgBT5rHaDkfh7Vzsbsg+Utx+VepTfNFSR5tRcsrMmupVnSNVAGxccDqfequCEJXIB4BI61IcMu4AhsHcc1CQWHBJHY1qlYzbvuSLI6A4OMDHHalRWdeEB4ODUQXJ5HSpGfgAHjrxSaBPuSbI2tUAcFwxJ/L9acqFXchfMwnP+zTIpHE3ngA7B6ZFSFkZMjduJywJ70mNWII1LMAMAZ6twBWzZxF0ReAeWLnjcCMc1kkKCACcZz71ph3UiMEMNwbGOMY4qZ6lQ0Ppb4BQ+T4JlcgBmuNvvgD/69ekY+brXH/CCzax8AaaJBiSYtMQB2JwP0Fdhn16V4UneTZ0S3G54IA5xxSAHOCckDPFO7ZP/AOumkjjnOOKgQYHpRS5Pp+tFFmGh8k2ix2I1K9ZmmMNviONzwvP/AOqqEaTJotkl2u0smZVIy2SxIPNZthezPLqEU5JiORGCM7gOhrc061ee3kmu5CAQGDyNn6cdq9Z03F6le1Vjnmi8qeRSBFhMhj0B9ahmKu0Ib7/G4Z596u6pH9pjJQZZAAy+nuRVOxhIlgSaMhWbOTyAO+a3T0u9zPfbZjLoNbCYSqXEZwI2+6pPQmol3zMuVJUdPlA/lV2/Im1aTzCTA5UMR3Ue34VqMtnbWcsu1pJ3JKpH90L2zVc21zJrsYVyDtCBeADgk+tZOlrGdeSK5kEccuYy5PAyOM+2a6OG0Nxp0iPCgcIW3M53E54Cj+dYsmlBPlnBWR/ug1akmmhKLTuOubSW1uGjuFIYcgMOo9q6vRNNT7L5l3CA8nMYLY2jHX8aqXK2Fhp2no0jvcxoS4xkkk9yeg9qdph1LU7rZYwKsYQPJNLk7F6f/qrnnJyj2OiHLGXc1ki/d4NuzbgcZG7j60x7aJossMkjpnkVp6fcxaRF+9HzMrKjyNw3PPFYWtXCRSp5NwkxkJ3JA3T8azpyctx1IRi/dWpNDFD9pXBAGNrZ5NXInSKNv3gVVYH72MfSuNa9nuWKRRLCg/jPLH8asWmn3V85DuWKLn5zgACtpQb3ZkrR6anW3d+s0JdWRPJBYfMOR6fWuf8AAbTSHUbOQkQzjeysM7uefxwaltIoop44542jQ8HPUc9asaPe2+l+JpFmAFvMMI56A9s1moKMXGJcqjbTfQz/ABDpNxpnlEZls5TuU8ZB9PaqFpFLPzh2O3HTOP8AD1r0XxZYLdeG57ggRpCdw78/4V53YXMsETlDjPbtn6d6VGo5w13HNJS02NF5olsIbOZcvEzOGA6ZHA4qnp8xR2YJllBLE8/zqW/jMUeE3E5DNx6+hqpFlpWbkgDBz6VcUrCbd0aKqsk0hQhZG+ZFJ+UfjXbeCLWa41i2V+gdQApxyT39a4WAxF0YRtsOMs/pXrfw3LXN55mCVSRdo64Y46e3FcOPbjSdjrwr9+59BQbkhRZSS6jBJ61IOmT6+tI2d3IwR15pTjd0Iz+lcG2hi9dQGM8DIpMDpxRjgd8UA4Jo6gB6deKMcZOaVe/1+lNTcFG5g3XkDb34GPpVIk5n4gaal1oE90iH7RCMgjqR7184+O5J0tYUUlgo3Oc8M3oa+sp2jWGT7QT5TDa20E8H2r5t+IGktY393azMjxMC0Uicq4/oe1VQahWT7nXTk50nDseRrbyPvZFJGOmajZSW2gH2A71d2tHdIqNg7s56U4KkM5jAJjXoc4zXuqR5vKUoxMJldmG77xP8XHUcd6naaWZMPJuIJY7u/wBRSXexp2khBHUnnP1/KltIGmmjCd+M/wBaelrhreyNCwvja2ohKcPyWVuldXYRBilo7B4ZUPAPUen1rjJlia1VhlGDMjIBxkH+owa6DRVcxQTwFXaFt4QE8+o9q5a0bq6Oum7blDWkF5pYCEyT2s7QEjklR0z71yrLtfBHGehNd0DpkEFwmn7ledjJIsn3t/1rkbyIRmZ3Ck5GMnOK3ot2sc1azd0UpG+YkcZ42g1Htw46NnnrTnAI+U/NnGPemkgH5jlc9v6V0mBNbpvZlIXIXvTYyMZC5b37Uu0jPGPQZ6ZpGULkAnP0/SkFgUkkjOF7jOM1KjMA3ljJzjcKb5LbgW5UjINSxBY8+Zk+oBxUtoaTGRAFuQSe4xwPet3QbKS/1iCCNAXkZUVR3J4qtpq27GXz12Z6Y756D6V6T8DdMjufF9kzICYd07nGRkDiubEVeWLaNqcD6MsrRbCwtbNPu28KxcDuBipj2FGdx3H+Km+ucYrx+pQHvyAKTIzj1oJ4zzxSdTwOPekMXPuPyoqPH+//AN9UVN5dl97/AMhHwl5pTa0S7JM5Zhzk+9d9bQPDpcAdSZJwHkDHkgmuR8O263V2sMxKoMuSTwcDIHvW/rNyPs0UkzsDGF+VTx0ztz3r3qju+VGSjpciu7rTk1khVdmA2iRTtH09xUN/fW1rMixRK8oySdx5Pp1rnnnZ5DuRUBBJYD+dTWaG6QROV+0H7rtyMH/PWj2dtWy+c04/slwFeTejSHgsc7voe1WHYW8EiASBQcnP+elVbPTLmVlVIwVBxgDA/A10ElisarDDukdVCuSM/Me3uKic0mlcuMW0VNMuF+zjMoMjAbnwDtTv16VS1G333jkDzWAHlupyAtaaaVE0luZdsCxAiXA6+lbey2cutsCsm1VDsPlI79e9O6TujJvSzOLlsXupYoiFVjjI9M/0rrdJ0m10qMvqGpRQqwAYRyZyAemB1qPUrCaJ4obeVJY5P9ZIi9B9ayRorx3ZUsHUjrjpUzXtFa9kVCpyPRXINRxqmsS4eSOBm8uDPIUds/Wu7+FXguy1HxfLbalIk0NoT+6/vsP6Vyo0okxoGYYbOG4H517H8KvCmoxapZ6zfkNBGjImflbp+ornxdaMYezi9zWjCSbqv+mcv8QfAKaNrjXNkqxWMrb0xwVPcCuL1Ffs1+xtmzCg2qTjDZ9a+pfEekxa1o1zZygFipMR7qwHH+FfNmo2DJPPBKoDHjYOMGufDVWnySfp6G0/3sedLXqcut+XctdITEGwGH8NSf2aNQfyEIBZfMhc8BhUNzYTxKwTdlRyD3rU8NwC/FrY/M17GSMZwAua9BtWvE5XdPU1oZrq58HarazIBOsecYyTtI5/KvN7eMFk3H5eSG7fl6161Nfq8xt7qELLCDHJt48xDwT9RXBtZtptw9vKOUY8KoYsO31rKjKzl56mko3St0JLmVVjVI0keVIVkKsOGQjnH0rOliCODCVj995wc/8A1q2YvLurRY2Mkbwg+VKgwEbsT3x6iq8Vq9xKTKVS4xgpEAVJA647CtFNW1IcGmNskMnlvAu8Btuw8/U4969y+CGhy2pmmuOoO4DqB6YryzTLJI7y3azUBIlwwcY5xyffntX0d8P4Fh8PgqgVpHJ6c4rzMXV55KC23O6MPZ0nLrsdMDnOeB60u4DqTTVOV6g/hS7uRxWFzmHDtk8duKaTgEgE9zjmmg8DjJz1p3TOeeO1G4C8557UnPXrz1NJ/DjBz0NCn5eM/h3piHZ/unmua8c6FFrGllkgiN3HkiQ4DbcdPeukXGDgVU1G2N1Dt+0GPHIwoOD61M1eOhdKXJNO58m+JdH+zfMFCtuIIHbHSuTnZFYiHJOPmZjzn2r6Q+InhG6kMmpSypdtIuwpHEIwuBxwOPxrxDX/AA6+mqWlV0BOdrDB5HY9x716ODxSkuSb1NMRR5v3lPY5hJQQx2AuBgnGBir8UgMi5+9GQM56+/FVrdFeORAq5AyGNQvlBgKPVTXpWT0OC7TuamoQrJp7ybgsitk4PJz7fSn+HdRFnd28PIQt8x9KzIZpJJ50lbIZAygjj0qJchsjtzmo5NHFmnPezO61bSXSW4uYF2qIxvcnoT0P41wzxvLMrPGQ+7nIyGNdlq2vW9roelX88TvM7iN0B7AYYkd+vSs3VZILfzp0O+OZVeF06EEDH0NZ0XJaMVTU5S4dJ2cQowMZ+Y9jz2qshJOO57VfluB5RRAdx+Z224JNUshSSVzkcZ7e9diOdkkL4bc+OSK6BtlxKruIowI/lx8ox6VzYzgEMBnt3rRVC1rhtrRZxtzg/Wokle5SvbQgmLiVi4OFPYcfhUxjjErqXThc/LyM+g96iuZY2RFt1ZVA5UnOPxpqHG3AA7EkUWBMv24EjYUjJGFyK95/Z8sfL+33jAfu4wn4t1P5CvCLWFcxsrAktg+1fUHwa0sab4KjZ1Je6bzDkdfSuDGP3Ukbw0TO8B6fpzTew7+9Ge2en60me54NecAueetKOnH503g+gHrik9OcDvzSGN3j0/Siovn9Z/zWiub6x/cl9w7HxnZH7LamSMjzs4Zx/B+AqHXZlnt42Ql8H5j2Pvjsajs4/PZiFZ2PJwMYH17U3UJRcOEhVQhYZVSeTX0qXvXIk9LFSFlk+UsAe7MO1bPha1+1ahiPpCpYsOg+nrzVvw7pSNOHuIy0bcjd0z269RW+5tNPtXitFVJHXazKOM5z+dZVa+vJFamlOh7vNIfbzMYoSzlVfOE+5j609EbzxtJjBHLN0IrJSUyzbmy0ajgEc5rSln8qIgsdpGMY5Nc/JyvTc3ck15ElstvIuMMx3YYMev0qW/h81ZAC2CMBT2P4VlJcvHKfkAA6ZParlvJcXJ3xKAFIyuc9KqScdWzKKVR2SJysMdsERW8zA3KOn41o2OnSvveFSrNwAAOM+1JpdrLNPgxs0hPTrXqPhvwtKQlxcxbIyOSx5/KuKti+R8sdWdKwqUeaehh+FvC8upt506Bnj43FcL9MV67CoihRFAUKoUBeAOKitoY4IhHEAEAwAP8ACpwx4AFYRu3zS3MKs09I7Dk5GeV+uK83+IPg6Ka5bUrSEqhO+Xa3f6V6MSPx96QqrLsZQy9CD0okr6rRipVHTlfofN9z5dta3ME1udwBEbvg9emawxpV5a6ybqxGGhQzKo9MV7Z488MQ3O42sKouMkDvXGS2rW0e3AWXb5f144Fa0MbvF6M6amGU1zw2Zz2o3UOuWkOoWe37bEgYrjH+8CP6U20+wXyxm42o4+6MZP09qSXTXsD51sCQThwnHPU5FblrpFmYnM0UUhbLsVbksemD2rapJOOhlTi4v3jiPEFnNp13LDbiSOOYDkjdke351nWcRhSR1OGUbQjZy/PUEcjpXe3lvcOWtpLfz1XC78DKgds1WOh2kc6G4byw44yMHpxz+lKOK5Y2lubugpSuiHwrpbXl4J1XljkBc5z6V9J6XaLYaZBbDA8tBuJ9Tya86+G+iqt8JiF8mBd4x3btn+demHnOTx6HvXEpupJz+SJxMkrU10Hg5XjmjJ4yM0zrz6Uo5x1qzkFB5xnnGaXPT9Kb1A3daU4HOeemOnNADs89B0pCcckj3pCSeOKQng/TimIdSOQehx2pueKM8jnk00AbgcggHjkEVla74e0zXrH7LfQR8DbHIF5T/wCt7Vp4PQnv1p4PHHXPNKye44ycXeLPk7xr4Yn0DUZ7eeDGxjtKj7y+vuCK4eUhWJYnk8fTtxX2L478Lw+KNHaLCpfwqTbytxz/AHT7GvkrXbC4sdRmt7+Jo5oyVdMYIOa9PBVm/clv+YV0prnj8yDTGjLNK+CFBTP9Km1qKKK4Q2uAJFDFc5KHuKoySYtNpRQF4/H1pzTJJCkoP7xRhlPcV2tO6ZzxdrosSA6jpH2GeQxCJzMu1dxcfTqT0p8UUy+EbYzROqCR1XeCCQDwcfjWVHM8c6vmRMMCWHUfStLVNbu9QjhW6YMsZKrkYyPfFDT0C+pjtyhTq4bhvaoiFkbBbaMccfpUsmAzdMHGd3Ue2abMIyFaL73Qr3961MyaxtjPdRov3C2PUjjvWprMC28gRVIhVQpZeST6gVFojCW7DySJGQ3C/wB70xV3XQBErS7kZTgEdTWLk+exrb3Dnp9qFQmDxnd3b60+AMcYyqnqaQ5c5YAIeATztFOXcAEU7lU9u/vWpkbWh20kt/aJEobzXVQOvevsbS7b7FptpbKBiKJVP1xzXzJ8FdGGp+N7MSDMdv8Av2HstfUpJJbnBNeTjJXnbsbr4UJwwI6460enX2o7DtR0+vpXJ1GIe5oOMHpRn1o6EZPBpDEz9KKNo9qKQj4chVxbsysVk4BAPJ59K6HStJa1t47y/QEt8wUjrW3Y6ZbQgS3qK91uBIA9Pan3AadZJSG2kkKCcAfhXrSq8+i2NVBU9XuUZbiWQbQi7QpABXA5HB/CqlvbznPmsM7cgscc1qWMazz+S7H5uQp9aspo8s0pDQSy5PygdAKzlUjT0ehpCE62qVynbREQ+Y3EnUEDgVK1nNfyAxkjspBrvNE8FT3kKskLog4yRxXfaV4I061t181DJIecbsAGuF427fs1c3lRhD+IzxzSvDk0k2ySIvJkAHFdxoXgK8e7D3EYit15ILYY/hXp9vp1pbRBYbdEx/EOp/GrIRUB2Db3PvXPJ1aj996eQfWoQVqUbGdpWhafp0aGG1USDqScmtXdwcHv0ApM/kaAdo9TmqjBQVkcc6kpu8ncdkDkfnQMc4wOetNPHTHP604ZyOcD0qrki/hzTidx5P8A9am/w9cf/qpD79aABkV1AZciuN8V6JEFEyD5N24rjofWuzJJbkjAqOeNJ4mRwCvp61hWpc6utzow9d0peR43qqMY5QsYAY8FeKzIpYobNgZldgw+QgKa9D8QeH5YkaSFRJDydg4IrzfVbdBKhKsDnBHqaVCs/gloehOlGoueBqwpAsTFbYgOvzeWMBh/+ulsvLuFZ2iGzeEjLDJFR21pdNbI32lSSOQRgAHtXWeDNFe9kWaeLGnwsSJOnmt6AenqaVV865Y7hC1JOctjsPDVj/Z+lRR4xI/ztj37VqLzwM8U0sM5GAfyoHfg5NbRjypJHlzm5Scn1JF5PHpikB4GcmkGQRz/AEpe59KZI5TgfoPeg89zkdxQDwucik4455FGwbinIXnmkI4GT065pM4/E0Z49gP1oACSOefpSAHH40ueevH1pM5GR0HtTEC5zx+tOJ4zmmZ47YPrSg45yOBTTEPBJxj1rzL4y+Ak8Q2bavpsR/tSBf3qr/y1Qd/qP1r0sHgDp9aVWIYMvBFVGTTTW40+Vnw7NZPsYzEhQce/HtUMDRwzRB1Yo4w46/lXvfxi+H0cTSa3o8RWOQkzRRD/AFb+o9jXz3eP5U5DqwIz+dexh66rJ33RnWpcqU47MS4kfzzF0K8A5pH3eUo5+StGawtp7OC/tr4uZB+8Qxf6px/CTnp6GltdLnvi2xyu05+5nOe4rb2kVqzNUZvZGSuW4IwPX+VRhyVzjA6D25rRl0i7Q4UoBuAJYEEH6VXnsZEj3LKrYO37vOfTFWpJ7EuEluNtp/ss6ycMe+e1dFfOmpaSrRAArz1ya52awEaNibc7YYheFH51e0Z55Gjtt5Eff5c4qJpP3l0NIXXusjNuVthuIJ3dB6+lOtYsyMGwAvr2rV1SySFWRQFV1XAznkdTn3qDTxGJAwADr3K53Glz3V0Ty66nsP7Odqp1DVLtDlY4hHkdiTzg/hXuWMg8HIriPhBpP9l+Do5WUebeOZCAMbV7D+ddv2FeJUnzzcjeSS0Qh6En7opD9eKUsM9aQkbR7fhWYg79Dmkzhe496CeBxQcZ56UAGPYUUn4Ciq0EfMsiTIZfIIeVjks3U+uPpWl4e8Kat4il3Rx+VZAcSAY5rX0bwhNr+pGVR5VuWJduy5PavZ9PtIdPs4bS2XbDGuAMY/GrniHLSn951OKpazV32/zPMtH8Bpp08RmG9ScMw5I+pr0ix0iwswjW8CbivBYZq8D0PU5zRz/EM1yKleTlN8z8x1MVKastF5C5AUBcDsABil3f/XpvPPqaVeelbHMO6jpjvzSE8/40mT+OKCSCRxQA9entRnH9KaCPenZ7DqenFCEHc5pc45GKT1z1NLznkY98Uhjt2R/Oj+lJznuMUoIBPHvigAU8+mfzpc0g5o6AY5FMQHHU4rj/ABT4f+0zieytN8vfy8CuwyMZzz1+tAOMVlUpqojooV5UZXichoPhNViWXV03P2gDdv8AaI/lXXIAihEVUVRgIowAPQUE9+/UUDgnJGKcIKKshVa0qrvIUdBS5Oe/pTc56mlGMentVmQ5eeB0pBhTuJOTgAn/AD0pQccZ4pQfriiwCjPJ7UmQOvp1xRnnJ64ppzjjigBSaDk4wKa+fbI/nQGBGecd80AKSNoJ+lJwT7+tGccEk00k9R1piElfAACby5wAenrk08k8UxcMVzk7M4P6Uo449+KAJN2Ac9DQoAbd3xjNMBx9OnNPK4Hr7g8GhAxT0KsoZW4ZWGQR6GvOPGfwl0LWoZptOtVtL0qSFVvkY/0r0XoD3/rSgg1V9dHZ+Q4TlDb/AIB8W+JfCGs+Fb6VbiCa3x1JHDDPfsRWz4S1CLW/Ns3hSDUYot67CQs6jqAOzDrj2r6v1XTrLVrU22qWsd1AeNrjkfQ9q+cfid8Pr3wTq8Wv6AjzadHKJFIGfK9VfHbGRXUq7qrkqb9H/mb05RTvT07rv6GJcHEzBRvH8e4Z59qzr2z+1y/ulKDnaD3P0rb19AqwXdom6C6QTIvdVbnB+lVEmRJOrsADkd89q1pTfKpIdeKvY567tDHbBCFLjjDfyxU/h+NbZJJZJE8zAIXrUGpiFY7dWaUmBiwZj8xJOcHHaokkTzwYgVUnnFdbvKJyK0Zal+dzcTHKEnH3uwrZ8D6W+s63DZJApErhM9No6kii105ZrYNGByuA5r1f4L+GvsrS6tMNvljyo8fxE9Tn6Vx1ayUXFbm0oWtI9Rt4YLSKO1twFjiTaijso4yfrU3Y5NNPp2ozkcjt1zXAZC5AHufWmnkAdMetB7+lNOecenHtQIM4GPSjO0H/AApMnIzjIoPByeRS6DHZH95aKTB/ytFMRWgto7WJY7ZFRE6KowCPT61MGyOOnvTQTjrzS5446dqS0WhTbbuxRycgc04ZwM80g459aMkEnoKBDuDQnIycjPr2pB8uM/8A66XOTyc+9AC9+vPegHGQOPSk4xyRj1oH40ALnBHFKOmO1Nz1OetA4zuOSTxjjFACg8ingjPb6Uzdg8dMUoOSOc/hQA8Gjp7YpoHH/wBalI5+9UoYoPTA9jQO3UYoB5xnGaA3GeeOKYB26c0p749PypucgDIpFJwMHgdvWgLjuSBkk96VcYI5603PTGMDrkUAnvnvigB3Q46UKoRQFAAzxQDj6Yozxjn+lMB3rS5AyeKbjp+f1oJGeTggdjQAoOAB70nc4oz6ngc0BuRjGTSGI3v37Uw5UgcYxT+ucjn0pD7AHnn0FMQA8GjnOTn8qAOSc96aDxznigBxHYUmQeCx57U0YFLu5OMk0tgHjgE4IxSjoB+tNBJGOppR1OBxTQMUkHIx0oB4xjPtSE5HH55oU5PtTEOJ7+tMdY5oZIpUWSJwUkjdcqw7g+op3AbtimOSuMZxVCueGfFTSLbQpY7O1bEPljyV/wCean+E+1eTS3ixl1dXyAdhJwAa9X+N0jnXbkTSYVVAQe2OK8Pb51wznfzkE124CCcH6s6MZN2h3shJLia4dV3E5xg461oaYhuJdhC7lGAPc9DWWJArMoJCjghetdF4ftJJUYg7dvzBRg59fpXfUfLE4oas6/w1prQ2ouXcMhGMdhX0R4ehitdDsIoV2r5Kvxxyea8A0G2n1i+GmaYokZCHlOTySfuj8AcntXv2iwXFtYQQXUplmjjCt6JjooPfArxa1+e73OybTgkjRycZxTT1BFDHPOMU3eOAep9ayZihWAbhuQCDjPcdKQnPpS5GNy4+tNOMcdaAEzjucdc0oOc9cetIQckjGO3/ANem4w2SDgnmjYB+P9pvyopv40VV0TqNz/Kjv74xxTVYH1xS7snA9KVh3JFGB25penX8qjVsjpT+/PSkAv0FHTketKfw64pqfe4oGOUjGSf/AK1AORimk5JB6AZpx6dBigQnU88Hp1py9Bxmm4+QHqPSl27gR0I60wF6jr+VPByMdqYq4OeOlOA5OD3o8wAElcjg9s04Djg/l6UnfrjJx9ad1I5+maQxqkYAztI4x0pwyDjp3oxnNIAAFA6Dge1CEJwF6cfSk+8fWlPfFI+B70XAUc43FQTSrnqRSY/LoaB93I4AoAUdMc4HGcUueM8gdKb0bZ/KlUZ57UDHct1yc0o5HfBpCP8ADrSdg3P40WHcdn27YpM+nagEUnr+tNiuB64zkUjEe2e9KScdelNx0xxzSYwbJPPSm55I4BFDcfhzRn9RRa4hSM9O3r0pMk9+KCcnpQQTnnmiwDC6iRYw6rKwyo4JIHXHtU2eo5/Goxxwac3FACg4zg/h6Uq5I6im5yRnvRktjHH0piH9s0ZyAO1JjHp0zQec00xNHk3x00kzRRX0YfeybTtH3iONufXFfP1xAYrnM6SCM469u3Jr7T1Gzj1PTrixmAKTxleRnaccN9RXy/rOmbb6a1lKODlQcdCDjOK6sJV9m3Do9f8AM3nH21NPrHT/ACPPzGYZGCbmUtxu7V2nhqGOON52mL4U4JGOg5/CqVt4dEd4WuZFaFGJITOTg4rv/A/hseI9Sm01TFDZxIGk67nXIyPxrqxFePKYU6TTudp8HNIjitJtURGbzNwilPRyep/DpXpIVVAGOMetMt7eO2tore3RY4YUCRoowFAp5PyntXmSd9WNvXQC3zDt/SkBznPagnt+FMZwM9crzUgPzluPTNJ1x/j1pkX3d3dxn9OKcME8jjtSGKR3HegdcAe1AHJzzihj1OOlADN6f7X60U75vaigR//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Postmortem slide of cut surface of lungs in a case of late-onset carmustine lung fibrosis from a woman who died 13 years after receiving carmustine for astrocytoma. There is extensive subpleural fibrosis, especially at the lung apices.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ronan O'Driscoll, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27860=[""].join("\n");
var outline_f27_13_27860=null;
var title_f27_13_27861="Rifampin and isoniazid: Patient drug information";
var content_f27_13_27861=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rifampin and isoniazid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27368?source=see_link\">",
"     see \"Rifampin and isoniazid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      IsonaRif&trade;;",
"     </li>",
"     <li>",
"      Rifamate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Rifamate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause hepatitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat TB (tuberculosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702331",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to isoniazid, rifampin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703781",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you had liver problems while taking isoniazid in the past.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may make liver disease worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of body fluids to orange.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A long-lasting change in color of contact lenses. Do not wear contacts while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694534",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid eating foods like aged cheeses and meats, soy sauce, soy beans, Miso soup, Italian green beans (fava beans), snowpea or broad bean pods, sauerkraut, kimchee, yeast extracts (Marmite), red or white wine, and beer including alcohol-free beer. Very bad side effects may happen. Ask your doctor for a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug is stopped, follow diet for at least 2 more weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11852 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-CCB6068CE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27861=[""].join("\n");
var outline_f27_13_27861=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218270\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218271\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028242\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028244\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028243\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028248\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028249\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028251\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028246\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028247\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028252\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028253\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/46/27368?source=related_link\">",
"      Rifampin and isoniazid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_13_27862="Membranous VSD short axis color";
var content_f27_13_27862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1182px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/55781/Membranous_VSD_short_movie.mp4?title=Membranous+VSD+short+axis+color\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Membranous VSD short axis color",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Moving short axis clip demonstrating left-to-right flow at a large membranous ventricular septal defect (VSD). The color flow jet of systolic left-to-right flow can be seen coursing from the left ventricular outflow tract into the right ventricle.",
"    <div class=\"footnotes\">",
"     LA: left atrium; RA: right atrium; RV: right ventricle; LVOT: left ventricular outflow tract; PA: pulmonary artery; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27862=[""].join("\n");
var outline_f27_13_27862=null;
var title_f27_13_27863="Clinical neurophysiology";
var content_f27_13_27863=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical neurophysiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27863/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27863/contributors\">",
"     Shahram Khoshbin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27863/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27863/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27863/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27863/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/13/27863/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The brain normally produces low voltage electrical activity. This can be measured via the electroencephalogram (EEG), which is ordinarily recorded from the scalp with small surface electrodes. The precise origin of this electrical activity is unknown, but the prevailing belief is that most of the activity represents dendritic synaptic potentials in cortical pyramidal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/1\">",
"     1",
"    </a>",
"    ]. Since there are normal EEG recordings characteristic of certain ages and states of consciousness, it is possible to recognize generalized malfunction of the brain with this modality, as well as localized or paroxysmal abnormalities.",
"   </p>",
"   <p>",
"    The body also produces electrical activity outside the central nervous system, which can be measured in health and disease. Such measurements, performed via peripheral nerve conduction studies, electromyelograms, and neuromuscular function studies, can be used for diagnostic and prognostic purposes.",
"   </p>",
"   <p>",
"    A review of clinical neurophysiology is presented here. Detailed discussions of the use of the various modalities described in this topic review are presented separately in topic reviews relating to specific diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ELECTROENCEPHALOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the EEG, electrical activity is recorded from many different standard sites on the scalp according to the international (10 to 20) electrode placement system (",
"    <a class=\"graphic graphic_figure graphicRef78990 \" href=\"UTD.htm?20/62/21476\">",
"     figure 1",
"    </a>",
"    ). The nasopharyngeal lead is a long electrode that is passed through the nose and rests on the back of the throat near the mesial aspect of the temporal lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/2\">",
"     2",
"    </a>",
"    ]. Since the typical EEG machine has 16 to 20 channels, a series of different 16 to 20 groups of electrode pairs are evaluated. Recording electrical activity requires measurement of voltage between two electrode sites. It is impossible to record from all possible pairs of electrodes at the same time.",
"   </p>",
"   <p>",
"    There are two different styles of recording:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the referential method (previously referred to as \"monopolar\"), a series of different electrodes are all referred to the same electrode (eg, the \"references\"), which is presumed to be relatively electrically inactive (this is similar to the limb leads of an electrocardiogram). Commonly used references are the ears (A1 and A2), vertex (C2) or a non-cephalic reference, such as a \"balanced neck-chest\" system.",
"     </li>",
"     <li>",
"      With the bipolar method (which utilizes leads that are similar to the chest leads of an electrocardiogram), a series of electrodes in a line are recorded serially as successive pairs. The first recording would be from the first and second electrodes, and the second recording would be from the second and third electrodes, and so on. Use of the different montages given various view of the electrical activity at different parts of the brain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electrical activity from any electrode pair can be described in terms of amplitude and frequency. Amplitude ranges from 5 &micro;V to 200 &micro;V. Frequency of EEG activity ranges from 0 Hz to approximately 20 Hz. The frequencies are described by Greek letters:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delta &mdash; 0 to 4 Hz",
"     </li>",
"     <li>",
"      Theta &mdash; 4 to 8 Hz",
"     </li>",
"     <li>",
"      Alpha &mdash; 8 to 12 Hz",
"     </li>",
"     <li>",
"      Beta &mdash; More than 12 Hz",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal EEG findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the normal awake adult with eyes closed, there is a prominent alpha rhythm observed in the posterior part of the head (",
"    <a class=\"graphic graphic_figure graphicRef62111 \" href=\"UTD.htm?25/11/25782\">",
"     figure 2",
"    </a>",
"    ). The amplitude of the alpha falls off anteriorly, which is frequently replaced by some low voltage beta activity. Often, a little low voltage theta activity is observed in fronto-central or temporal regions.",
"   </p>",
"   <p>",
"    The alpha rhythm disappears (or blocks) when the eyes open. This rhythm (which is prominently posterior, blocks eye opening, and is usually in the alpha frequency range) is frequently called the alpha rhythm. However, since the alpha rhythm occasionally may not be in the alpha frequency range and some alpha frequency activity in the EEG may not be the alpha rhythm, semantic confusion sometimes arises concerning the term \"alpha.\" Thus, \"alpha\" has been associated with alertness and normality of level of consciousness.",
"   </p>",
"   <p>",
"    With drowsiness (which is stage I sleep), the alpha rhythm gradually disappears, fronto-central beta activity may become more prominent and fronto-central-temporal theta activity becomes most significant. As sleep becomes deeper, high voltage single or complex theta or delta waves, which are called vertex sharp waves, appear centrally. Stage II sleep is characterized by increased numbers of vertex sharp waves and centrally predominant runs of sinusoidal 12 to 14 Hz activity called sleep spindles occur. Deeper sleep, characterized by progressively more and higher voltage theta and delta activity, is not usually seen in routine EEG recordings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Abnormal EEG findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities of the EEG are either focal (only one area of the brain) or generalized (whole brain). Additional abnormalities are either continuous or intermittent. An abnormality that suddenly appears and disappears is called paroxysmal.",
"   </p>",
"   <p>",
"    The accurate interpretation of EEGs requires significant experience. There are a wide variety of normal and variant wave forms as well as artifacts that must be recognized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Slow wave abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased slow activity, meaning the presence of theta and delta activity, in a recording performed when awake is virtually always abnormal. Focal delta activity is usually irregular in configuration and is termed polymorphic delta activity (PDA) (",
"    <a class=\"graphic graphic_figure graphicRef68743 \" href=\"UTD.htm?8/22/8550\">",
"     figure 3",
"    </a>",
"    ). PDA is usually indicative of a focal brain lesion.",
"   </p>",
"   <p>",
"    Another type of delta activity is intermittent, frontally-predominant, and rhythmic; this is called FIRDA (frontal intermittent rhythmic delta activity) (",
"    <a class=\"graphic graphic_figure graphicRef82445 \" href=\"UTD.htm?22/9/22677\">",
"     figure 4",
"    </a>",
"    ), and it is a nonspecific sign of brain abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28837034\">",
"    <span class=\"h3\">",
"     Abnormalities in encephalopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized theta and delta activity is a sign of an encephalopathy. As a general rule, EEG is a sensitive test for encephalopathies. Different patterns of slow wave are associated with different types of encephalopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common pattern with metabolic encephalopathies is generalized slowing with moderate or high wave amplitude (",
"    <a class=\"graphic graphic_figure graphicRef59514 \" href=\"UTD.htm?33/59/34741\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/3\">",
"     3",
"    </a>",
"    ]. One frequent pattern observed with hepatic and renal encephalopathy, which may be mistaken for epileptogenic activity, is the so-called \"liver waves\" or \"triphasic delta waves\" (",
"    <a class=\"graphic graphic_figure graphicRef71331 \" href=\"UTD.htm?16/1/16406\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/4\">",
"     4",
"    </a>",
"    ]. With hypoxic encephalopathies, different degrees of slow waves with usually very low amplitudes are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased beta activity is frequently due to a sedative drug or any centrally active compound, including most depressants, neuroleptics, benzodiazepines, or even alcohol and \"illicit\" substances (",
"    <a class=\"graphic graphic_figure graphicRef66590 \" href=\"UTD.htm?19/31/19957\">",
"     figure 7",
"    </a>",
"    ). In general, a toxic encephalopathy is indicated by generalized slowing and beta activity.",
"   </p>",
"   <p>",
"    With infectious encephalopathies, there is an admixture of slow activity and the presence of epileptogenic activity as discussed below. In herpes encephalitis, an EEG pattern is identified, which is referred to as periodic lateralized epileptic discharges (PLEDs) (",
"    <a class=\"graphic graphic_waveform graphicRef81622 \" href=\"UTD.htm?17/54/18278\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=see_link\">",
"     \"Herpes simplex virus type 1 encephalitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Epileptogenic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;EEG is particularly useful in the analysis of seizure disorders. Epileptiform discharges are common between overt seizures (interictally) as well as during seizures (ictally). These are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link&amp;anchor=H3#H3\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\", section on 'Interictal epileptiform discharges'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epileptiform discharges can be generalized or focal. The classic generalized abnormality is the 3 Hz spike and wave pattern which underlies the petit mal absence attack in children (",
"    <a class=\"graphic graphic_waveform graphicRef73940 \" href=\"UTD.htm?11/6/11368\">",
"     waveform 2",
"    </a>",
"    ). A typical focal abnormality is a focal single spike followed by a slow wave (",
"    <a class=\"graphic graphic_figure graphicRef56977 \" href=\"UTD.htm?21/41/22166\">",
"     figure 8",
"    </a>",
"    ). This abnormality can be seen in focal epilepsy or secondary generalized epilepsies. Occasionally, the abnormal activity spreads to the other hemisphere. If the abnormal electrical activity spreads rapidly to the entire brain, the EEG will be indistinguishable from that of a generalized seizure (",
"    <a class=\"graphic graphic_figure graphicRef52674 \" href=\"UTD.htm?17/59/18359\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activations, such as hyperventilation, photic stimulation, sleep, sleep deprivation, and drugs, are useful in inducing epileptic activity and increasing test sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/8\">",
"     8",
"    </a>",
"    ]. Since it is possible to miss infrequent epileptic activity, multiple recordings are frequently helpful.",
"   </p>",
"   <p>",
"    The use of EEG in the evaluation of patients with seizures and epilepsy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVOKED POTENTIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stimulus in any sensory modality, whether visual, auditory, or somatosensory, produces a change in the EEG. However, compared to the background EEG, the change is usually small in magnitude, with the exact configuration critically dependent upon the nature of the stimulus and the site of recording on the scalp. The evoked potential is also dependent upon and time-locked to the stimulus, and, in order to see it, the stimulus must be repeated many times and the EEG averaged (",
"    <a class=\"graphic graphic_figure graphicRef54490 \" href=\"UTD.htm?36/34/37411\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/2,9,10\">",
"     2,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evoked potentials can be utilized to test the integrity of a pathway in the CNS. The most common current use of evoked potentials is to test the speed of conduction in a particular pathway. As an example, multiple sclerosis is a disease of central myelin; if myelin is damaged, conduction is slow and evoked potentials are delayed. Since many multiple sclerosis plaques are clinically silent but can be detected with this electrical test, evoked potentials are quite useful in making the diagnosis of multiple sclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=see_link\">",
"     \"Diagnosis of multiple sclerosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evoked potentials are sometimes used as a confirmatory test in the evaluation of brain death and also as a prognostic tool in patients with hypoxic ischemic encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of brain death\", section on 'Evoked potentials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\", section on 'Somatosensory evoked potentials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Visual evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual evoked potentials (VEPs), which were the first to become popular, are ordinarily obtained by repetitively alternating the black and white squares of a checkerboard. Each eye is stimulated individually and responses are measured from the occipital area of the scalp. Normally, the major wave is a large positive wave at about 100 millisecond latency. The wave is delayed with multiple sclerosis or optic neuritis (",
"    <a class=\"graphic graphic_figure graphicRef61470 \" href=\"UTD.htm?35/8/35968\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Such slowing is not specific for multiple sclerosis. Other conditions include ocular conditions (such as glaucoma), compressive lesions of the optic nerve (such as pituitary lesions), and pathological conditions of the optic radiations or occipital cortex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Auditory evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auditory stimulation produces very complex waveforms. Stimulation with brief clicks produces six small waves in the first 10 milliseconds.",
"   </p>",
"   <p>",
"    The sources of this electrical activity are in serial ascending structures in the brainstem. Thus, since it is possible to study the integrity of the brainstem with these waves, the test has been used to assess \"brainstem death\" in cases suspected of \"brain death\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. These waves may also be delayed in multiple sclerosis (",
"    <a class=\"graphic graphic_waveform graphicRef58097 \" href=\"UTD.htm?18/10/18597\">",
"     waveform 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Somatosensory evoked potentials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatosensory evoked potentials (SEPs) are the averaged electrical responses in the central nervous system to somatosensory stimulation. As with sensory nerve action potentials (SNAPs) in the peripheral nervous system (see below), most components of SEPs represent activity carried in the large sensory fibers of the dorsal column, medial lemniscus &mdash; primary sensorimotor cortex pathway. Testing the speed of conduction in this pathway permits an assessment of the integrity of the somatosensory system.",
"   </p>",
"   <p>",
"    SEPs from the upper extremity are commonly produced by stimulation of the median nerve at the wrist and are best recorded from a site on the contralateral parietal area. The cerebral SEP to this type of stimulation was the first EP to be discovered. SEPs from the lower extremity are produced by stimulation of the posterior tibial nerve at the ankle or the peroneal nerve at the fibular head; they are recorded best at the vertex of the head (",
"    <a class=\"graphic graphic_figure graphicRef68888 \" href=\"UTD.htm?14/32/14853\">",
"     figure 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is possible to localize a lesion in the somatosensory pathway by using short latency SEPs from subcortical structures. Although several systems of electrode placement can be used, the one that appears to produce potentials of greatest amplitude is based upon an active electrode placed over the cervical spine and an \"inactive\" reference site, such as vertex of the head. There are four components that can be identified, all negative peaks, which are referred to as N9, N11, N13, and N14 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The N9 component clearly originates from the brachial plexus and is best recorded with electrodes placed directly over the plexus itself.",
"     </li>",
"     <li>",
"      The N13 component, which originates from the dorsal column nuclei, is the largest component and is occasionally the only peak identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By stimulating leg nerves, it is possible to obtain EPs at all levels of the neuraxis, including those over the spinal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     NERVE CONDUCTION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of modalities are used to evaluate the integrity of peripheral nerves. These principally include sensory and motor nerve conduction studies and late responses. These are reviewed here briefly and discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=see_link\">",
"     \"Overview of nerve conduction studies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link\">",
"     \"Nerve conduction studies: Late responses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sensory nerve conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cell bodies of sensory neurons are located in the dorsal root ganglia. Each neuron has a central process entering the spinal cord through the dorsal horn and a peripheral process connecting to a sensory receptor in the skin or deep tissues of the limb. The receptors transduce somatosensory stimuli into electrical potentials that eventually give rise to action potentials in the axons; these are transmitted along the peripheral process to the central process. This is called a sensory nerve action potential (SNAPs). These studies can be done orthodromically in the direction of conduction or antidromically in the distal part of major peripheral nerves (",
"    <a class=\"graphic graphic_figure graphicRef53170 \" href=\"UTD.htm?2/16/2309\">",
"     figure 13",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a variety of functional types of sensory neurons, each with a characteristic spectrum of axonal diameters. Neurons are myelinated or unmyelinated, but the unmyelinated fibers cannot be routinely measured. Many sensory axons with differing function and size coexist in sensory nerves and with motor axons in mixed nerves.",
"   </p>",
"   <p>",
"    The two goals of sensory nerve conduction studies are the assessment of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of functioning axons (estimated by measuring the amplitude of SNAP).",
"     </li>",
"     <li>",
"      The state of myelin of these axons (estimated by the conduction velocity of SNAP).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with axonal degeneration neuropathies, the primary feature is reduced sensory action potential amplitudes; this can be observed, for example, in diabetic neuropathy. The conduction velocity may be slightly slowed, but only to the extent that the largest axons are gone; in this setting, the measured conduction velocity reflects the velocity of the largest remaining axons. In addition, slowing of conduction is the primary feature in demyelinating neuropathies, such as Guillain-Barr&eacute; Syndrome, familial neuropathies, and in compression and entrapment neuropathies, such as carpal tunnel syndrome. In radiculopathies, both the sensory action potential amplitudes and conduction velocities are normal. This is because the lesion is virtually always proximal to the dorsal root ganglion, and the cell body and its peripheral process remain normal. Sensory action potentials similarly remain normal with lesions of the central nervous system (",
"    <a class=\"graphic graphic_figure graphicRef55496 \" href=\"UTD.htm?15/25/15765\">",
"     figure 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Motor nerve conduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are significant differences between sensory and motor nerve conduction that depend in large part upon differences of anatomy. Motor neurons have cell bodies in the anterior horn of the spinal cord and send their axons to innervate muscle fibers. Motor axons are always intertwined with sensory axons. Unlike pure sensory nerves (eg, the sural nerve), there are no pure motor nerves. However, it is possible to study motor nerve axons separate from sensory axons by electrically stimulating the nerve and recording from the muscle fibers it innervates. The amplitude of the compound muscle action potential is very much larger than the nerve action potential since each motor axon typically innervates hundreds of muscle fibers. The amplitude of the muscle action potential is indicative of the number of activated muscle fibers.",
"   </p>",
"   <p>",
"    However, the amplitude is not indicative of the number of motor axons in the nerve. As an example, the number of axons can be diminished and the action potential can remain normal if the process of collateral reinnervation of muscle fibers by the remaining axons has been complete. Conversely, the number of axons can be normal and the action potential diminished if there is diminished synaptic transmission at the neuromuscular junction or if there is loss of muscle fibers. If a neuropathy progresses and collateral reinnervation fails to keep pace, the size of the muscle action potential declines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Motor nerve conduction velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synaptic transmission between nerve and muscle is required to produce a muscle action potential. The delay associated with this process, which is referred to as the distal motor latency, prevents direct calculation of the velocity of motor nerve conduction from a single stimulus location. If the nerve is stimulated supramaximally in two places, virtually identical muscle action potentials will result; the major difference is the different latencies from the time of stimulation. In turn, the difference in the latencies is due to the difference in the distances from the sites of stimulation to the muscle. Dividing the distances between the two stimulus sites by the difference in the travel times produces a conduction velocity for the segment of nerve between the two sites of stimulation. As with the sensory action potential, measurements of the muscle action potential are ordinarily made to the time of onset; hence, the calculated conduction velocity refers to the fastest (and largest) axons in the nerve (",
"    <a class=\"graphic graphic_figure graphicRef73171 \" href=\"UTD.htm?32/11/32948\">",
"     figure 15",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    With axonal degeneration neuropathies (the most common variety of generalized neuropathies), motor nerve conduction studies are not significantly abnormal until the process is moderately advanced. A focal neurapraxic lesion (eg, carpal tunnel or other compression or entrapment neuropathies) leads to slowing of conduction and decrement of amplitude across the segment including the lesion. However, studies of the nerve distal to the lesion are fully normal. Studies of nerve segments proximal to the lesion reveal normal conduction velocity with an unchanging reduced action potential amplitude.",
"   </p>",
"   <p>",
"    Quite dramatic nerve conduction findings are seen with a focal total neurapraxic lesion (eg, acute trauma or laceration). In this setting, although the nerve is fully normal below the lesion, electrical stimulation proximal to the lesion produces no response (similar to the patients' attempts to activate the muscle). In radiculopathy, motor nerve conduction studies will ordinarily be normal. In central nervous system disease, there will ordinarily be no change in motor nerve conduction unless there is involvement of anterior horn cells. In demyelinating neuropathies, there is slowing of conduction velocity and prolongation of distal motor latency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Late responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studying the most proximal segments of nerves is difficult, as the nerves are deep and not easily accessible as they leave the spinal column. Nevertheless, it is useful to study the proximal segments of a nerve, since processes such as radiculopathies and certain neuropathies such as Guillain-Barr&eacute; affect this segment predominantly.",
"   </p>",
"   <p>",
"    The so-called late responses, the H-reflex and the F-response, provide a relatively easy technique for the study of the proximal segments of nerves. These responses are produced in certain circumstances after an electrical stimulus to a peripheral nerve and are \"late\" with respect to the muscle response (the M-response) produced by the orthodromic volley of action potentials traveling to the muscle directly from the electrical stimulus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=see_link\">",
"     \"Nerve conduction studies: Late responses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ELECTROMYOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography (EMG) is the clinical study of the electrical activity of muscle fibers individually and collectively. The desired goal of EMG analysis is the characterization of a disease process as neurogenic or myopathic, or normal.",
"   </p>",
"   <p>",
"    Electromyography is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NEUROMUSCULAR JUNCTION STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common disorder affecting the neuromuscular junction is myasthenia gravis (MG) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Repetitive nerve stimulation study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard neurophysiological study for MG is the repetitive nerve stimulation study or Jolly test. In this test, a motor nerve is repeatedly stimulated and the muscle action potentials are recorded. Normally, the action potential is the same each time; with MG, however, the action potential amplitude may decline on successive stimulations with rates of stimulation of 2 to 10 Hz. A decline of more than 10 percent in amplitude between the first and fourth potentials is considered pathologic (",
"    <a class=\"graphic graphic_figure graphicRef65387 \" href=\"UTD.htm?27/7/27760\">",
"     figure 16",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Repetitive nerve stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In Eaton-Lambert myasthenic syndrome, repetitive nerve stimulation yields a progressive increase in the amplitude of the muscle action potential. In this setting, rates of 10 to 20 Hz are needed and a potentiation of 200 percent or more is required for the test to be considered pathologic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\", section on 'Neurophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Single fiber EMG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single fiber EMG is sensitive for the diagnosis of MG [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27863/abstract/15\">",
"     15",
"    </a>",
"    ]. In this test, a small needle is used that can detect the action potentials from a pair of muscle fibers of the same motor unit. The time between the firing of two muscle fibers from the same motor unit should be very stable. Due to the slow and uncertain function of the neuromuscular junction with MG, there may be an increase in the variability of the time between filling of these two muscle fibers. This is called increased jitter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Single-fiber electromyography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=see_link\">",
"       \"Patient information: EEG (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28837089\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an electroencephalogram (EEG), electrical activity generated by the cerebral cortex is recorded from many different standard sites on the scalp according to the international electrode placement system. The electrical activity is typically described in terms of amplitude and frequency. In a normal adult, this can vary according to the brain region sampled and the sleep-wake cycle. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Electroencephalogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal EEG patterns may be focal or generalized. Specific patterns have been associated with epilepsy syndromes, certain forms of encephalopathy, and central nervous system infections. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Abnormal EEG findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evoked potentials measure the speed of conduction of a neural impulse in response to a specific stimulus. The most commonly used are visual evoked potentials, brainstem auditory evoked potentials, and somatosensory evoked potentials. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evoked potentials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nerve conduction studies assess the integrity of the peripheral nerves. Measurements of the nerve conduction velocity and the amplitude of the action potential can identify a neuropathic process and also assess whether it is primarily affecting axons or myelin. Focal neuropathic lesions can often be localized using nerve conduction velocities. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nerve conduction studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late responses (H-reflex and F-response) provide a means of studying proximal segments of nerves that are not accessible to peripheral stimulation. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Late responses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electromyography (EMG) measures electrical activity of muscle fibers individually and collectively. EMG aids in the characterization of a disease process as neurogenic or myopathic, or normal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"       \"Overview of electromyography\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurophysiologic tests, repetitive nerve stimulation and single fiber EMG are useful in the diagnosis of disorders affecting the neuromuscular junction. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Neuromuscular junction studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/1\">",
"      Schaul N. The fundamental neural mechanisms of electroencephalography. Electroencephalogr Clin Neurophysiol 1998; 106:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/2\">",
"      American Electroencephalographic Society Guidelines in Electroencephalography, Evoked Potentials, and Polysomnography. J Clin Neurophysiol 1994; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/3\">",
"      Markand ON. Electroencephalography in diffuse encephalopathies. J Clin Neurophysiol 1984; 1:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/4\">",
"      Fisch BJ, Klass DW. The diagnostic specificity of triphasic wave patterns. Electroencephalogr Clin Neurophysiol 1988; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/5\">",
"      Synek VM. Prognostically important EEG coma patterns in diffuse anoxic and traumatic encephalopathies in adults. J Clin Neurophysiol 1988; 5:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/6\">",
"      Gotman J, Marciani MG. Electroencephalographic spiking activity, drug levels, and seizure occurrence in epileptic patients. Ann Neurol 1985; 17:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/7\">",
"      Goodin DS, Aminoff MJ, Laxer KD. Detection of epileptiform activity by different noninvasive EEG methods in complex partial epilepsy. Ann Neurol 1990; 27:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/8\">",
"      Leach JP, Stephen LJ, Salveta C, Brodie MJ. Which electroencephalography (EEG) for epilepsy? The relative usefulness of different EEG protocols in patients with possible epilepsy. J Neurol Neurosurg Psychiatry 2006; 77:1040.",
"     </a>",
"    </li>",
"    <li>",
"     Chiappa KH. Evoked Potentials in Clinical Medicine, 3rd, Lippincott, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/10\">",
"      Nuwer MR. Fundamentals of evoked potentials and common clinical applications today. Electroencephalogr Clin Neurophysiol 1998; 106:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/11\">",
"      Khoshbin S, Hallett M. Multimodality evoked potentials and blink reflex in multiple sclerosis. Neurology 1981; 31:138.",
"     </a>",
"    </li>",
"    <li>",
"     Stockard JJ, Pope-Stockard JE, Sharbrough FW. Brainstem auditory evoked potentials in neurology: Methodology, interpretation and clinical applications. In: Electrodiagnosis in clinical neurology, 3rd, Aminoff AM (Ed), Churchill-Livingstone, New York 1992. p.503.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27863/abstract/13\">",
"      Jones SJ. Short latency potentials recorded from the neck and scalp following median nerve stimulation in man. Electroencephalogr Clin Neurophysiol 1977; 43:853.",
"     </a>",
"    </li>",
"    <li>",
"     Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders, Butterworth-Heinemann, Boston 1998.",
"    </li>",
"    <li>",
"     Stalberg E, Trontelj JV. Single Fiber Myography, Raven Press, New York 1994.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5274 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27863=[""].join("\n");
var outline_f27_13_27863=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28837089\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ELECTROENCEPHALOGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal EEG findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Abnormal EEG findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Slow wave abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28837034\">",
"      - Abnormalities in encephalopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Epileptogenic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVOKED POTENTIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Visual evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Auditory evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Somatosensory evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NERVE CONDUCTION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sensory nerve conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Motor nerve conduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Motor nerve conduction velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Late responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ELECTROMYOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NEUROMUSCULAR JUNCTION STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Repetitive nerve stimulation study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Single fiber EMG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28837089\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5274|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/62/21476\" title=\"figure 1\">",
"      EEG electrode placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/11/25782\" title=\"figure 2\">",
"      EEG normal awake adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/22/8550\" title=\"figure 3\">",
"      EEG focal slow activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/9/22677\" title=\"figure 4\">",
"      EEG frontal intermittent delta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/59/34741\" title=\"figure 5\">",
"      EEG generalized slow activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/1/16406\" title=\"figure 6\">",
"      EEG high amplitude slow waves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/31/19957\" title=\"figure 7\">",
"      EEG barbiturate effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/41/22166\" title=\"figure 8\">",
"      EEG focal epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/59/18359\" title=\"figure 9\">",
"      EEG tonic clonic seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/34/37411\" title=\"figure 10\">",
"      Recording vis evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/8/35968\" title=\"figure 11\">",
"      Examples vis evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/32/14853\" title=\"figure 12\">",
"      Somatosensory evoked potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/16/2309\" title=\"figure 13\">",
"      Nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/25/15765\" title=\"figure 14\">",
"      Sensory nerve conduction study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/11/32948\" title=\"figure 15\">",
"      Motor nerve conduction study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/7/27760\" title=\"figure 16\">",
"      EMG repetitive stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5274|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/54/18278\" title=\"waveform 1\">",
"      EEG lateral epileptic activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/6/11368\" title=\"waveform 2\">",
"      EEG petit mal epilepsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?18/10/18597\" title=\"waveform 3\">",
"      Auditory evoked potentials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35130?source=related_link\">",
"      Diagnosis of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=related_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/62/1001?source=related_link\">",
"      Herpes simplex virus type 1 encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39251?source=related_link\">",
"      Nerve conduction studies: Late responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/31/2554?source=related_link\">",
"      Overview of nerve conduction studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/0/18434?source=related_link\">",
"      Patient information: EEG (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_13_27864="Pericarditis tutorial";
var content_f27_13_27864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    J point and concave ST segment elevation seen diffusely in most of the precordial and limb leads are the hallmarks of pericarditis. There are no reciprocal ST changes. PR depression is evident in some leads.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27864=[""].join("\n");
var outline_f27_13_27864=null;
var title_f27_13_27865="Screening the newborn for hearing loss";
var content_f27_13_27865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening the newborn for hearing loss",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Lisa M Adcock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Drifa Freysdottir, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27865/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/13/27865/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant hearing loss is the most common disorder at birth, occurring in 1 to 2 per 1000 newborns. Hearing loss leads to delayed language development, difficulties with behavior and psychosocial interactions, and poor academic achievement. Early intervention with speech and language therapy and amplification (eg, hearing aids) improves language outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/1\">",
"     1",
"    </a>",
"    ]. Universal newborn hearing screening (UNHS) identifies congenital hearing loss at an earlier age, allowing for earlier interventions.",
"   </p>",
"   <p>",
"    Screening for hearing loss in the newborn will be reviewed here. The etiology, evaluation, and management of hearing impairment in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"     \"Treatment of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of hearing loss is defined by measuring the hearing threshold in decibels (dB) at various frequencies. Normal hearing has a threshold of 0 to 20 dB. Hearing loss ranges from mild to profound [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/2\">",
"     2",
"    </a>",
"    ] and is defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild &mdash; 20 to 40 dB",
"     </li>",
"     <li>",
"      Moderate &mdash; 41 to 60 dB",
"     </li>",
"     <li>",
"      Severe &mdash; 61 to 90 dB",
"     </li>",
"     <li>",
"      Profound &mdash; &gt;90 dB",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence of moderate, severe, and profound bilateral permanent hearing loss is estimated at 1 in 900 to 2500 newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of neonatal hearing loss can result from conductive, sensorineural, and mixed defects (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"UTD.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conductive loss is generally caused by abnormalities of the outer or middle ear, which limits the amount of external sound that gains access to the inner ear (cochlea and vestibular apparatus). Cochlear function remains normal because the inner ear develops separately from the external and middle ears.",
"     </li>",
"     <li>",
"      Sensorineural hearing loss (SNHL) involves the cochlea or auditory neural pathway. Auditory neuropathy (AN), one type of SNHL, is caused by absent or severely distorted auditory brainstem responses with preservation of conductive and cochlear function.",
"      <br/>",
"      <br/>",
"      Most neonatal hearing impairment is caused by SNHL. Approximately one-half of these cases are due to genetic causes; the remaining causes are acquired. Risk factors associated with acquired SNHL include congenital infections, hyperbilirubinemia, and admission to a newborn intensive care unit (NICU) (",
"      <a class=\"graphic graphic_table graphicRef74313 \" href=\"UTD.htm?30/8/30859\">",
"       table 2",
"      </a>",
"      ). Infants admitted to the NICU are at increased risk for auditory neuropathy compared to those admitted to the normal nursery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'NICU admissions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Mixed loss is a combination of conductive and SNHL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RATIONALE FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening newborns for hearing loss leads to earlier detection and intervention in patients with congenital hearing impairment. Early intervention can improve speech and language development, and educational achievement in affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Earlier detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening newborns detects patients with hearing impairment at an earlier age than relying solely on identifying clinical signs of hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Caregivers and clinicians do not usually detect hearing loss until there is recognition of delayed speech and language milestones.",
"   </p>",
"   <p>",
"    This point was best illustrated by a controlled trial of 53,781 newborn infants who were born in four English hospitals from 1993 to 1996 that alternated periods of time between universal newborn hearing screening (UNHS) and no screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/5\">",
"     5",
"    </a>",
"    ]. Overall, 106 cases of bilateral permanent hearing impairment per 100,000 target population were identified. After adjustment for severity of hearing loss, infants with hearing loss born during periods of screening compared to those without screening were more likely to be detected at an earlier age (odds ratio [OR] 5, 95% CI 1-23) and to receive earlier intervention (OR 8, 95% CI 1.5-41). In a follow-up study, the proportion of seven- to nine-year-old children with permanent hearing impairment who were identified before six months of age was higher during periods of UNHS compared to no screening (74 versus 31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Earlier diagnosis improves outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on several controlled studies of long-term outcome, it appears that earlier diagnosis and intervention in hearing impaired infants can improve language and developmental outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ]. The beneficial effect of early detection and intervention on language development was best demonstrated in a controlled study of 120 children with bilateral permanent hearing loss who were from the birth cohort of the previously mentioned trial comparing universal newborn hearing screening (UNHS) to no screening [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following findings were noted when children who were diagnosed with hearing loss by nine months of age were compared to those diagnosed after nine months of age at eight years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All the patients who were detected by nine months of age had been identified by UNHS.",
"     </li>",
"     <li>",
"      Children whose hearing loss was confirmed by nine months of age compared to those with confirmation of permanent hearing loss after nine months of age had better receptive and language abilities.",
"     </li>",
"     <li>",
"      There was no difference in speech development between the two groups.",
"     </li>",
"     <li>",
"      There were no differences in the severity of hearing loss, the frequency of other disabilities (such as cerebral palsy, visual impairment and learning disability), or parental socioeconomic status between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent report, patients who were identified before nine months of age compared to those diagnosed later also had better reading and communication skills when evaluated at primary school age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results were reported from a population-based study from the Netherlands that compared outcome at three to five years of age of children with permanent hearing impairment identified by newborn screening with those diagnosed by distraction screening at nine months of age between 2002 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/2\">",
"     2",
"    </a>",
"    ]. Multivariate analysis showed the newborn screening group had higher scores for developmental, social development, gross motor development and quality of life testing when evaluated at age three to five years of age.",
"   </p>",
"   <p>",
"    In a prospective study from the Rhode Island UNHS program of infants with hearing loss, enrollment in an early intervention group before three months of age compared to enrollment after three months of age appeared to have beneficial effects on language when patients were tested at 12 to 16 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/10\">",
"     10",
"    </a>",
"    ]. However, this study was limited by the small number of patients with hearing loss in each group, especially those with moderate to profound early loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SCREENING TESTS FOR HEARING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) Task Force on Newborn and Infant Hearing defined an effective neonatal hearing screening test as one that detects hearing loss of &ge;35 dB in the better ear and is reliable in infants &le;3 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two electrophysiologic techniques meet these criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Auditory brainstem responses (ABR)",
"     </li>",
"     <li>",
"      Otoacoustic emissions (OAE)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both ABR and OAE techniques are inexpensive, portable, reproducible, and automated. They evaluate the peripheral auditory system and the cochlea, but cannot assess activity in the highest levels of the central auditory system. These tests alone are not sufficient to diagnose hearing loss; thus, any child who fails one of these screening tests requires further audiologic evaluation. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Further evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Auditory brainstem response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening ABR measures the summation of action potentials from the eighth cranial nerve (cochlear nerve) to the inferior colliculus of the midbrain in response to a click stimulus. Other names for this test include the screening ABR (SABR), brainstem auditory evoked response (BAER), and automated auditory brainstem response (AABR). Approximately 4 percent of infants screened with ABRs are referred for further audiologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. ABR is the screening test needed to detect auditory neuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The screening ABR utilizes click stimuli presented at 35 dB. Three surface electrodes placed on the forehead, nape, and mastoid detect waveform recordings generated by the auditory brainstem response to the click stimuli. The morphology and latency of the waveforms are compared to normal and a pass or fail reading is generated. Delayed or absent waves suggest a neurologic or cochlear deficit. Screening ABR requires 4 to 15 minutes for testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Otoacoustic emissions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otoacoustic emission (OAE) testing measures the presence or absence of sound waves (ie, OAEs) generated by the cochlear outer hair cells of the inner ear in response to sound stimuli. A microphone at the external ear canal detects these low-intensity OAEs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apparatus for OAE screening consists of a miniature microphone placed into the infant's outer ear canal. The microphone produces a stimulus (clicks or tones) and detects sound waves as they arise from the cochlea. The device also measures the signal-to-noise ratio to ensure accuracy.",
"   </p>",
"   <p>",
"    The tests most commonly used for clinical purposes are the distortion product OAEs (DPOAEs) and the transient OAEs (TOAEs). They are classified by the stimuli used to produce the cochlear basal membrane vibrations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DPOAEs are detected when the cochlea is stimulated with two specific frequencies, F1 (65 dB) and F2 (55 dB) that result in a single predictable frequency response. These frequencies travel through the middle ear to the cochlea, where a third tone is generated at the outer hair cell level. Normal cochlear stimulation produces DPOAEs at a specific frequency that is predicted by the formula, (2 &nbsp;x &nbsp;F1) - F2.",
"     </li>",
"     <li>",
"      TOAEs utilize a click stimulus that results in the emission of several frequencies at the same time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OAE testing generally requires approximately four to eight minutes. Approximately 5 to 21 percent of infants screened with this technique are referred for further audiologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparison of ABR and OAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a comparison between the two neonatal screening methods:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Test time &mdash; OAE tends to require less patient preparation time and a shorter test time than ABR [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/15\">",
"       15",
"      </a>",
"      ]. ABR may also present time constraints because infants need to be asleep when tested. In contrast, OAE can be performed when the infant is awake, feeding, or sucking on a pacifier.",
"     </li>",
"     <li>",
"      Interference &mdash; OAE is sensitive to background noise and noise generated by the baby [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/16\">",
"       16",
"      </a>",
"      ]. This noise interference is greater when the recorded frequency is below 1500 Hz. Thus, screening with OAE can be improved by recording higher frequencies, which are more important for understanding speech [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. OAE, unlike ABR, is not subject to movement artifact [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False positive results &mdash; More infants appear to have hearing loss by OAE than by ABR during the first three days of life, most likely a false positive result that is due to occlusion of the external ear canal by vernix [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/18-21\">",
"       18-21",
"      </a>",
"      ]. This can occur in 19 to 25 percent of newborns screened by OAE during the first three days after birth [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. Cleaning of vernix can increase the pass rates [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tympanic membrane mobility &mdash; OAE requires a normal middle ear. Thus, decreased tympanic membrane mobility can reduce screening pass rates with this technique. The magnitude of this problem was illustrated in a series of 200 infants, in which the pass rate in the 23 percent of infants with decreased tympanic membrane mobility was lower with OAE than ABR screening (33 versus 95 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Auditory neuropathy &mdash; Infants at risk for developing auditory neuropathy include those with severe hyperbilirubinemia or neonates who are admitted to NICUs. ABR will detect the hearing loss in infants with auditory neuropathy, but OAE will not, which may lead to a false negative result [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/4,24,25\">",
"       4,24,25",
"      </a>",
"      ]. Thus, ABR should always be used to screen hearing in infants who are at risk for auditory neuropathy (eg, infants with hypoxia, prematurity, hyperbilirubinemia, or neurologic impairment).",
"     </li>",
"     <li>",
"      Relative costs &mdash; Although the actual screening cost is lower for OAE compared to ABR, the overall cost of screening and audiologic evaluation may be lower with ABR because of the lower referral rate for audiologic assessment. One study evaluated screening programs initiated at two sites, one using automated ABR administered by neonatal nurses and the other using OAE performed by master's level audiologists [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/26\">",
"       26",
"      </a>",
"      ]. Less time was needed for testing with OAE than with ABR (5 versus 13 minutes), but the rate of referral for further testing was higher with OAE (15 versus 4 percent). Although the costs before discharge were similar for the two programs, the increased referral rate with OAE increased the overall cost per infant screened.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these comparisons, we suggest that ABR should be included in any screening program to detect hearing loss in the newborn, especially in populations (eg, premature infants) at risk for auditory neuropathy. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SELECTIVE SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to identify hearing impaired patients is to test newborns who are at increased risk for hearing loss. Major risk factors for neonatal sensorineural hearing loss (SNHL) include (",
"    <a class=\"graphic graphic_table graphicRef74313 \" href=\"UTD.htm?30/8/30859\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Admission to a NICU for at least two days.",
"     </li>",
"     <li>",
"      Syndromes associated with SNHL (eg, Waardenburg syndrome).",
"     </li>",
"     <li>",
"      Family history of hereditary childhood SNHL.",
"     </li>",
"     <li>",
"      Craniofacial anomalies (eg, anomalies of the pinna or ear canal).",
"     </li>",
"     <li>",
"      Congenital infection (eg, cytomegalovirus, toxoplasmosis, rubella, syphilis, herpes) or bacterial meningitis.",
"     </li>",
"     <li>",
"      Severe hyperbilirubinemia requiring exchange transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 10 to 30 percent of newborns have one or more of these risk factors. An infant&rsquo;s risk of having a hearing disability rises as the number of risk factors increases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/27\">",
"     27",
"    </a>",
"    ]. A targeted screening program could identify 50 to 75 percent of all cases of moderate to profound bilateral hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/3,28,29\">",
"     3,28,29",
"    </a>",
"    ]. In a retrospective study of permanent childhood hearing impairment in the United Kingdom, screening newborns with a NICU admission, positive family history, or craniofacial abnormality detected approximately 60 percent of infants with hearing impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, selective screening alone would delay the detection of hearing loss in a substantial number of children with congenital hearing loss who do not have any identifiable risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/3,6,14,19,30-33\">",
"     3,6,14,19,30-33",
"    </a>",
"    ]. As a result, health care organizations, professional societies, and the United States Preventive Task Force recommend universal screening for newborn infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Rationale for screening'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Universal screening'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     NICU admissions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants admitted to the NICU are at increased risk for hearing loss including auditory neuropathy (AN), with about a 2 percent rate of hearing loss.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 4250 infants screened by ABR for hearing loss in a single NICU from 1999 to 2003, 2.1 percent (95 neonates) failed the hearing screening. All patients had sensorineural hearing loss (SNHL), including 71 with cochlear abnormalities and 24 with AN [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Netherlands, the prevalence of hearing loss in infants admitted to the NICU was 1.8 percent in infants based upon data from the NICU hearing screening and the national neonatology databases for 2002 to 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/35\">",
"       35",
"      </a>",
"      ]. Risk factors associated with hearing loss included central nervous system disorders, cardiopulmonary compromise, intrauterine infection, and craniofacial, chromosomal and syndromal anomalies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Premature infants are at increased risk for SNHL. In a nested case-control Norwegian study, for example, children with birthweights less than 1500 g had a six-fold greater risk for hearing loss compared to children with birth weights between 3500 and 3999 g [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the increased risk for SNHL, especially AN, in patients admitted to the NICU, the Joint Committee on Infant Hearing (JCIH), which encompasses seven national organizations including the American Academies of Pediatrics, Audiology, and Otolaryngology-Head and Neck Surgery, recommends ABR screening for these patients since OAE screening will fail to detect those with AN [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Follow-up after discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risk of hearing loss for patients admitted to the NICU, at least one audiologic reassessment between 24 and 30 months of age is recommended by the Joint Committee on Infant Hearing for any infant requiring more than five days of NICU care and one or more of the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"     37",
"    </a>",
"    ]. This assessment should be performed even if the infant passed the newborn hearing screen prior to discharge.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Received extracorporeal membrane oxygenation (ECMO) therapy",
"     </li>",
"     <li>",
"      Received mechanical ventilation",
"     </li>",
"     <li>",
"      Exposed to nephrotoxic drugs such as aminoglycosides (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/39/22129?source=see_link\">",
"       tobramycin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ) and loop diuretics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"       furosemide",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperbilirubinemia that required exchange transfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, very low birth weight premature infants (birth weights below 1500 g) are at risk of experiencing progressive or delayed-onset hearing loss. As a result, these infants should have follow-up monitoring with a diagnostic hearing test by 12 months adjusted chronologic age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     UNIVERSAL SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1990's, the development of rapid, low-cost screening tests made it feasible for all newborns to be screened for hearing during birth hospitalization. The goal of universal newborn hearing screening (UNHS) is early recognition and treatment of hearing impairment, which may maximize linguistic competence and literary development of children who are deaf or hard of hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37,40\">",
"     37,40",
"    </a>",
"    ]. With the widespread adoption of UNHS, the age at identification of hearing loss has decreased from a range of 24 to 30 months to 2 to 3 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of UNHS was demonstrated in an analysis by the Center of Disease Control and Prevention (CDC) based upon surveillance data from the Early Hearing Detection and Intervention Programs in all 50 states and United States territories [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/42\">",
"     42",
"    </a>",
"    ]. Nearly 500 more infants with documented hearing loss were identified in 2007 compared to 2001 in the 21 states that had reported data for both years. As of 2007, 97 percent of infants were screened for hearing loss in the United States.",
"   </p>",
"   <p>",
"    In a prospective study from Belgium, further evaluation of 170 consecutive infants who failed UNHS (from a database representing the equivalent of 87,000 screened newborns [0.2 percent]) confirmed permanent hearing loss in 116 patients including bilateral loss in 68 infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/43\">",
"     43",
"    </a>",
"    ]. In half of the patients, hearing loss was severe with median thresholds of 70 dB nHL and 80 dB nHL in cases with unilateral and bilateral involvement, respectively. An etiology for the hearing loss was determined in about half of the patients. In these cases with an identified cause, genetic disease, perinatal problem, and congenital cytomegalovirus infection were diagnosed in 67, 20 and 19 percent of patients, respectively.",
"   </p>",
"   <p>",
"    Unfortunately, UNHS cannot identify all cases of pediatric hearing loss since hearing disability can evolve after the newborn period. This is shown by a review of cochlear implant candidates in which 30 percent had passed their initial hearing screen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/44\">",
"     44",
"    </a>",
"    ]. In a longitudinal study following a birth cohort of 35,688 infants, only 49 percent of children found to have permanent hearing loss at school entry had failed their initial UNHS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a 2008 statement, the United States Preventive Services Task Force (USPSTF) recommended UNHS based upon its review of the evidence that demonstrated currently available inexpensive screening tests can accurately identify newborns with permanent hearing loss, and early detection improved language outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/1,46\">",
"     1,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The USPSTF statement supports the recommendation of the Joint Committee on Infant Hearing (JCIH) in 2007 of implementing an integrated, interdisciplinary system of UNHS to detect and treat early hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"     37",
"    </a>",
"    ]. The JCIH includes seven professional societies; American Academies of Audiology, Pediatrics (AAP), Otolaryngology-Head and Neck Surgery, the American Speech-Language-Hearing Association (ASHA), the Council on Education of the Deaf, Directors of Speech and Hearing Programs in State Health and Welfare Agencies, and the Alexander Graham Bell Association for the Deaf and Hard of Hearing.",
"   </p>",
"   <p>",
"    The JCIH and USPSTF recommendations include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All newborns should be screened before they reach one month of age. Either otoacoustic emissions (OAE) or auditory brainstem response (ABR) can be used in a single stage or two stage UNHS protocol. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'UNHS protocols'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Audiologic assessment of all infants who fail their screening test by three months of age (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Further evaluation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"       \"Evaluation of hearing impairment in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intervention for those infants with significant hearing impairment by six months of age designed to meet the individualized needs of the infant and family. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=see_link\">",
"       \"Treatment of hearing impairment in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Program attributes",
"    </span>",
"    &nbsp;&mdash;&nbsp;To fulfill these recommendations, a screening program with a medical director and adequate trained staff should be established at each birth hospital.",
"   </p>",
"   <p>",
"    Attributes of an effective screening program include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/11,37\">",
"     11,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening a minimum of 95 percent of infants before hospital discharge. Either OAE or ABR can be used for normal term infants but for infants at risk for auditory neuropathy (eg, infants admitted to the NICU), screening ABR should be used. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'NICU admissions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Comparison of ABR and OAE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A false-positive rate (infants with a positive screening test who do not have hearing loss) &le;3 percent and a rate of referral for audiologic testing after a positive screening result &le;4 percent.",
"     </li>",
"     <li>",
"      A false-negative rate (infants with significant hearing loss who are missed by the screening test) of zero.",
"     </li>",
"     <li>",
"      A follow-up rate of infants referred for audiologic assessment and for infants who were not screened in their birthing hospital (whose parents did not refuse screening) of at least 95 percent.",
"     </li>",
"     <li>",
"      Rescreening for infants who are readmitted within the first month of life for conditions associated with potential hearing loss (eg, hyperbilirubinemia).",
"     </li>",
"     <li>",
"      An effective communication system that ensures results of screening tests from the birth hospital are conveyed to the family and the designated primary care provider and referral of infants who fail the screening test for audiologic assessment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     UNHS protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two types of universal screening protocols routinely used are single- or two-stage UNHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Single stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single-stage UNHS utilizes a single screening test, either OAE or ABR, which detects 80 to 95 percent of ears with hearing impairment. With either single test, there is a high false positive rate resulting in a substantial number of referred infants with normal hearing for audiologic assessment, thereby increasing the overall cost of UNHS. Referral for audiologic evaluation is generally required for 4 percent of infants screened with ABR [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] and between 5 to 21 percent of infants screened with OAE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/14\">",
"     14",
"    </a>",
"    ]. The prevalence of moderate to severe hearing loss is estimated to be one case for every 900 to 2500 newborn infants. Thus, for one case of significant hearing loss, the number of infants with normal hearing referred for audiologic evaluation would range from 40 to 500 patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Two stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-stage screening protocol uses two screening tests. In this protocol, only patients who fail the initial test require a second screening study, and only patients who fail both tests are referred for audiologic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/47\">",
"     47",
"    </a>",
"    ]. Two studies that utilized a two stage UNHS reported that approximately 900 to 1400 infants would need to be screened to identify one case of bilateral hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/5,48\">",
"     5,48",
"    </a>",
"    ]. It is estimated that one of every 45 infants from the well-baby nursery referred for audiologic evaluation by a two stage UNHS would have moderate to profound bilateral permanent hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two-stage compared to single stage UNHS decreases the referral rate for audiologic assessment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Taiwan, referral rates decreased from 5.8 to 1.8 percent after screening was changed from a single (OAE) to two stage protocol (OAE followed by ABR) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of the 346 newborns referred to a Dutch single center after initially failing the first stage of OAE screening, second (ABR) stage screening found 21 percent had normal hearing [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/50\">",
"       50",
"      </a>",
"      ]. Bilateral sensorineural with or without conductive hearing loss in one or both ears occurred in 43 percent of infants, unilateral sensorineural hearing loss with or without conductive loss in 15 percent, and conductive hearing loss in one or both ears occurred in 20 percent of infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two-stage screening may miss infants with hearing loss, because it inaccurately assumes that all infants who fail the initial screen but pass the second have normal hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/47,51\">",
"     47,51",
"    </a>",
"    ]. As an example, a study conducted in seven birthing centers demonstrated that two-stage UNHS (OAE and ABR) failed to detect a number of infants with hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/47\">",
"     47",
"    </a>",
"    ]. In this study, UNHS identified 158 of 86,634 infants with hearing loss who failed both stages of UNHS. In addition, 4 percent of infants (n = 3465) failed the initial OAE but passed the ABR, and were presumed to have normal hearing. Audiologic assessment using visual reinforcement audiometry (VRA) was performed at &ge;8 months in 44 percent of these infants (n = 1520) and identified 21 additional patients with hearing loss. Most of these patients had mild hearing loss and in 9 infants hearing loss was bilateral. The number of hearing impaired infants missed by UNHS in this study was probably underestimated because only 44 percent of patients who failed the first but passed the second test underwent VRA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the well baby nursery setting, we suggest performing two-stage UNHS primarily to decrease the number of infants with normal hearing who would need referral for further audiologic assessment. In many nurseries, the OAE is used as the initial test because it takes less time to administer, its cost is lower than ABR, it is not dependent on the infant being asleep, as is the case for ABR, and there is a low incidence of auditory neuropathy in infants admitted to the well nursery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/52\">",
"     52",
"    </a>",
"    ]. Infants who fail the OAE test are then screened using ABR. However, for infants admitted to the NICUs, we suggest ABR as the screen due to the increased risk of auditory neuropathy in this population. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'NICU admissions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For all infants, continued surveillance by the primary care provider for hearing problems is recommended and includes assessment of developmental milestones, auditory skills, parental concerns, and the status of the middle-ear during routine well child visits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, increased oversight by the primary care provider is suggested for infants who fail the initial screen but pass the second screening test as they are still at risk for hearing impairment.",
"   </p>",
"   <p>",
"    If a program decides to utilize only a one-stage UNHS, we suggest screening with ABR, which results in a lower false positive rate and lower referral rate for audiologic assessment than OAE. In addition, ABR (but not OAE) can detect infants with auditory neuropathy (AN) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. This is especially important if the screening population includes infants who are at risk for AN such as premature infants or those with hyperbilirubinemia. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Comparison of ABR and OAE'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Infants who failed UNHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success of a UNHS program is dependent upon ensuring that every infant who fails the initial screening test be assessed by audiologic evaluation by three months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"     37",
"    </a>",
"    ]. However, infants with significant hearing loss can be missed if they cannot be located due to inadequate tracking procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned CDC report, the number of infants who had failed UNHS who were lost-to-follow-up decreased from 64 to 46 percent from 2005 to 2007 in 44 states and territories [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/42\">",
"     42",
"    </a>",
"    ]. In Massachusetts and Colorado the UNHS programs actively follow-up with families and providers, resulting in a failure rate of only about 6 percent.",
"   </p>",
"   <p>",
"    Poor socioeconomic status is associated with loss to follow-up for audiologic evaluation after a positive screening test.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 39,153 newborns screened in Rhode Island, infants with traditional Medicaid insurance were significantly less likely to be rescreened than those with commercial health insurance or managed care Medicaid [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were reported in a retrospective review with fewer NICU graduates with Medicaid coverage than those with private insurance returning for follow-up (51 versus 78 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/54\">",
"       54",
"      </a>",
"      ]. Infants with Medicaid coverage and hearing loss also obtained hearing aids at a later age (50 versus 28 weeks of age).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from Massachusetts from 2002 to 2003, 11 percent of infants who did not pass the hearing screening test were lost to follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/55\">",
"     55",
"    </a>",
"    ]. Children were at increased risk for not returning to follow-up if their mothers were nonwhite, covered by public insurance, or smokers during pregnancy.",
"   </p>",
"   <p>",
"    Other barriers to adequate follow-up include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient support system to track patients with a positive screening test",
"     </li>",
"     <li>",
"      Primary care provider lack of knowledge regarding screening test results",
"     </li>",
"     <li>",
"      Challenges to families in obtaining services",
"     </li>",
"     <li>",
"      Insufficient number of audiologists to perform further evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Targeting these challenges especially for at-risk groups may improve return rates for further audiologic evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Reassessment of at-risk infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with risk factors for hearing loss and who have passed the neonatal screening, still are at-risk for hearing loss. As a result, the Joint Committee on Infant Hearing recommends audiologic reassessment between 24 and 30 months of age for any infant with the following risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of permanent childhood hearing loss",
"     </li>",
"     <li>",
"      Congenital infections such as cytomegalovirus, herpes simplex, rubella, syphilis, and toxoplasmosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link\">",
"       \"Overview of TORCH infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Craniofacial anomalies including those that involve the pinna, ear canal, ear tags, ear pits, and temporal bone anomalies",
"     </li>",
"     <li>",
"      Syndromes associated with deafness including Waardenburg syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H24#H24\">",
"       \"The genodermatoses\", section on 'Waardenburg syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Culture-positive postnatal infections associated with sensorineural hearing loss including bacterial and viral meningitis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"       \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reassessment of hearing may also be needed in NICU survivors who are also at risk for hearing loss. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'NICU admissions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost of UNHS in statewide programs ranges from $7 to $30 per infant screened [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/11,26\">",
"     11,26",
"    </a>",
"    ]. A higher rate of referral for audiologic assessment will increase the cost. This rate is comparable to that for metabolic screening, although the incidence of hearing impairment is higher. The cost of identifying one affected child is approximately $4000 to $22,000 for hearing loss compared to $10,000 for phenylketonuria and $40,000 for hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/24\">",
"     24",
"    </a>",
"    ]. Additional cost savings may accrue if UNHS results in fewer children who require special education and fewer adults with resultant disability [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     State laws",
"    </span>",
"    &nbsp;&mdash;&nbsp;By 2007, all the states in the United States had implemented newborn screen programs for hearing. As a result, approximately 97 percent of newborn infants born in the United States are screened before hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition, universal newborn and infant hearing screening laws have been passed in 41 of the 50 states and legislation is pending in two other states. Practitioners should know whether UNHS is mandated in their state, including the specific legal requirements. Information for each state is available at the following web site: (",
"    <a class=\"external\" href=\"file://www.asha.org/advocacy/state/default.htm\">",
"     file://www.asha.org/advocacy/state/default.htm",
"    </a>",
"    , accessed October 29, 2009).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     FURTHER EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual reinforcement audiometry (VRA) is the gold standard for hearing assessment for non-verbal children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/57\">",
"     57",
"    </a>",
"    ]. However, VRA cannot be performed reliably before the infant is eight to nine months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/58\">",
"     58",
"    </a>",
"    ]. Until VRA can be performed, infants who fail a screening test should have a diagnostic ABR performed, which includes testing with click stimuli and tone burst stimuli from loud (80 to 90 dB) to soft (0 to 20 dB). The audiological evaluation of infants is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of hearing impairment in children\", section on 'Behavioral testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13123006\">",
"    <span class=\"h1\">",
"     QUALITY ASSURANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite, the recommendation from medical societies and the United States Preventive Services, the implementation of developing an integrated, interdisciplinary system of UNHS that detects and treats early hearing loss is challenging as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based review of UNHS in Colorado in 2006 and 2007 (covering 204,694 births) revealed 98 percent screening in the newborn period. However, of the newborns with abnormal screening results, only 82 percent received targeted follow-up. Those infants lost to follow-up constituted a high risk group for hearing loss because they were more likely to have had low APGAR scores",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low birthweight [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      National data for 2007 documented 97 percent of newborns were screened for hearing loss although only 85.4 percent were tested by 1 month of age [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/42\">",
"       42",
"      </a>",
"      ]. Forty-six percent of infants with an abnormal initial screen were never documented as having had a follow-up diagnostic evaluation. Enrollment in early intervention by six months of age was documented in 60.8 percent of infants with abnormal hearing. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a 10-year quality assurance review of the two-stage screening program for Dutch NICU graduates demonstrated 96 percent of patients were screened before one month of corrected gestational age, and 82 percent tested before six weeks of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27865/abstract/60\">",
"     60",
"    </a>",
"    ]. Two thirds of the patients with hearing loss were diagnosed before three months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/19/34097?source=see_link\">",
"       \"Patient information: Screening for hearing loss in newborns (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant hearing loss occurs in one to two newborns per 1000 live births. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newborn screening detects hearing loss at an earlier age, resulting in earlier intervention (eg, use of hearing devices, and speech and language therapy). Earlier detection and intervention (before 10 months of age) improves language development. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Rationale for screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two electrophysiologic techniques, auditory brainstem responses (ABR) and otoacoustic emissions (OAE), are routinely used as screening tests. Both tests are portable, automated, and inexpensive, making them well suited to newborn screening. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Screening tests for hearing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Targeted selective screening for at-risk infants would identify 50 to 75 percent of all cases of moderate to profound bilateral hearing loss. &nbsp;As a result, hearing loss in a substantial number of hearing impaired neonates would be delayed with only selective screening. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Selective screening'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Universal screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All the states in the United States have implemented UNHS programs and most states have laws mandating UNHS. Clinicians should be familiar with their state laws. Information for each state is available at the following web site: (",
"      <a class=\"external\" href=\"file://www.asha.org/about/legislation-advocacy/state/issues/overview.htm\">",
"       www.asha.org/about/legislation-advocacy/state/issues/overview.htm",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'State laws'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two types of UNHS include one-stage, which utilizes a single screening test (ie, ABR or OAE), or two-stage, which utilizes two screening tests. In the two-stage UNHS, only patients who fail the initial test receive a second screening study, and only patients who fail both tests are referred for audiologic assessment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Screening tests for hearing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Universal screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When UNHS is implemented, we suggest the use of a two-stage UNHS versus the one-stage protocol (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). At our institution, we use OAE as the initial test in healthy term infants, followed by ABR if the OAE is abnormal. For infants admitted to the neonatal intensive care unit, we use ABR to screen for hearing loss. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'UNHS protocols'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a one-stage UNHS is utilized, we suggest ABR be used as the screening test versus OAE (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants who fail a screening test require additional audiologic evaluation. Infants less than eight months of age should be referred for diagnostic ABR. Hearing loss should be confirmed by visual reinforcement audiometry (VRA) when VRA can be performed reliably (usually greater than eight months of age). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Further evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although UNHS has improved the early recognition of hearing impairment, there are still infants with hearing loss not detected by UNHS. Therefore, a normal hearing screen should not be completely reassuring. Monitoring of infants for hearing loss should continue during routine primary care visits, particularly those who are at-risk",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those who failed the initial stage of screening of a two-stage UNHS. In addition, infants who pass the neonatal screening but have a risk factor for hearing loss (",
"      <a class=\"graphic graphic_table graphicRef74313 \" href=\"UTD.htm?30/8/30859\">",
"       table 2",
"      </a>",
"      ) should have audiologic assessment performed by 24 to 30 months of age. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/1\">",
"      US Preventive Services Task Force. Universal screening for hearing loss in newborns: US Preventive Services Task Force recommendation statement. Pediatrics 2008; 122:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/2\">",
"      Korver AM, Konings S, Dekker FW, et al. Newborn hearing screening vs later hearing screening and developmental outcomes in children with permanent childhood hearing impairment. JAMA 2010; 304:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/3\">",
"      Thompson DC, McPhillips H, Davis RL, et al. Universal newborn hearing screening: summary of evidence. JAMA 2001; 286:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/4\">",
"      Berg AL, Spitzer JB, Towers HM, et al. Newborn hearing screening in the NICU: profile of failed auditory brainstem response/passed otoacoustic emission. Pediatrics 2005; 116:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/5\">",
"      Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment. Wessex Universal Neonatal Hearing Screening Trial Group. Lancet 1998; 352:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/6\">",
"      Russ SA, Rickards F, Poulakis Z, et al. Six year effectiveness of a population based two tier infant hearing screening programme. Arch Dis Child 2002; 86:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/7\">",
"      Kennedy C, McCann D, Campbell MJ, et al. Universal newborn screening for permanent childhood hearing impairment: an 8-year follow-up of a controlled trial. Lancet 2005; 366:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/8\">",
"      Kennedy CR, McCann DC, Campbell MJ, et al. Language ability after early detection of permanent childhood hearing impairment. N Engl J Med 2006; 354:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/9\">",
"      McCann DC, Worsfold S, Law CM, et al. Reading and communication skills after universal newborn screening for permanent childhood hearing impairment. Arch Dis Child 2009; 94:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/10\">",
"      Vohr B, Jodoin-Krauzyk J, Tucker R, et al. Early language outcomes of early-identified infants with permanent hearing loss at 12 to 16 months of age. Pediatrics 2008; 122:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/11\">",
"      Erenberg A, Lemons J, Sia C, et al. Newborn and infant hearing loss: detection and intervention.American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998- 1999. Pediatrics 1999; 103:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/12\">",
"      Pickett BP, Ahlstrom K. Clinical evaluation of the hearing-impaired infant. Otolaryngol Clin North Am 1999; 32:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/13\">",
"      van Straaten HL. Automated auditory brainstem response in neonatal hearing screening. Acta Paediatr Suppl 1999; 88:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/14\">",
"      Finitzo T, Albright K, O'Neal J. The newborn with hearing loss: detection in the nursery. Pediatrics 1998; 102:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/15\">",
"      Hahn M, Lamprecht-Dinnesen A, Heinecke A, et al. Hearing screening in healthy newborns: feasibility of different methods with regard to test time. Int J Pediatr Otorhinolaryngol 1999; 51:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/16\">",
"      Hall JW 3rd. Screening for and assessment of infant hearing impairment. J Perinatol 2000; 20:S113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/17\">",
"      Headley GM, Campbell DE, Gravel JS. Effect of neonatal test environment on recording transient-evoked otoacoustic emissions. Pediatrics 2000; 105:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/18\">",
"      Callison DM. Audiologic evaluation of hearing-impaired infants and children. Otolaryngol Clin North Am 1999; 32:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/19\">",
"      Stewart DL, Mehl A, Hall JW 3rd, et al. Universal newborn hearing screening with automated auditory brainstem response: a multisite investigation. J Perinatol 2000; 20:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/20\">",
"      Olsha M, Newmark M, Bresloff I, et al. Otological evaluation of newborns who failed otoacoustic emission screening. J Basic Clin Physiol Pharmacol 1999; 10:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/21\">",
"      Doyle KJ, Rodgers P, Fujikawa S, Newman E. External and middle ear effects on infant hearing screening test results. Otolaryngol Head Neck Surg 2000; 122:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/22\">",
"      Eavey RD. Abnormalities of the neonatal ear: otoscopic observations, histologic observations, and a model for contamination of the middle ear by cellular contents of amniotic fluid. Laryngoscope 1993; 103:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/23\">",
"      Hall JW 3rd. Development of the ear and hearing. J Perinatol 2000; 20:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/24\">",
"      Stone KA, Smith BD, Lembke JM, et al. Universal newborn hearing screening. J Fam Pract 2000; 49:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/25\">",
"      Rhee CK, Park HM, Jang YJ. Audiologic evaluation of neonates with severe hyperbilirubinemia using transiently evoked otoacoustic emissions and auditory brainstem responses. Laryngoscope 1999; 109:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/26\">",
"      Lemons J, Fanaroff A, Stewart EJ, et al. Newborn hearing screening: costs of establishing a program. J Perinatol 2002; 22:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/27\">",
"      Bielecki I, Horbulewicz A, Wolan T. Risk factors associated with hearing loss in infants: an analysis of 5282 referred neonates. Int J Pediatr Otorhinolaryngol 2011; 75:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/28\">",
"      Fortnum H, Davis A. Epidemiology of permanent childhood hearing impairment in Trent Region, 1985-1993. Br J Audiol 1997; 31:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/29\">",
"      Chu K, Elimian A, Barbera J, et al. Antecedents of newborn hearing loss. Obstet Gynecol 2003; 101:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/30\">",
"      Harrison M, Roush J. Age of suspicion, identification, and intervention for infants and young children with hearing loss: a national study. Ear Hear 1996; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/31\">",
"      Stein, L. On the real age of identification of congenital hearing loss. Audiology Today 1995; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/32\">",
"      Parving A. The need for universal neonatal hearing screening--some aspects of epidemiology and identification. Acta Paediatr Suppl 1999; 88:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/33\">",
"      Kountakis SE, Skoulas I, Phillips D, Chang CY. Risk factors for hearing loss in neonates: a prospective study. Am J Otolaryngol 2002; 23:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/34\">",
"      Xoinis K, Weirather Y, Mavoori H, et al. Extremely low birth weight infants are at high risk for auditory neuropathy. J Perinatol 2007; 27:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/35\">",
"      van Dommelen P, Mohangoo AD, Verkerk PH, et al. Risk indicators for hearing loss in infants treated in different neonatal intensive care units. Acta Paediatr 2010; 99:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/36\">",
"      Engdahl B, Eskild A. Birthweight and the risk of childhood sensorineural hearing loss. Paediatr Perinat Epidemiol 2007; 21:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/37\">",
"      American Academy of Pediatrics, Joint Committee on Infant Hearing. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. Pediatrics 2007; 120:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/38\">",
"      Harlor AD Jr, Bower C, Committee on Practice and Ambulatory Medicine, Section on Otolaryngology-Head and Neck Surgery. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics 2009; 124:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/39\">",
"      Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. Arch Dis Child Fetal Neonatal Ed 2008; 93:F462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/40\">",
"      Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003; 348:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/41\">",
"      Porter HL, Neely ST, Gorga MP. Using benefit-cost ratio to select Universal Newborn Hearing Screening test criteria. Ear Hear 2009; 30:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/42\">",
"      Centers for Disease Control and Prevention (CDC). Identifying infants with hearing loss - United States, 1999-2007. MMWR Morb Mortal Wkly Rep 2010; 59:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/43\">",
"      Declau F, Boudewyns A, Van den Ende J, et al. Etiologic and audiologic evaluations after universal neonatal hearing screening: analysis of 170 referred neonates. Pediatrics 2008; 121:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/44\">",
"      Young NM, Reilly BK, Burke L. Limitations of universal newborn hearing screening in early identification of pediatric cochlear implant candidates. Arch Otolaryngol Head Neck Surg 2011; 137:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/45\">",
"      Watkin PM, Baldwin M. Identifying deafness in early childhood: requirements after the newborn hearing screen. Arch Dis Child 2011; 96:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/46\">",
"      Nelson HD, Bougatsos C, Nygren P, 2001 US Preventive Services Task Force. Universal newborn hearing screening: systematic review to update the 2001 US Preventive Services Task Force Recommendation. Pediatrics 2008; 122:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/47\">",
"      Johnson JL, White KR, Widen JE, et al. A multicenter evaluation of how many infants with permanent hearing loss pass a two-stage otoacoustic emissions/automated auditory brainstem response newborn hearing screening protocol. Pediatrics 2005; 116:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/48\">",
"      Prieve BA, Stevens F. The New York State universal newborn hearing screening demonstration project: introduction and overview. Ear Hear 2000; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/49\">",
"      Lin HC, Shu MT, Lee KS, et al. Comparison of hearing screening programs between one step with transient evoked otoacoustic emissions (TEOAE) and two steps with TEOAE and automated auditory brainstem response. Laryngoscope 2005; 115:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/50\">",
"      Holster IL, Hoeve LJ, Wieringa MH, et al. Evaluation of hearing loss after failed neonatal hearing screening. J Pediatr 2009; 155:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/51\">",
"      Norton SJ, Gorga MP, Widen JE, et al. Identification of neonatal hearing impairment: evaluation of transient evoked otoacoustic emission, distortion product otoacoustic emission, and auditory brain stem response test performance. Ear Hear 2000; 21:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/52\">",
"      Berg AL, Prieve BA, Serpanos YC, Wheaton MA. Hearing screening in a well-infant nursery: profile of automated ABR-fail/OAE-pass. Pediatrics 2011; 127:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/53\">",
"      Vohr BR, Moore PE, Tucker RJ. Impact of family health insurance and other environmental factors on universal hearing screen program effectiveness. J Perinatol 2002; 22:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/54\">",
"      Oghalai JS, Chen L, Brennan ML, et al. Neonatal hearing loss in the indigent. Laryngoscope 2002; 112:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/55\">",
"      Liu CL, Farrell J, MacNeil JR, et al. Evaluating loss to follow-up in newborn hearing screening in Massachusetts. Pediatrics 2008; 121:e335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/56\">",
"      Shulman S, Besculides M, Saltzman A, et al. Evaluation of the universal newborn hearing screening and intervention program. Pediatrics 2010; 126 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/57\">",
"      Vohr BR, Carty LM, Moore PE, Letourneau K. The Rhode Island Hearing Assessment Program: experience with statewide hearing screening (1993-1996). J Pediatr 1998; 133:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/58\">",
"      Widen JE, Folsom RC, Cone-Wesson B, et al. Identification of neonatal hearing impairment: hearing status at 8 to 12 months corrected age using a visual reinforcement audiometry protocol. Ear Hear 2000; 21:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/59\">",
"      Christensen M, Thomson V, Letson GW. Evaluating the reach of universal newborn hearing screening in Colorado. Am J Prev Med 2008; 35:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27865/abstract/60\">",
"      van Dommelen P, van Straaten HL, Verkerk PH, Dutch NICU Neonatal Hearing Screening Working Group. Ten-year quality assurance of the nationwide hearing screening programme in Dutch neonatal intensive care units. Acta Paediatr 2011; 100:1097.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4985 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-125.39.66.150-851E2265C2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27865=[""].join("\n");
var outline_f27_13_27865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RATIONALE FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Earlier detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Earlier diagnosis improves outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SCREENING TESTS FOR HEARING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Auditory brainstem response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Otoacoustic emissions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparison of ABR and OAE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SELECTIVE SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NICU admissions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Follow-up after discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      UNIVERSAL SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Program attributes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      UNHS protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Single stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Two stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Infants who failed UNHS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Reassessment of at-risk infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      State laws",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      FURTHER EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13123006\">",
"      QUALITY ASSURANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4985\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4985|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/62/5101\" title=\"table 1\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/8/30859\" title=\"table 2\">",
"      Risk factors for hearing loss",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/19/34097?source=related_link\">",
"      Patient information: Screening for hearing loss in newborns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29927?source=related_link\">",
"      Treatment of hearing impairment in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_13_27866="Epidemiology and risk factors for exocrine pancreatic cancer";
var content_f27_13_27866=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and risk factors for exocrine pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Carlos Fernandez-del Castillo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Ramon E Jimenez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/13/27866/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/13/27866/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the only potentially curative treatment for exocrine pancreatic cancer, but because of the late presentation of the disease, only 15 to 20 percent of patients are candidates for pancreatectomy. Furthermore, the prognosis of pancreatic cancer is poor even in those with potentially resectable disease. The five-year survival following pancreaticoduodenectomy is only about 25 to 30 percent for node-negative and 10 percent for node-positive tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk factors for carcinoma of the exocrine pancreas will be reviewed here. The pathology, molecular pathogenesis, clinical manifestations, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13513?source=see_link\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 45,220 patients are diagnosed with cancer of the exocrine pancreas annually, and almost all are expected to die from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/1\">",
"     1",
"    </a>",
"    ]. Pancreatic cancer is the fourth leading cause of cancer-related death in the United States among both men and women. The majority of these tumors (85 percent) are adenocarcinomas arising from the ductal epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Worldwide, pancreatic cancer is the eighth leading cause of cancer deaths in men (138,100 deaths annually) and the ninth in women (127,900 deaths annually) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/2\">",
"     2",
"    </a>",
"    ]. In general, pancreatic cancer affects more individuals inhabiting the",
"    <span class=\"nowrap\">",
"     Western/industrialized",
"    </span>",
"    parts of the world; the highest incidence is reported among Maoris in New Zealand, native Hawaiians, and Black American populations, while people living in India and Nigeria have the lowest reported incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease is rare before the age of 45, but the incidence rises sharply thereafter. The incidence is greater in males than females (male-to-female ratio 1.3:1) and in blacks (14.8 per 100,000 in black males compared to 8.8 per 100,000 in the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hereditary risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for familial aggregation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genetic factors is suggested by the fact that 5 to 10 percent of patients with exocrine pancreatic cancer have a first degree relative with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. In multiple case-control and cohort studies of kindreds with familial aggregations, the risk developing pancreatic cancer for an individual with a family history of the disease ranges from 1.5 to 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/12-20\">",
"     12-20",
"    </a>",
"    ]. Risk appears to be particularly high for individuals from families with a case of young-onset pancreatic cancer (under the age of 50) in the kindred [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients from affected families present at an earlier age than those with noninherited disease, and smoking appears to contribute to the risk of developing pancreatic cancer in affected families [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Segregation models support a dominant susceptibility gene for pancreatic cancer that is carried by approximately seven in every 1000 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies suggest that between 3 and 16 percent of patients with pancreatic cancer have a known genetic syndrome that predisposes them to the disease or a strong family history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/7,10-12,24\">",
"     7,10-12,24",
"    </a>",
"    ]. Hereditary factors can predispose to pancreatic cancer directly or indirectly, as with hereditary chronic pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hereditary pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary pancreatitis is an autosomal dominant disorder that accounts for a small fraction of cases of chronic pancreatitis. The majority of affected individuals develop symptoms before the age of 20, and often before the age of five. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link\">",
"     \"Hereditary pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary pancreatitis is associated with a markedly increased risk of pancreatic cancer, although it accounts for a very small fraction of pancreatic cancer cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The magnitude of risk was evaluated in a French study of 78 families with 200 patients with hereditary pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/26\">",
"     26",
"    </a>",
"    ]. The cumulative risk of pancreatic cancer in affected family members was 10, 19, and 54 percent at 50, 60, and 75 years, respectively. The standardized incidence ratio compared to the general population was 87 (95% CI 42-113). The risk was highest in smokers and in those with diabetes mellitus.",
"   </p>",
"   <p>",
"    Similar findings were noted in a study of 112 families in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/27\">",
"     27",
"    </a>",
"    ]. The cumulative risk of pancreatic cancer at 70 years from symptom onset was 44 percent (standardized incidence ratio 67). There was an increasingly high risk after age 50.",
"   </p>",
"   <p>",
"    Not surprisingly, the mortality rate compared to the general population is significantly increased in patients with hereditary pancreatitis who develop pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, mortality does not appear to be increased in patients without pancreatic cancer.",
"   </p>",
"   <p>",
"    Autosomal dominant hereditary pancreatitis is most often associated with mutations in serine protease 1 gene (PRSS1) on chromosome 7q35, which encodes cationic trypsinogen. Rarely, autosomal-dominant-appearing hereditary pancreatitis is identified in a kindred that does not have an identifiable PRSS1 mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=see_link&amp;anchor=H2#H2\">",
"     \"Hereditary pancreatitis\", section on 'Genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A consensus committee of the European Registry of Hereditary Pancreatic Diseases, Midwest Multi-Center Pancreatic Study Group, International Association of Pancreatology recommended screening for pancreatic cancer in individuals with hereditary pancreatitis starting at age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/30\">",
"     30",
"    </a>",
"    ]. No definitive statement was made regarding the frequency of screening or the optimal surveillance strategy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Screening for high-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Inherited cancer susceptibility syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancer aggregates in some families; approximately 5 to 10 percent of individuals with pancreatic cancer have a family history of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/7,31\">",
"     7,31",
"    </a>",
"    ]. There are two broad categories of hereditary risk for pancreatic cancer: defined syndromes in which patients are at risk for a number of malignancies, including pancreatic cancer (",
"    <a class=\"graphic graphic_table graphicRef61283 \" href=\"UTD.htm?11/14/11500\">",
"     table 1",
"    </a>",
"    ), and familial pancreatic cancer. However, combined, these known genetic factors account for less than 20 percent of the observed familial aggregation, suggesting that other as yet unidentified susceptibility genes may exist. The contribution of some of these genes to the molecular pathogenesis of pancreatic cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13513?source=see_link\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697144\">",
"    <span class=\"h4\">",
"     Hereditary breast cancer: BRCA and PALB2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary Breast and Ovarian Cancer (HBOC) is characterized by the presence of germline mutations in two cancer susceptibility genes, BRCA1 and BRCA2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Germline mutations in BRCA1 and especially BRCA2, are associated with an increased risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. BRCA2 mutations are found in as many as 12 to 17 percent of patients with familial pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13513?source=see_link\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Furthermore, an estimated 1.7 to 10 percent of patients of Ashkenazi Jewish origin who have pancreatic cancer carry a BRCA mutation, many of whom do not have a family history of typical BRCA-associated cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/35,36,38-41\">",
"     35,36,38-41",
"    </a>",
"    ]. Because of this, some have suggested that the diagnosis of pancreatic cancer in an Ashkenazi individual should prompt referral for BRCA testing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 1 percent of",
"    <span class=\"nowrap\">",
"     non-BRCA1/BRCA2",
"    </span>",
"    deficient familial breast cancers are caused by germline defects in the PALB2 (Partner And Localizer of BRCA2) gene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H14277448#H14277448\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Mutations in palb2 gene'",
"    </a>",
"    .). The PALB2 protein binds with BRCA2 protein and stabilizes it in the nucleus; the",
"    <span class=\"nowrap\">",
"     BRCA2/PALB2",
"    </span>",
"    complex is part of the Fanconi Anemia DNA repair pathway that acts in double-stranded DNA repair. Mutations in the PALB2 gene confer an increased risk of both breast and pancreatic cancer. PALB2 mutations have been identified in 1 to 3 percent of familial pancreatic cancer kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. The absolute magnitude of risk for pancreatic cancer in affected individuals is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697181\">",
"    <span class=\"h4\">",
"     Peutz-Jeghers syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germline mutations in other genes, such as PRSS1 and STK11 (germline mutations of which are associated with Peutz-Jeghers syndrome [PJS]), have been associated with an increased risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In individuals with PJS, the lifetime risk may be as high as 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697198\">",
"    <span class=\"h4\">",
"     Familial atypical multiple-mole melanoma (FAMMM) syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in CDKN2A (also called the multiple tumor suppressor-1 gene) characterize the familial atypical multiple-mole melanoma (FAMMM) syndrome, a disorder associated with multiple nevi, cutaneous and ocular malignant melanomas, as well as pancreatic cancers. A variant syndrome is described (the FAMMM-pancreatic carcinoma syndrome) in several families who have a specific 19-base-pair deletion in the p16 gene (the p16 Leiden mutation) and whose cumulative risk of pancreatic carcinoma by age 75 is as high as 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/9,48-50\">",
"     9,48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"     \"Inherited susceptibility to melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697213\">",
"    <span class=\"h4\">",
"     Ataxia-telangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia-telangiectasia is associated with an increased risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"     \"Ataxia-telangiectasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697222\">",
"    <span class=\"h4\">",
"     Lynch syndrome and FAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the Lynch syndrome may be at an increased risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)\", section on 'Extracolonic cancers in Lynch syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not as well defined, there may also be an increase in risk in familial adenomatous polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H696925\">",
"    <span class=\"h4\">",
"     Familial pancreatic cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial pancreatic cancer is defined as an inherited predisposition based upon family clustering in families in which there are multiple first and second degree relatives with ductal pancreatic adenocarcinoma in the absence of a known genetic susceptibility syndrome. Having multiple family members with pancreatic cancer increases the risk of non-affected family members developing the disease, and the risk is closely tied to the number of first-degree relatives with the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/6,20\">",
"     6,20",
"    </a>",
"    ]. In one study from the National Familial Pancreas Tumor Registry, the risk of developing pancreatic cancer was 18-fold higher when two or more first-degree relatives were affected, and 57-fold higher in kindreds with three or more affected family members [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific gene defect responsible for familial pancreatic cancer has not been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Predictive models",
"    </span>",
"    &nbsp;&mdash;&nbsp;PancPRO is a statistical model for assessing the probability that an individual carries a germline deleterious mutation of a susceptibility gene for pancreatic cancer and the risk of developing a future pancreatic cancer based on the individual's family history [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/59\">",
"     59",
"    </a>",
"    ]. The model was based upon a Bayesian modeling framework originally developed for BRCAPRO (which assesses the probability of inheriting a deleterious BRCA mutation) and initially tested using prospective data on 961 families enrolled in the National Familial Pancreatic Cancer Tumor registry [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/60\">",
"     60",
"    </a>",
"    ]. On average, the model calculated higher risk scores for individuals who developed pancreatic cancer than for those who remained disease-free. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although this model may represent an accurate predictor of the likelihood of developing a pancreatic cancer in high risk families, external validation in other populations is needed. In addition, the best way to screen individuals who are identified as being at higher than average risk is not established.",
"   </p>",
"   <p>",
"    Screening of individuals from high-risk families using endoscopic ultrasound (EUS) and CT can detect predominantly asymptomatic early pancreatic neoplasms, including noninvasive precursor lesions such as intraductal papillary mucinous neoplasms (IPMNs) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Screening for high-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other inherited risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides the rare, highly penetrant familial syndromes discussed above, the genetic risk factors for pancreatic cancer are largely unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18033984\">",
"    <span class=\"h4\">",
"     ABO blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABO blood type is an inherited characteristic that has been associated with the risk of several gastrointestinal malignancies, including pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Blood type is determined by the presence or absence of human blood group antigens, glycoproteins that are expressed on the surface of red blood cells and several other types of cells, including pancreatic cancer cells.",
"   </p>",
"   <p>",
"    The relationship between blood type and pancreatic cancer risk was examined in two large independent prospective cohorts (the Nurses' Health Study and the Health Professionals Follow-up Study) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/63\">",
"     63",
"    </a>",
"    ]. Compared with blood group O, individuals with Non-O blood group (type A, AB, or B) were significantly more likely to develop pancreatic cancer (adjusted hazard ratio for incident pancreatic cancer 1.32, 1.51. and 1.72, respectively), and the association was nearly identical in the two cohorts. Overall, 17 percent of the 316 pancreatic cancer cases were attributable to inheriting a non-O blood type.",
"   </p>",
"   <p>",
"    These findings are supported by the results of a genome-wide association study that identified variants in the ABO locus that were associated with susceptibility to pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these data suggest that ABO blood group status may represent a common inherited susceptibility for pancreatic cancer, additional studies are needed to confirm these findings and establish the potential mechanisms by which ABO blood group influences the risk of pancreatic cancer. An interaction between non-O blood type and colonization with Helicobacter pylori has been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Helicobacter pylori'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nonhereditary chronic pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some data suggesting that patients with nonhereditary chronic pancreatitis (both tropical and nontropical) are at increased risk of developing pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. In a report from the International Pancreatitis Study Group, for example, 2015 patients with chronic pancreatitis were followed for a mean of 7.4 years during which a total of 56 pancreatic cancers were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/68\">",
"     68",
"    </a>",
"    ]. The expected number of cases of cancer calculated from country-specific incidence data and adjusted for age and sex was 2.13, yielding a standardized incidence ratio (the ratio of observed to expected cases) of 26.3. The cumulative risk reached 1.8 percent at 10 years and 4 percent at 20 years, independent of the type of pancreatitis. A less pronounced relationship has been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/69\">",
"     69",
"    </a>",
"    ]. In any event, the population attributable risk has been estimated to be 1.3 percent, suggesting that a relatively small proportion of pancreatic cancers might be avoided if pancreatitis could be prevented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diabetes mellitus, glucose metabolism, and insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous epidemiologic studies describe an association between diabetes mellitus and pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/14,71-80\">",
"     14,71-80",
"    </a>",
"    ]. In a meta-analysis of 35 cohort studies (predominantly of patients with type 2 diabetes) the pooled relative risk (RR) for pancreatic cancer in diabetics compared to patients without diabetes was 1.94 (95% CI 1.66-2.27) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and other data suggest that diabetes may be a consequence of, rather than a cause of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. This was illustrated in a study that compared 512 patients with newly diagnosed pancreatic cancer to 933 controls of similar age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/83\">",
"     83",
"    </a>",
"    ]. Compared to controls, diabetes was more prevalent in pancreatic cancer cases (47 versus 7 percent) and more likely to have been diagnosed in the preceding two years (74 versus 53 percent). After pancreaticoduodenectomy, diabetes resolved in 17 of 30 patients (57 percent) with new-onset diabetes, while its prevalence was unchanged in the 11 patients who had longstanding diabetes.",
"   </p>",
"   <p>",
"    Even in the absence of frank diabetes mellitus, abnormal glucose metabolism and insulin resistance have been associated with pancreatic cancer. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective cohort study, employees of 84 Chicago-area businesses were screened for postload plasma glucose levels and followed for an average of 25 years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/84\">",
"       84",
"      </a>",
"      ]. Compared to controls with a postload plasma glucose of 119",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or less, the relative risk of mortality from pancreatic cancer was 1.65, 1.6, and 2.15 for those with levels of 120 to 159 (6.7 to 8.8",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      160 to 199 (8.9 to 11.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      respectively, even after adjusting for age, race, cigarette smoking, and body mass index.",
"     </li>",
"     <li>",
"      Data from the Nurses' Health Study suggests that diets associated with a high glycemic load may increase the risk of pancreatic cancer in those who already have an underlying degree of insulin resistance. A dietary glycemic index (an estimate based upon dietary records of the postprandial blood glucose response compared to a reference food) of 180 women who developed pancreatic cancer during an 18-year period was compared with that of 88,622 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/85\">",
"       85",
"      </a>",
"      ]. A significantly increased risk for pancreatic cancer was not detected when comparing those in the highest quintile with those in the lowest (relative risk [RR] 1.53, 95% CI 0.96-2.45). In contrast, the risk was significantly increased among women who were both overweight and sedentary (RR 2.67, 95% CI 1.02-6.99).",
"     </li>",
"     <li>",
"      An association between prediagnosis serum levels of glucose, insulin, insulin resistance, and pancreatic cancer risk was suggested in a case-cohort study within the Alpha-Tocopherol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Cancer Prevention study, a primary prevention trial enrolling 29,133 male Finnish smokers aged 50 to 69 [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/86\">",
"       86",
"      </a>",
"      ]. Fasting serum concentrations of glucose and insulin, and levels of insulin resistance (with the interval between serum collection and follow-up up to 16.7 years) were assessed. The study included 169 incident cases of pancreatic cancer that were diagnosed after the fifth year of follow-up and 400 randomly selected controls.",
"      <br/>",
"      <br/>",
"      After adjustment for age, years of smoking, and body mass index, higher prediagnosis serum concentrations of glucose and insulin, as well as insulin resistance were significantly correlated with the risk of pancreatic cancer. The positive associations were stronger among the cases that occurred more than 10 years after baseline (highest versus lowest quartile for glucose, hazard ratio [HR] 2.16, 95% CI 1.05 to 4.42; for insulin, HR 2.90, 95% CI 1.22-6.92; for insulin resistance, HR 2.71, 95% CI 1.19 to 6.18). The prospective study design, with a minimum five year follow-up prior to the detection of incident pancreatic cancer, minimizes the possibility that the identified insulin and glucose abnormalities resulted from \"subclinical\" pancreatic cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism underlying this association is unclear. However, at least some data suggest that the increased risk of pancreatic cancer in patients with metabolic diseases such as diabetes mellitus and other states of insulin resistance as well as obesity may be mediated by reduced levels of plasma adiponectin, a fat-derived hormone that has insulin-sensitizing and anti-inflammatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data linking high glucose levels with an elevated risk of pancreatic cancer have led some to suggest that the new onset of diabetes in a thin older adult should prompt consideration of screening for early diagnosis of a potentially resectable pancreatic cancer. At least three studies have addressed the utility of CT screening for early detection of pancreatic cancer in adults with new-onset diabetes. Two uncovered mainly unresectable tumors, but they selected patients for screening based upon the presence of cancer-related symptoms. A third series from the Mayo Clinic suggested that CT scans done at the time of newly diagnosed diabetes in otherwise asymptomatic patients were more likely to show potentially resectable tumors than scans performed six months later [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/88\">",
"     88",
"    </a>",
"    ]. Whether higher resectability rates translated into higher cure rates was not addressed.",
"   </p>",
"   <p>",
"    CT screening of all older subjects with new onset diabetes in order to discover a small number of pancreatic cancers is not feasible. Identification of those features that differentiate pancreatic cancer-associated diabetes from other cases with new-onset diabetes would help direct efforts to the subset of individuals who would most benefit from screening CT, but these factors have not yet been established. Thus, screening CT scans are not warranted in older otherwise asymptomatic adults with new-onset atypical diabetes. This subject is addressed in detail below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Screening for high-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Environmental risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several environmental risk factors have been implicated in the risk of pancreatic cancer, including tobacco use, diet, alcohol and high caloric intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;In multiple cohort and case-control studies, the relative risk for developing pancreatic cancer among smokers was at least 1.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/89-96\">",
"     89-96",
"    </a>",
"    ]. The risk increases with the amount of cigarettes consumed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/92,93,96\">",
"     92,93,96",
"    </a>",
"    ] and may be particularly high in heavy smokers who also have homozygous deletions of the gene for the carcinogen metabolizing enzyme glutathione S-transferase T1 (GSTT1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excess risk decreases with smoking cessation. In a large prospective study, the relative risk of pancreatic cancer among current smokers was 2.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/97\">",
"     97",
"    </a>",
"    ]. The risk fell by 48 percent by two years after discontinuing smoking and leveled off 10 to 15 years after stopping, eventually falling to the level of nonsmokers. It has been estimated that cessation of smoking could eliminate approximately 25 percent of pancreatic cancer deaths in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/94,97\">",
"     94,97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Obesity and physical inactivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest a link between high body mass, lack of physical activity, and pancreatic cancer risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/98-104\">",
"     98-104",
"    </a>",
"    ]. These relationships can be illustrated by the result of a representative cohort study which was based upon follow-up data from the Health Professionals Follow-up Study and the Nurses' Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/98\">",
"     98",
"    </a>",
"    ]. A body mass index (BMI) of at least 30",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    was associated with a significantly increased risk of pancreatic cancer compared with a BMI of less than 23",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (relative risk 1.72, 95% CI 1.19-2.48). Height was also associated with an increased risk (relative risk 1.81, 95% CI 1.31-2.52). An inverse relationship was also observed for moderate physical activity when comparing the highest versus the lowest categories (relative risk 0.45, 95% CI 0.29-0.70), particularly among those with a BMI of at least 25",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"   </p>",
"   <p>",
"    Others",
"    have suggested that overweight and obese individuals develop pancreatic cancer at a younger age than do patients with a normal weight, and that they also have lower rates and duration of survival once pancreatic cancer is diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the relationship between diet and pancreatic cancer are inconclusive. A \"Western\" dietary pattern (high intake of fat",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    meat, particularly smoked or processed meats) has been linked to the development of pancreatic cancer in many [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/93,105-107\">",
"     93,105-107",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. Several [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/111-113\">",
"     111-113",
"    </a>",
"    ] case-control studies report a protective effect from the consumption of fresh fruits and vegetables, but prospective studies have not observed such an association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/15\">",
"     15",
"    </a>",
"    ]. Lower serum levels of lycopene (a carotenoid present in fruits) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    have been found in subjects who subsequently developed pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/114\">",
"     114",
"    </a>",
"    ]. However, whether dietary or supplemental intake of these nutrients is associated with a reduced risk of pancreatic cancer is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Coffee and alcohol consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the impact of coffee and alcohol ingestion on the risk of pancreatic cancer have been conflicting. Two pooled analyses suggest if there is an effect, it is small and limited to heavy drinkers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The relationship between alcohol use and pancreatic cancer is confounded by cigarette smoking.",
"   </p>",
"   <p>",
"    Similarly, the relationship between coffee intake and pancreatic cancer risk has been controversial, with some studies indicating an elevated risk with higher levels of consumption, and others, no relationship. A meta-analysis of 37 case-control and 17 cohort studies concluded that the pooled relative risk (RR) of pancreatic cancer for highest versus lowest intake of coffee was 1.13 (95% CI 0.99-1.29), and it remained not statistically significant when the analysis was limited to those studies that adjusted for smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Aspirin and NSAID use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory data suggest a possible inhibitory effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDs on pancreatic tumorigenesis. However, available epidemiologic data in humans are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/120-128\">",
"     120-128",
"    </a>",
"    ]. In fact, preliminary data from the Nurses' Health study, in which 88,378 women without cancer were followed for up to 18 years, raise the possibility that extended regular use of aspirin might",
"    <strong>",
"     increase",
"    </strong>",
"    the risk of pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/125\">",
"     125",
"    </a>",
"    ]. Compared to nonusers, participants who ingested 14 or more aspirin tablets weekly (but not fewer) for four or more years had a significantly increased relative risk of pancreatic cancer (RR 1.86). The findings did not change appreciably when obesity and smoking were taken into account.",
"   </p>",
"   <p>",
"    Despite these data, studies of other large cohorts have not found any link between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use and pancreatic cancer risk, even among individuals using aspirin &ge;30 times monthly for over 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     History of partial gastrectomy or cholecystectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two- to fivefold increased risk of developing pancreatic cancer 15 to 20 years after partial gastrectomy has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/129\">",
"     129",
"    </a>",
"    ]. An increased incidence has also been observed in patients who underwent cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/14,130-132\">",
"     14,130-132",
"    </a>",
"    ], although discordant data have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. A possible explanation for both associations is elevated levels of circulating cholecystokinin, since exogenous cholecystokinin promotes the growth of transplantable human pancreatic adenocarcinoma cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between H. pylori infection and pancreatic cancer has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. In a case control trial, the risk appeared to be greatest in patients infected with CagA strains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the mechanisms underlying the association between H pylori and increased pancreatic cancer risk have not been determined, a link has been proposed between H pylori infection and chronic hyperacidity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/138\">",
"     138",
"    </a>",
"    ], as well as between inheritance of non-O blood type and infection with non-CagA strains of H pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Other inherited risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hepatitis B virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case control study found an association between pancreatic cancer and serologic markers that indicated past exposure to hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/139\">",
"     139",
"    </a>",
"    ]. Additional data are needed to confirm this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SCREENING FOR HIGH-RISK PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative resection is the only potentially curative treatment for pancreatic cancer, yet only 15 to 20 percent of patients are candidates for pancreatectomy at the time of diagnosis. Furthermore, even among those undergoing resection, only a minority (about 20 percent of those with node-negative and 10 percent of those with node-positive disease) will survive beyond two years. Given that outcomes appear better following resection of small invasive cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/140\">",
"     140",
"    </a>",
"    ], it is hoped that early detection and treatment will improve outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Routine screening is of limited utility in average-risk individuals given the low incidence of pancreatic cancer and the lack of a low-cost noninvasive diagnostic test with high sensitivity and specificity. However, certain groups who have a significantly elevated risk of pancreatic cancer, such as those with hereditary pancreatitis and some inherited cancer susceptibility syndromes, might benefit from screening to detect early pancreatic lesions that can be treated (",
"    <a class=\"graphic graphic_table graphicRef83695 \" href=\"UTD.htm?29/53/30555\">",
"     table 2",
"    </a>",
"    ). Two noninvasive precursor lesions to pancreatic cancer have been identified: intraductal papillary mucinous neoplasm (IPMN) and high-grade pancreatic intraepithelial neoplasia (PanIN). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Pancreatic intraepithelial neoplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H14#H14\">",
"     \"Pathology of exocrine pancreatic neoplasms\", section on 'Intraductal papillary-mucinous neoplasms (IPMN)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Screening studies in high-risk cohorts have shown that early preinvasive pancreatic lesions can be detected in a substantial number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/8,141-145\">",
"     8,141-145",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early report, a program of endoscopic retrograde cholangiopancreatography (ERCP), spiral CT, endoscopic ultrasound (EUS), and assay of serum tumor markers carcinoembryonic antigen and CA 19-9 detected suspicious findings in 7 of 14 patients who had two or more family members with pancreatic cancer in at least two generations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/8\">",
"       8",
"      </a>",
"      ]. At surgery, all seven had histologic evidence of widespread PanIN, and there were no invasive cancers.",
"     </li>",
"     <li>",
"      Another report prospectively evaluated a program of EUS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRI, assay for the tumor marker CA 19-9, and genetic testing (with the specific strategy chosen based on estimated magnitude of risk) in 51 patients from 43 families with a history of pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/141\">",
"       141",
"      </a>",
"      ]. There were ten neoplasms detected in nine patients (18 percent detection rate), including five pancreatic lesions (two cancers, three IPMNs), and four extrapancreatic neoplasms (two ovarian cancers at the time of prophylactic hysterectomy, one retroperitoneal carcinoid, and one papillary thyroid carcinoma). Five patients had potentially curative pancreatic surgery (one total pancreatectomy for pancreatic cancer, four partial pancreatectomies for pancreatic intraepithelial neoplasia and IPMN). Of the 24 who underwent genetic testing, seven were positive for",
"      <span class=\"nowrap\">",
"       BRCA1/2",
"      </span>",
"      mutations.",
"     </li>",
"     <li>",
"      A prospective study from the American Cancer of the Pancreas Screening (CAPS) Consortium evaluated one-time screening with CT, MRI, and EUS in 225 asymptomatic high-risk individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/143\">",
"       143",
"      </a>",
"      ]. Ninety-two individuals (42 percent) were found to have at least one pancreatic mass (84 cystic, 3 solid) or a dilated pancreatic duct (n = 5) by any of the screening modalities. CT, MRI, and EUS detected a pancreatic abnormality in 11, 33, and 43 percent of high-risk individuals, respectively. Of the 85 high risk individuals who had proven or suspected neoplasms, 82 were IPMNs and three were pancreatic endocrine tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, arguments against screening are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The yield of screening has not been uniformly high. A five-year prospective screening study of annual screening with EUS and MRI in 76 asymptomatic high-risk individuals found only one IPMN [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/146\">",
"       146",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While both PanIN and IPMNs clearly act as precursor lesions to invasive pancreatic cancer, whether early identification and treatment will improve outcomes is uncertain, given that only a small fraction of progress to invasive cancer. There is no test available to determine malignant potential. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathology of exocrine pancreatic neoplasms\", section on 'Intraductal papillary-mucinous neoplasms (IPMN)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathology of exocrine pancreatic neoplasms\", section on 'Pancreatic intraepithelial neoplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No study has ever shown that screening improves survival [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although imaging surveillance of high-risk family cohorts is pursued at some centers, this practice has been considered by many to be investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/147\">",
"     147",
"    </a>",
"    ]. A consensus committee of the European Registry of Hereditary Pancreatic Diseases, Midwest Multi-Center Pancreatic Study Group, International Association of Pancreatology recommended screening for pancreatic cancer in individuals with hereditary pancreatitis age 40 or more [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/30\">",
"     30",
"    </a>",
"    ]. There are no guidelines from the",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     American Gastroenterological Association",
"    </a>",
"    or the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    for screening of patients at high risk for pancreatic cancer.",
"   </p>",
"   <p>",
"    <br/>",
"    A 2007 consensus conference on inherited diseases of the pancreas proposed that screening for pancreatic cancer be restricted to individuals with a &gt;10-fold increased risk of the disease (",
"    <a class=\"graphic graphic_table graphicRef83695 \" href=\"UTD.htm?29/53/30555\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/148\">",
"     148",
"    </a>",
"    ]. However,",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines for patients with inherited BRCA mutations do not suggest routine screening for pancreatic cancer. In addition, guidelines from several expert groups do not recommend screening for pancreatic cancer in patients with Lynch syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link&amp;anchor=H21758716#H21758716\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\", section on 'Extracolonic tumors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    No definitive statement was made regarding the optimal surveillance strategy. Even among groups that advocate screening, there is no consensus as to when to start screening, the optimal frequency, or best surveillance strategy for early diagnosis of the disease in high-risk patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although there are no clear guidelines on when to start screening, most expert recommendations are based on the mean age at which pancreatic cancer develops and the youngest age of onset of pancreatic cancer in the family. Given the documented phenomenon of anticipation in familial pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/149\">",
"       149",
"      </a>",
"      ], the consensus group recommended that for familial pancreatic cancer, screening be considered at age 40 to 45, or 10 to 15 years younger than the youngest relative with pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/150\">",
"       150",
"      </a>",
"      ]. In addition, as smoking reduces the age of disease onset [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/151,152\">",
"       151,152",
"      </a>",
"      ], it is probably reasonable to begin screening up to a decade earlier in smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/148\">",
"       148",
"      </a>",
"      ]. For patients with Peutz-Jeghers syndrome, screening is recommended at age 25 to 30. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link&amp;anchor=H21759690#H21759690\">",
"       \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\", section on 'Pancreatic cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is also no consensus on how often screening should be repeated, with opinion varying from one to three years. The consensus group suggested tailoring individual recommendations, taking into account additional factors such as the patient&rsquo;s level of concern, clinical history, and study protocols [",
"      <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal screening modality is also unclear. CT has the lowest sensitivity for pancreatic neoplasms, and other disadvantages include radiation exposure and inability to image nondilated pancreatic ducts. ERCP is associated with a risk of pancreatitis. EUS has a higher sensitivity than CT for diagnosing pancreatic cancer, a high positive predictive value for PanIN in high-risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/8\">",
"     8",
"    </a>",
"    ], and it can detect mural nodules within IPMN, a finding that may be associated with an increased risk of malignancy. Limitations include high interobserver variability, cost, and complications associated with endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/150\">",
"     150",
"    </a>",
"    ]. Furthermore, the diagnostic value of both EUS and ERCP is limited in patients with chronic pancreatitis because the intraductal and tissue changes associated with chronic inflammation prevent the early detection of premalignant lesions or small malignant tumors.",
"    <span class=\"nowrap\">",
"     MRI/MRCP",
"    </span>",
"    provides a non-invasive method for screening while avoiding the risk of radiation exposure and pancreatitis; the diagnostic accuracy for IPMN is equal to or greater than that of CT or ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/153\">",
"     153",
"    </a>",
"    ]. Secretin-enhanced MRCP increases pancreatic secretion and may increase sensitivity for small duct lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5511899#H5511899\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Endoscopic ultrasound'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5511927#H5511927\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'CT scan and magnetic resonance imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\", section on 'EUS'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The expert consensus group on inherited diseases of the pancreases could not reach a consensus on the specific approach to screening in high-risk individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/148\">",
"     148",
"    </a>",
"    ]. They recommended that surveillance be performed only as part of a peer-reviewed screening protocol. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major risk factors for pancreatic cancer are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cigarette smoking (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Cigarette smoking'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      High body mass and lack of physical activity (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Obesity and physical inactivity'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Nonhereditary chronic pancreatitis (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Nonhereditary chronic pancreatitis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      A role for familial aggregation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genetic factors is suggested by the fact that 5 to 10 percent of patients with pancreatic cancer have a first degree relative with the disease (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Hereditary risk factors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Hereditary pancreatitis is an autosomal dominant disorder that accounts for a small fraction of cases of chronic pancreatitis. The majority of affected individuals develop symptoms before the age of 20 and often before the age of five (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Hereditary pancreatitis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Germline mutations in known cancer-causing genes, such as BRCA1, BRCA2, and STK11 (the gene mutated in Peutz-Jeghers syndrome) are associated with an increased risk of pancreatic cancer (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Inherited cancer susceptibility syndromes'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Ataxia-telangiectasia is associated with an increased risk of pancreatic cancer (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=see_link\">",
"       \"Ataxia-telangiectasia\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal timing and frequency of screening for pancreatic cancer in individuals at elevated risk is uncertain. Some expert groups recommend screening for high-risk individuals who have a 5 or 10-fold or higher risk of pancreatic cancer (",
"    <a class=\"graphic graphic_table graphicRef83695 \" href=\"UTD.htm?29/53/30555\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/13/27866/abstract/150,154\">",
"     150,154",
"    </a>",
"    ]. The optimal time to begin screening is unclear, but some groups recommend beginning at age 40 for those with hereditary pancreatitis and 10 years before the age at which pancreatic cancer was first diagnosed in individuals with an inherited predisposition. In patients with PJS, screening for pancreatic cancer is recommended at age 30 years. &nbsp;There is no consensus on the appropriate interval for screening and also no consensus as to the optimal screening strategy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Screening for high-risk patients'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/3\">",
"      Boyle P, Hsieh CC, Maisonneuve P, et al. Epidemiology of pancreas cancer (1988). Int J Pancreatol 1989; 5:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/4\">",
"      Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1973-1996. National Cancer Institute, Bethesda, MD 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/6\">",
"      Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/7\">",
"      Klein AP, Hruban RH, Brune KA, et al. Familial pancreatic cancer. Cancer J 2001; 7:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/8\">",
"      Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/9\">",
"      Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 1991; 6:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/10\">",
"      Bartsch DK, Kress R, Sina-Frey M, et al. Prevalence of familial pancreatic cancer in Germany. Int J Cancer 2004; 110:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/11\">",
"      Lynch HT, Fitzsimmons ML, Smyrk TC, et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990; 85:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/12\">",
"      Ghadirian P, Boyle P, Simard A, et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991; 10:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/13\">",
"      Falk RT, Pickle LW, Fontham ET, et al. Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol 1988; 128:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/14\">",
"      Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/15\">",
"      Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/16\">",
"      Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 2010; 102:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/17\">",
"      Ghadirian P, Liu G, Gallinger S, et al. Risk of pancreatic cancer among individuals with a family history of cancer of the pancreas. Int J Cancer 2002; 97:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/18\">",
"      Fernandez E, et al. Cancer Epidemiol Biomarkers Prev 1994; 3:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/19\">",
"      Schenk M, Schwartz AG, O'Neal E, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst 2001; 93:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/20\">",
"      Jacobs EJ, Chanock SJ, Fuchs CS, et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer 2010; 127:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/21\">",
"      James TA, Sheldon DG, Rajput A, et al. Risk factors associated with earlier age of onset in familial pancreatic carcinoma. Cancer 2004; 101:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/22\">",
"      McWilliams RR, Rabe KG, Olswold C, et al. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005; 104:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/23\">",
"      Klein AP, Beaty TH, Bailey-Wilson JE, et al. Evidence for a major gene influencing risk of pancreatic cancer. Genet Epidemiol 2002; 23:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/24\">",
"      Hemminki K, Li X. Familial and second primary pancreatic cancers: a nationwide epidemiologic study from Sweden. Int J Cancer 2003; 103:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/25\">",
"      Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/26\">",
"      Rebours V, Boutron-Ruault MC, Schnee M, et al. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. Am J Gastroenterol 2008; 103:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/27\">",
"      Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/28\">",
"      Whitcomb DC, Applebaum S, Martin SP. Hereditary pancreatitis and pancreatic carcinoma. Ann N Y Acad Sci 1999; 880:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/29\">",
"      Rebours V, Boutron-Ruault MC, Jooste V, et al. Mortality rate and risk factors in patients with hereditary pancreatitis: uni- and multidimensional analyses. Am J Gastroenterol 2009; 104:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/30\">",
"      Ulrich CD, Consensus Committees of the European Registry of Hereditary Pancreatic Diseases, Midwest Multi-Center Pancreatic Study Group, International Association of Pancreatology. Pancreatic cancer in hereditary pancreatitis: consensus guidelines for prevention, screening and treatment. Pancreatology 2001; 1:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/31\">",
"      Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol 2013; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/32\">",
"      Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/33\">",
"      Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/34\">",
"      Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/35\">",
"      Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62:3789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/36\">",
"      Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003; 95:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/37\">",
"      Iqbal J, Ragone A, Lubinski J, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012; 107:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/38\">",
"      Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009; 27:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/39\">",
"      Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000; 60:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/40\">",
"      Oz&ccedil;elik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997; 16:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/41\">",
"      Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/42\">",
"      Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/43\">",
"      Tischkowitz MD, Sabbaghian N, Hamel N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology 2009; 137:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/44\">",
"      Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet 2010; 78:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/45\">",
"      Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/46\">",
"      Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/47\">",
"      Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/48\">",
"      Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000; 87:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/49\">",
"      Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/50\">",
"      Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/51\">",
"      Swift M, Chase CL, Morrell D. Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 1990; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/52\">",
"      Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/53\">",
"      Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012; 2:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/54\">",
"      Park JG, Park YJ, Wijnen JT, Vasen HF. Gene-environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. Int J Cancer 1999; 82:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/55\">",
"      Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review. Cancer 1996; 78:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/56\">",
"      Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/57\">",
"      Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 2012; 30:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/58\">",
"      Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34:1394.",
"     </a>",
"    </li>",
"    <li>",
"     PancPRO model available for use of health care professionals at file://astor.som.jhmi.edu/BayesMendel (Accessed on May 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/60\">",
"      Wang W, Chen S, Brune KA, et al. PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007; 25:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/61\">",
"      Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/62\">",
"      Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/63\">",
"      Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/64\">",
"      Annese V, Minervini M, Gabbrielli A, et al. ABO blood groups and cancer of the pancreas. Int J Pancreatol 1990; 6:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/65\">",
"      Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 2010; 102:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/66\">",
"      Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. Cancer Res 2010; 70:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/67\">",
"      Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/68\">",
"      Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/69\">",
"      Ekbom A, McLaughlin JK, Karlsson BM, et al. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 1994; 86:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/70\">",
"      Duell EJ, Lucenteforte E, Olson SH, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23:2964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/71\">",
"      Huxley R, Ansary-Moghaddam A, Berrington de Gonz&aacute;lez A, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/72\">",
"      Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/73\">",
"      Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/74\">",
"      Chow WH, Gridley G, Nyr&eacute;n O, et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/75\">",
"      Calle EE, Murphy TK, Rodriguez C, et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/76\">",
"      Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/77\">",
"      Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/78\">",
"      Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007; 96:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/79\">",
"      Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/80\">",
"      Aggarwal G, Kamada P, Chari ST. Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers. Pancreas 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/81\">",
"      Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/82\">",
"      Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008; 134:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/83\">",
"      Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008; 134:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/84\">",
"      Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/85\">",
"      Michaud DS, Liu S, Giovannucci E, et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/86\">",
"      Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 2005; 294:2872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/87\">",
"      Bao Y, Giovannucci EL, Kraft P, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 2013; 105:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/88\">",
"      Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007; 102:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/89\">",
"      Mack TM, Yu MC, Hanisch R, Henderson BE. Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 1986; 76:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/90\">",
"      Farrow DC, Davis S. Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 1990; 45:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/91\">",
"      Ghadirian P, Simard A, Baillargeon J. Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case-control study in Quebec, Canada. Cancer 1991; 67:2664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/92\">",
"      Lynch SM, Vrieling A, Lubin JH, et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 2009; 170:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/93\">",
"      N&ouml;thlings U, Wilkens LR, Murphy SP, et al. Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 2005; 97:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/94\">",
"      Silverman DT, Dunn JA, Hoover RN, et al. Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1994; 86:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/95\">",
"      Duell EJ, Holly EA, Bracci PM, et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002; 94:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/96\">",
"      Bosetti C, Lucenteforte E, Silverman DT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 2012; 23:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/97\">",
"      Fuchs CS, Colditz GA, Stampfer MJ, et al. A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 1996; 156:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/98\">",
"      Michaud DS, Giovannucci E, Willett WC, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001; 286:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/99\">",
"      Stolzenberg-Solomon RZ, Adams K, Leitzmann M, et al. Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol 2008; 167:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/100\">",
"      Luo J, Margolis KL, Adami HO, et al. Obesity and risk of pancreatic cancer among postmenopausal women: the Women's Health Initiative (United States). Br J Cancer 2008; 99:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/101\">",
"      Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009; 301:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/102\">",
"      O'Rorke MA, Cantwell MM, Cardwell CR, et al. Can physical activity modulate pancreatic cancer risk? a systematic review and meta-analysis. Int J Cancer 2010; 126:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/103\">",
"      Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010; 170:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/104\">",
"      Aune D, Greenwood DC, Chan DS, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol 2012; 23:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/105\">",
"      Silverman DT, Swanson CA, Gridley G, et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1998; 90:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/106\">",
"      Thi&eacute;baut AC, Jiao L, Silverman DT, et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. J Natl Cancer Inst 2009; 101:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/107\">",
"      Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer 2012; 106:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/108\">",
"      Michaud DS, Giovannucci E, Willett WC, et al. Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 2003; 157:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/109\">",
"      Michaud DS, Skinner HG, Wu K, et al. Dietary patterns and pancreatic cancer risk in men and women. J Natl Cancer Inst 2005; 97:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/110\">",
"      Rohrmann S, Linseisen J, N&ouml;thlings U, et al. Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2013; 132:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/111\">",
"      Norell SE, Ahlbom A, Erwald R, et al. Diet and pancreatic cancer: a case-control study. Am J Epidemiol 1986; 124:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/112\">",
"      Howe GR, Jain M, Miller AB. Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case-control study. Int J Cancer 1990; 45:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/113\">",
"      Gold EB, Gordis L, Diener MD, et al. Diet and other risk factors for cancer of the pancreas. Cancer 1985; 55:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/114\">",
"      Burney PG, Comstock GW, Morris JS. Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr 1989; 49:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/115\">",
"      Han X, Li J, Brasky TM, et al. Antioxidant intake and pancreatic cancer risk: The Vitamins and Lifestyle (VITAL) Study. Cancer 2013; 119:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/116\">",
"      Nkondjock A, Ghadirian P, Johnson KC, et al. Dietary intake of lycopene is associated with reduced pancreatic cancer risk. J Nutr 2005; 135:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/117\">",
"      Michaud DS, Vrieling A, Jiao L, et al. Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Cancer Causes Control 2010; 21:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/118\">",
"      Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2012; 23:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/119\">",
"      Turati F, Galeone C, Edefonti V, et al. A meta-analysis of coffee consumption and pancreatic cancer. Ann Oncol 2012; 23:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/120\">",
"      Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst 2002; 94:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/121\">",
"      Bradley MC, Hughes CM, Cantwell MM, et al. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer 2010; 102:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/122\">",
"      Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/123\">",
"      Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/124\">",
"      Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/125\">",
"      Schernhammer ES, Kang JH, Chan AT, et al. A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst 2004; 96:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/126\">",
"      Jacobs EJ, Connell CJ, Rodriguez C, et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 2004; 96:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/127\">",
"      Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994; 54:3568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/128\">",
"      Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/129\">",
"      Offerhaus GJ, Tersmette AC, Tersmette KW, et al. Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Review of the literature with the emphasis on risk assessment and underlying mechanism. Mod Pathol 1988; 1:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/130\">",
"      Hyv&auml;rinen H, Partanen S. Association of cholecystectomy with abdominal cancers. Hepatogastroenterology 1987; 34:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/131\">",
"      Chow WH, Johansen C, Gridley G, et al. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999; 79:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/132\">",
"      Ekbom A, Yuen J, Karlsson BM, et al. Risk of pancreatic and periampullar cancer following cholecystectomy: a population-based cohort study. Dig Dis Sci 1996; 41:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/133\">",
"      Schernhammer ES, Michaud DS, Leitzmann MF, et al. Gallstones, cholecystectomy, and the risk for developing pancreatic cancer. Br J Cancer 2002; 86:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/134\">",
"      Friedman GD. Cholecystectomy not confirmed as a risk factor for pancreatic cancer. Int J Cancer 1995; 61:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/135\">",
"      Smith JP, Solomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 1990; 35:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/136\">",
"      Stolzenberg-Solomon RZ, Blaser MJ, Limburg PJ, et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst 2001; 93:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/137\">",
"      Raderer M, Wrba F, Kornek G, et al. Association between Helicobacter pylori infection and pancreatic cancer. Oncology 1998; 55:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/138\">",
"      Risch HA. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 2003; 95:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/139\">",
"      Hassan MM, Li D, El-Deeb AS, et al. Association between hepatitis B virus and pancreatic cancer. J Clin Oncol 2008; 26:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/140\">",
"      Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma. A collective study. Cancer 1996; 78:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/141\">",
"      Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 2010; 16:5028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/142\">",
"      Ludwig E, Olson SH, Bayuga S, et al. Feasibility and yield of screening in relatives from familial pancreatic cancer families. Am J Gastroenterol 2011; 106:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/143\">",
"      Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology 2012; 142:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/144\">",
"      Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: surveillance and treatment strategies for affected families. Pancreatology 2001; 1:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/145\">",
"      Kimmey MB, Bronner MP, Byrd DR, Brentnall TA. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56:S82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/146\">",
"      Langer P, Kann PH, Fendrich V, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut 2009; 58:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/147\">",
"      Collisson E, Tempero M. Blinded by the light: molecular imaging in pancreatic adenocarcinoma. Clin Cancer Res 2011; 17:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/148\">",
"      Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007; 56:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/149\">",
"      McFaul CD, Greenhalf W, Earl J, et al. Anticipation in familial pancreatic cancer. Gut 2006; 55:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/150\">",
"      Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010; 139:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/151\">",
"      Neglia JP, FitzSimmons SC, Maisonneuve P, et al. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med 1995; 332:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/152\">",
"      Fernandez E, La Vecchia C, Porta M, et al. Pancreatitis and the risk of pancreatic cancer. Pancreas 1995; 11:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/153\">",
"      Albert J, Schilling D, Breer H, et al. Mucinous cystadenomas and intraductal papillary mucinous tumors of the pancreas in magnetic resonance cholangiopancreatography. Endoscopy 2000; 32:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/13/27866/abstract/154\">",
"      Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013; 62:339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2480 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-0B08567BAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27866=[""].join("\n");
var outline_f27_13_27866=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hereditary risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hereditary pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Inherited cancer susceptibility syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H697144\">",
"      Hereditary breast cancer: BRCA and PALB2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H697181\">",
"      Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H697198\">",
"      Familial atypical multiple-mole melanoma (FAMMM) syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H697213\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H697222\">",
"      Lynch syndrome and FAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H696925\">",
"      Familial pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Predictive models",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other inherited risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18033984\">",
"      ABO blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nonhereditary chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diabetes mellitus, glucose metabolism, and insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Environmental risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Obesity and physical inactivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Coffee and alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Aspirin and NSAID use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - History of partial gastrectomy or cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hepatitis B virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SCREENING FOR HIGH-RISK PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2480|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/14/11500\" title=\"table 1\">",
"      Inher syndromes pancreas CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/53/30555\" title=\"table 2\">",
"      Potential candidates for screening for pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/60/23497?source=related_link\">",
"      Ataxia-telangiectasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19386?source=related_link\">",
"      Clinical features and diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37288?source=related_link\">",
"      Hereditary pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13513?source=related_link\">",
"      Molecular pathogenesis of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33288?source=related_link\">",
"      Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_13_27867="IBM versus polymyositis";
var content_f27_13_27867=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differentiation between inclusion body myositis and polymyositis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Inclusion body myositis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Polymyositis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sex",
"      </td>",
"      <td>",
"       Male &gt; female",
"      </td>",
"      <td>",
"       Female &gt; male",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Age",
"      </td>",
"      <td>",
"       Rare before 50",
"      </td>",
"      <td>",
"       Common before 50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Onset",
"      </td>",
"      <td>",
"       Insidious",
"      </td>",
"      <td>",
"       Acute or subacute",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Course",
"      </td>",
"      <td>",
"       Slowly progressive",
"      </td>",
"      <td>",
"       More rapid",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Distribution of weakness",
"      </td>",
"      <td>",
"       Variable, may be primarily distal",
"      </td>",
"      <td>",
"       Proximal, symmetric",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Creatine kinase",
"      </td>",
"      <td>",
"       Normal or &lt;10x normal",
"      </td>",
"      <td>",
"       Often &gt;10x normal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       EMG",
"      </td>",
"      <td>",
"       Myopathic or mixed myopathic and neurogenic",
"      </td>",
"      <td>",
"       Myopathic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle biopsy",
"      </td>",
"      <td>",
"       Inflammation, rimmed vacuoles, inclusions",
"      </td>",
"      <td>",
"       Inflammation, fiber necrosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Response to therapy",
"      </td>",
"      <td>",
"       Generally poor",
"      </td>",
"      <td>",
"       Expected",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27867=[""].join("\n");
var outline_f27_13_27867=null;
var title_f27_13_27868="Follow-up blood lead testing in infants under 6 months";
var content_f27_13_27868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Schedule for follow-up blood lead testing in infants*&bull;",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Venous blood lead level",
"        <br/>",
"        (BLL; &micro;g/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Early follow-up",
"        <br/>",
"        (first 2-4 tests after identification or until BLL begins to decline)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Later follow-up",
"        <br/>",
"        (after BLL begins to decline)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;10",
"       </td>",
"       <td>",
"        According to local lead screening guidelines for children",
"       </td>",
"       <td>",
"        According to local lead screening guidelines for children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-14",
"       </td>",
"       <td>",
"        3 months&Delta;",
"       </td>",
"       <td>",
"        Within 6-9 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-19",
"       </td>",
"       <td>",
"        1-3 months&Delta;",
"       </td>",
"       <td>",
"        Within 3-6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20-24",
"       </td>",
"       <td>",
"        1-3 months&Delta;",
"       </td>",
"       <td>",
"        Within 1-3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-44",
"       </td>",
"       <td>",
"        2 weeks-1 month&loz;",
"       </td>",
"       <td>",
"        Within 1 month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;45",
"       </td>",
"       <td>",
"        Within 24 hours&loz;",
"       </td>",
"       <td>",
"        As directed by clinician managing chelation treatment",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * After 6 months of age, recommendations from Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention (Centers for Disease Control and Prevention 2002) should be followed.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      If infants are breastfeeding, also follow recommendations as discussed in \"Childhood lead poisoning: Management\", section on 'Breastfeeding'.",
"      <br>",
"       &Delta; Some case managers or primary care providers may choose to repeat blood lead tests on all new patients within a month to ensure that their BLL levels are not rising more quickly than anticipated. Seasonal variation of BLLs exists and may be more apparent in colder climate areas. Greater exposure in the summer months may necessitate more frequent follow-ups.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Consultation with a clinician experienced in the management of children with BLLs in this range is strongly advised.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ettinger AS, Gurthrie Wengrovitz A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at",
"     <a href=\"file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=\"_blank\">",
"      file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27868=[""].join("\n");
var outline_f27_13_27868=null;
var title_f27_13_27869="Contents: Obstetrics calculators";
var content_f27_13_27869=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Obstetrics calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Obstetrics calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42067\">",
"           Calculator: Estimated Date of Delivery (EDD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21759\">",
"           Calculator: Estimated Date of Delivery (EDD) (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/55/9074\">",
"           Calculator: Gestational age from Estimated Date of Delivery (EDD)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-85799DC5A1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_13_27869=[""].join("\n");
var outline_f27_13_27869=null;
var title_f27_13_27870="Interpregnancy interval and pregnancy outcome";
var content_f27_13_27870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prevalence of adverse perinatal outcomes according to interpregnancy interval among 173,205 singleton infants born alive in Utah from 1989 to 1996",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Zhu, BP, Rolfs, RT, Nangle, BE, Horan, JM. Effect of interval between pregnancies on perinatal outcomes. N Engl J Med 1999; 340:589.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27870=[""].join("\n");
var outline_f27_13_27870=null;
var title_f27_13_27871="Partial penile glans injury";
var content_f27_13_27871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Partial penile glans injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoATwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1Vh8xFSqvHJNKgy7HqKeB2FeWj1bEQYgY5I+tSAngZP508rjjHFPRARjHNUgImU7ec/nUODg8n86vbQeOcjiq0ow2AOlaJitqQRqxkyc8e9DAq5Iz/SpUGOtOCgjGfwqkVpchhjYEE8n1qwUYngnBqZY8kAc+4qZUGzDA8dTQxN3ZS5A47VWkJ3kkmr9xhARj8ap/ebtWUmCQiqdmScU3DZ5JqTAAI7CgDPNZSYJCQZIJJINTjI5Jz+NMU4FPz8vBGKVwaAEuSc8elPBJPJOfemqMDFSKeRnmkmFh+zPJHP1pQgA749KVM9xT8bRu7Gqu2Kw0Lg5JqN0ZjlSakGWPI4pSwXhuKaY7EQZuT81SL8wyM8U8qHHXPvRsC57H61Vw3I2XCk9fY1EVYcAn161ONzdBk0Khz8x5zzxRe41oVjv9SffNSAZB6g9anePdkZqJgyEDtRsPcbvIPGcUryYHXg9s0wL82M80Mg6EfnTuJpDQ5yDk1IW+XOajdQPu04NlemRTRLQ1gSN39ajKkcgkGps5BNRN0yOvWgQmDtI3dffpUKhiDzk1I5O0HH6U5MFc4FFxWK21geSfpSOT0yadI7GTG3K+tNkBouNqxAzEfLuP506HGzilZDyTwQKgVGBbGOvemhaM1V4JxzU0QBHIpgT5mHvU6DaB3zWVzQXaMZIp4UdhSgFztp2zBxg4pq4FdiVfpUMgJINWpQuc9TVeVxgDPtWkWFiM8GljTLLwcmo5M5G0jPYVPbRtuXByRWiKtZFlI8A4PAOc0/ruJ6dqS3YKpUnnPNNkfAJzx/OpkyLalW7YEnH41BEoAJ9qc7F24wAaXkHjpWbKfYTZn6mlCbfxpynHPenswPaoYiErg0pHtUmR15xSMOQazKQuMjOKfEuDilXHAHFPAPbimAAfN1qTG45NRrnPJqVQMYoQmhp4zjmjG4HP60Y4pR7mquJCJ8o7E07r97FOQDkZ4oIyKewhARjGRmgHGc84pmw5znindAc9adxiZwxJqOQ7sgdaJHw2BkmiNepPftSvfYdraskTAXBHNNkUFOPzpQCAfQ0jEY4qkSRFBkEmkUhD6j0qTy+vJxSSYUA46UAyNgPzqMr8xzUzFSc1E3Q+tMQ1vl680xW7AdKe44BPWmBSeehpCYm0EngConUlh9al2/MNtLxu60xEDklsYpEBwc1KcBuBg0RpuBJGeaZLLLHk59acH5C54zzTWIDnPrUYz5maxudCL8THIzSySgfe6+lVRIR/9eiTG3OTmrQrCl+euTUM+TjA4pobPQnpzT0OFBJz9auJWw2FASCeo5q5ANr570yJM/MOlTxAFirAHvWqJkxhbLdMgimFcoaJJArnHb9KYrEg5z/9apY7EQUA8DikY4wBwBUzrjpUJB4BrKQgx0x1pG6YPWlAO4Ure9ZNjQqDOOaeRzg9aavHSnKRzyaAHDII5pwGDk9aRBuNSEHdSAQZzkU7OTzxR7UEZoEOA96QnHWgYz70h5B60XAA2eBTgxXnPFNzil+p4ppiH7gQMcGo5n289TTcgHjpTJSduO1O40gVQW3A571LzkEVCmQRUm4jrR6g2OB3cnGKQKAMk96bu7ikDZNUmIkccHioS3GCeKeG3ZBprDHNPcQxkIOe1KQD9aGcYwOTTMkU7isJj1powPrTnB61GwxycmgBGbcwx0pSAQcdajTJY0ucN0oT6iaI2yp5GaWN2wcDvUmAcnHtTY+nTvTRJYlB8zFPjQH5qa4+bNCvjgHistjYSY88n8qhJIz1xT2+d+fzofHPcelWhrRES5zmnl8rmoZWIOEGaj3EYxn3q0Ulc0o2URjkYH86mjYRyZzn3qgh3J/MCnxoyAlmLZHGa0QcqJJGUyNz35qWFdxyP/1VSyQ+c8e9XEIHRs0mKSsh8oy2e3c1EyjIPanOQTwTTC+PlrKWhKExtJFMxzzSGQ7iTQzYUk1kykhwIyeaEY7jgcVHE2F6cVJH3x0qUx2JBkdDT43YN04pgPy04N0oDcnBBFHTPpUZxu4z74pobnJ6UmTYlzSH7wzSI6k4px5PXikLYOMY70jNgY4oODxUTsF+tVsIR3wfal35PtULfNSg46ihNlOxN79qY2QeSaQtTC/rVXsLqPXjODzS7jjGeah3f/XoDcdaEwJ9+ACefak3bh2ANRHPUHioPNxJtA4zzRzWGlct8A0Eio1J/CnE5xVKRLQpzUb89OKfjjrSHG3pk00SRR5XrzQe5604nAxSADacnn0p+Qn3GE8e9OTpUbY706PhfxppiaJ3YbyM5pmelMkJDEgcmmOx47HNZo2RMuRkU0KTxzTVIzycipAapARMuGyTSEKDgZ5p7sGz2xxUEh+cEYNWilqTwsPMwO/WrMrKw6/NjFUImGSTViSQAdO1aoTWpFtO7pwevNXY1O1T3znFVoOQcdc9atbiuORxxUsUnfQa/APoKjDZ64p78oQag5BAxWUmC2HMOenSmgbhTuTmnxjj3rNq4XsCoNgzTgvSkckLkdaQOdoyKTsNEh+78tIDimF8kCkJ4xUjJFbJNKBk9cCokbFPU4PPSkxku0Y49eopyKwHU4pFYYyKUMKdjNtg2AM1AzDPNLK351GG5pkoMgUgI9aGqJuG68UFpErNnp1qCQnHHNODep5oYDpiga0ERjjkUhlCPg9KcOfpTWHPY4pD0JQc0bRmheAPSlA59KZI9acSPpTVpGOKpMh7in9KaRkHmlJz1NNIBzVCEA7GnfLjFRFhnPTFAbJ96Lg0NbOenNKnQ896GGO+aVMEcimhMbK2WPPOahLA57Ypf4yc5JPamO4zxjd3qUjUepwPT6UjTMrEY696YznAzjHtUZk3HgfjVscS3G2Qc4prAFwc4FRo4UDBFBkZjx92qQ0iaNVIPGefyqORyW2kHNTDCID3x19qiRxkZ4GeDWiDm6lm0xnn05qck5J9KqhvmJB4HAxUsZJYgkdOaUiXrqPY5A9AKiz8wAxilc4OMVGGGeDzWMmBP3oGfXHtTRkjJ6UEEGouIcAe9IxxgE0jHPfmmnLHkUmUhzHaPem7gQKdJgrj1qpI+wGlYpak5fZ1FNWfJ9KpPdrgdzTVulP8XXtSaH6mvHIMc0rSDPU4rK+2DAANBus8buvagg0C/PXPvT88A9/WqUMgYgkkirkbjtVJEN2H7SeajcEdamBB74pD70NDTKhODnBpS/FSOMmmYz70rGgi525NB579adtPamk5pCJAeKUn1NMHFKM96BWHqT60MRmgdKa2DVJ6ENai7s57UBvTmod37w57VIjcYpp6g0RvjvSg+9D9ajYletAEhGc+9OjJ29O/pVZpO1SxNlecdapMlpkLNtzkDHrVckZJTrSSSEsSAOvekWQfxAA44xTSLQxyxA/WliDE5IGBQcdQQe1SKE7g800iubQkJPljbjGcHFCFSRtz9KGUgcY5pI/9ZyBx6VaHHYsFjswRx0zio/usCMMvof60u45YE5pgwCPmNaIknhHB9Dxx0qymFxng9KrQcIQD+dTDJ/rUSKGzEh/rTY+HJof7xxQp4HGaxkySctwMHFLnIwRTAcfhTXJAxnJNSJDoyCeKlyAMnFVQ23A7U2WbA6kg9gOtNIrcfcyqq+4rHvb1Ezkj6VcMMlxncdidvWrFtp9shDbQ7Du3NJ6DTSOVa4ubhm+zWsjHpkLgUwWWsOQwtxGT6tXfRRIoGANvtUhVQelTuP2luhxUOl6qcF/LA781bSwukOZCD9K6aR1HSoHclv4cVcYoh1GZUCSR/ezirUUg6A806Qf9NEzULJIOQ6/Sqt2FuW1fHsaejFup49azTO8ZO9Mj1Wp4JNy5Q/UUrDsX1wRgimkY4xUJmJHTmjzOOaVhokDfNg0j/e+tQvycg4zTuSBzUNFuNh4bGD+tPVgSahfgADNIrc5HWkTYsDFMYemcUiNxSSE+tNEDGPOKEYDrTW64pm7tTAkd+SailbPfikI4zTG6U9xEYGCVb8xVmLBXr3qm7fP1IqeMnB2jIzVITKTPnIyB601TlsHHNQyOMkY5zQQAox1q7DRMXPO0DA9akVyRyMVBFjODUyHPYgfSmMm8wFApxTo+T8vXpnFNCZbaOQe4pPkQhWyR700WmiYLk5B5IyQajkfGck4p8bgAhuPQ1WuG+RtvT0rVCvdmjZHcOfrz3q0F5yPyqlprHYM9cVcJCkkHjFRIT3GTdc4qPPWnSScDrj+VQOcnk8HiueRJOGyM++KQ5ySxAFRNJtAAqu8xlbHSMdz3oQ0TvKHG1PlHdjULSLEQScj1pplCrwuVU9cdaxNZvgi5BPpilKRcY8zNeTUQTtHLZxgVfsAyDMjE5rlfDay3t207qVQDHPeus3KiHHPrUpN6scrR91FwygLVaa+VPvMBWXdXpRTzyemKqRxmU75zkf3e1UotmbLsmoyzOUtU47uelKlu8gzPO/0U4FRo2DhcfSpF8x+pNaJEif2bCxLLJJ/30aSSydF+RmIHcGpFLIQecVOkhYZHFHNboHNJdTJd7iLOxw49Gp9lqMby7HBjl/unvVm6RJMlPlk+lZF7AJVIYbZV6MOop2T2NFPmVmdATuXcCc+tKpJHviud0rVXEptLn/XAcN/eFbKPz6ilYNdi4rY608sOKgV+Bk1KpBxzz61EkO4/OT1NIRj2pwwPSmNxzmoJuG4jjrQzccVEXzkigtnIzzRYQ7ccnNHUUwHIprvj600Ie3Axxiq7n5j83FPdyRjimZGORmqSEN+83JBqxG3BxjrVMHBIBFSxsAPvGrSuJma2NxXvk9aXevQfiaXrkEEc0kijBJAx15qhpjo3HTHHrU6S+jde1Uix2gqM/wBKmt+mWzmg0si6smWBAxgc+9QSSl5Tjt2NSoyqhOM46kelRKEkJYYz3IqkCJiW8vcucn35qpJkbjk4HpVoDOQOD2AqvLwcbc+taoI7mlZgIBhuMCrgIYHJxgfnVGw5RQBwRV4LhM8de1ZzFLchcED29arE5fH8I5NWJ34PXHrVEy4d3P0FYpXJY+diOP4jUMbrGG3kVWluMkhT89IoaSMDZntmpNow01K2oXz7SI/u1lwxvfXC+YPlH3q1nscn5CdmTnNJbQkOVj57E0KPVltpKyLJvU0238uBPMKjGFGaibUJbhR8uwHqB1FTTeXaQHAG85wPWsrzi3KAM3c+lXyu5lBX2LiiVn3tg/3amXzAMnBHeqUTsCquxBPNWyrohZW3eo9qfK7GypFiFsvnhvXFXInUHk1Qjfyx8oHNPhmWV8PgN2PaizQpUi6X3cKMU5VOPl49RURPlkBsfWpopQSQccVDd9jnlGxUuSd3BIYVRmDPkN97tWtdBZFOOTWVJkZB4YdKqLITsc9rG+Ipcxk+ZEc/UelbmmX4uoI5EIORWXqBDoQ341neF7ja89uTgo3H0qpI0jK53sJJAHrUwGDwarWTMygDmrm0pyeQah6oGCSHkGmu/HHNNbrmiMfLUCbHpxnpmow2SSTnNI+VHXioyaLCJCecg0FwfvDPvUDPlTg4NIJARtI5qrCJgwwcilLAjH9Krs/ykZA5pxfBwadiWD4Vs4/+vSxFdpz60xyMex601GUAjPeqQFY5JYt1zx7UjfOcHkClAznaD1pyqF/GmUhEQc/nU8cfTJOPT1pI8H5eABzUu4DJzyBQWmRSoSPlBHbNSRRhUXIw3rQjLIST07cVMFAjwOQPzqkNvoQMOQOfYimnIbGateXjHAz7ioJBtYNggVomEdWWbFscYrQ+8OOvvVGHDRcZDdcmtCNQFwxyfX0qJimU7k5Y7uDisG/lYZCduPqa3NSfyoXbOSBwPU1hQpvO4jkc/U1iEFfUjsol373Y5PUGtaMYjO04XPOarCMKoY8t6GnYLAliME9B2o0Nr3JsFzhT+7A71FcTR26FiQMelKbhVTH3cd65/wAQ32XSCI43d/Wrirq5lJa2EmuZLyViuQucVNCPIXbtyp9+aoW6hUzk4Hp3rQgKOhJzuPHtW6iddOFkOEgzk8Z7EUkcriQAMwQ1ZSJJMHI47ipEhJDEqGC+1J07m10izE4lUK+OneoWgCSboz8tRhPLYtyopBO4HGMe9K3czlG2xpROJUCyjtwad5O0/upPzrNkuCqYbK+hFQw3sqybSc56E96ylStqjncLmhM7ofm4J/Wqc0wcHs4qY3O/b5mMGobm3WcboWAcelZp2dmYzpmHqMvHPfrWHoc2NflUdCoq1rMzwuyyjaaw/C1wJtdmY9sLWjehlG9z17SgOAc1pvyuO1ZGnvtAOecVoGcdO9S1oaS3IJPl4zmo1cg9eKS5YhsmoDkNxU7iLMjgk4/GoWcDpTQ230Oaid+eaLCSJA5Jx3PrRnnPeo9+KTeR+NWJsVt2eKcrgnJPSomlOTg01nUD5SNwoYiV5ME470RSKAfrVZmL43HA706IAKcLxmqSAekmGbaCecHNSqQynjmoemcA4yafGvAAOT39qLAmTRsAvIAAHUUSEBQVOc96VflHzDgj6U3JGAowD75pG0V1HDO0EEVbgJkZSD9aqhNpGeSav24wuTTTsE3ZBIAfukHHaq0x3DvjrxU0snOMYPcDioJN20mJj9BVoUNCS2IB6gr3x2rSAwvJ69CKzLRvlAK4PfA71oxt8uFwwHeiSHMytbkIMUY5Zjk/Ss3z0iwoB3HtRrU7PeSPHwq/KpJqpAjKjSvksfxxWajoOGxpI+4jd1NLcSxxnP5VHAoODgk44NNmMcTMzL8uaTSuaIrzNvLF8gn3rAeMSagZCw2xjFa1y2clOC3H0Fcfr1+LUeTC2MH5m9a1jorjpx9pOxpalrMVt8iYZh2WshvEU0asVwFbj6VydxcSSSEq+KbGJXXCByfaleUt9D1VGEFZanYWPiW5DbFdW3cAV2sNzqWl20Fzq1sUtZsbWryexjO4SmFsIc5HHNdlr3jabWPD0emSoFZcAyZzgD0p8ko9bnPWq3kko6dTuo5YL2HfCwMb9MVXng8rJAz7V5PY61eaRdiJZTLbqQd4PFeraVqkGqWCzIw3EcitYu75WrMmceVKSd0QT71QyDBHZe1VEfcQGOB9OlaEpBBVe/PrVExOHyWBQngAUmYSWg/fHLEqbjvFRvIbGYNn930NRM3lT/MD/vDtUs8pdUErIY24yRXNOCZnexDqkEOrWTIcA4OHHY1w2gwzaVdyRXK4fzOuOo9a6XUY3tnzBJgE529qy9XlkuLdZSh81T94elZ3a0aM5xV7o9A0y6DwqR3FaIcseK4/w1cs8CHPQV00Dkvg/pVXurkstTZZfwqGMEqOakZvlOPXiomJU7QOtNEdBHLcZNRbic4GTTiwyRnNQPKA+PXtRYVyQP0/Wk3jJOCaGbKE8D2qvI5zxwO1UiLgzZJ+vrTt3Qj8aqlm39cU5m8vBGKYMmMuCdxPNOhcBTk85rPaQgnJyadC42n5u9NaCNORmEhGSBU0LLweaikwrOSQcn8afCVJGORSNErlsZclgTj3pikFwDn86eCoG0cDrzTFOG7cdKlmsSyByDnj6VaU/Lkk9KpockHOanZhjvj+dBMtSOTrjr/IVEoO44bGKkGCepxSqSCwxuXHU96uJY23+WbJUbvfof8A69WbyfyLVnxggcEVTBG8EYA6baTWJmFgE7u351cthSRgXBZ5RuY4PODV6JwqnnAx6VVjDPIMrk1YEbKCWbC+lZoaLUNwqpjBx06U262SxOW4jA796ZgKn7tQw9qr37n7G+7K8gYoGzH17UFsLBs43sMKorzmSKW9mLyk4POK6LXl8/UGUMSkeBgn86ht7U7jha6KdO61Lpz5FdbszBpyBRiPNXLK1MQZlQZPH0rXjsy23kgir0lgyoskXzA/eBrdQQSry2Zk2T+TG8M6gxN6is680aK5O+wkCv3jPc+1dDJb4kw6naRkcVTubVRH5kRZJAcgjoabgmrDjWs7nJTFrabZexMGTqOxq74f1s2moNCrFIJDlAT0HpUutPJeBVcbpFHJxXK6hBLAoli6oc4rmqRfQ6qbT17nutrMhtVcMrHaCcc1VnuSc/vFVRzjFcV4M1s3NoqFiW6EZ6V0dyIyrF/wpt8yujGouW6ZdkuopipB4xhqr3qFIgQflxkfWsCWUWq4LckjGD0Fa7z+dp2M9RwKyl2Zyc1tiC8kAtDcO/QgYqETotuyOBtcHFZd9Pt02SIsMr0qGCUXVrGvmfMozx3rBu2iBu+51XhWF/sgCjpwTXURAxAAdO9ct4EuPMR1PRTjmuukCpJ1JLcAU4xtEm92O3NnGM570k5IyfwpynpnpUcxJUk4wKEiZMrySc4H61G+ByTTjjjn3qJiA2CetUS2K8gJ5JGP1qCSU8noKbO+Mc4GapyzkjH93qaZNyczHOB27mm+dkjcRk1SaYj2qJ5Rjr9KLgXHlAXsBn8agjvlQEFgDmszUb5baAySNgCptE8M3Wr2X225kaJpWJVAcYXjFAHan5pG28gH8jUiL82BxiqsjbXYqcHNTwMGbG4kikaJFvbxwQKB1xtOPWo8lsnNIrZHznHpSNIli2I3kNkelWWxuDVViBUkkgg+lTo2c84FSKW45uu7aCKYxwp7nrTm+714ob7ox+taRuCZCzAuAw/TpVTW3LLCvUgE1eOSN20/WsbxNKY4YXB7EAg1bZctipbzEylVJHarEYJzulyw6isa2uCI8bjn0qb7RIHynXHJ9amyFE2pLuOEBc8npmqWqTKYTx05OKoTzBo0WViTu79qkunjeE5ZiRwBVJBLQ5+3tGld3YnLNmtaCxI7YA9aQ3EdrGGdSM98U2LXLQtgyEMPeuhNbIa0LgtvUZq1CADhsjjpUdvqVpKflk9q0kjSdN0bqe3B5q1JoejM2W2Eg+XoP0rOmjYEqyjb3rdKPFngAVTvI0MTArk/zquYTgcVqkZUOSoAPSuT1AtHkjoOtd7eJGgZWXK+tcfrMYLtsA2nihxUkOnU5XZmR4eujY6v+7J2SdR6V6cZg9qHLZ9Aa8jAaO4G37wORXdaLe/abNFBye+TXMla6NqrurkN3dBrqBFyWaQg59qvXd09s6Et+7fj0xXONufWNiPjyz+pNa3iecQ6PyRuGACaykrpnFzWdjH1K7N5esqg+XnaNvfFX4LZ4IAIztkkOAoPNZGmxFI1uCCUByR612fhvT3mn+1TqQW6Ke30pKFyHPsbXhKI2t5tkXllGa7C5UZVugBrFtrZYL2HAOGWtu4bCjGKc1bRDj0GSycADoKid8KwJyx6is+a6xuUn5s8fSn+YeNx5xms0OQ6SXHbjvVd3yev1qGWQBsbsk1Uup/LBJ5NMzbHXdx82AelUxLkcsPWqzT78nP51A8oGdpODzQBZdySDnA681WnuAkec4xyTVd7gkE/w9zmsuNJtd1RbG1z5QP71x6elAXNfw3psniHUvPlBNjC2VB6OfWvXbFUht1jUBQvGAKz9C0yLT7COCJQFQADitVMAEHHFWtC42e5zLnDnJHXgVLbnluufWqYZmLgnPNXIVKpzxxUFomJZyOSpHbtUgyAQBk1ECSQevvnpUiHdgDp09aRaJoCQCCuKsKx2+2aq+aASvb0p0cm0ZqQZY3ALxkUeZuXjPFVy/y5yTTYJSxOOmcYq4sLFrduj5GPU1i+KVdrWHIGNx5rYDtkjaeD0qj4gi87TZAud6fOPw61o9inschCyNuK9j0qdA6srKcZ4yelVbZMOwcrgnIxV1XyNhPyjkGkkSmJdRu5UHbxyTTvK2Nt378jNIvzAruL+uKZbsv2hlB+UcVUN7ibL8JjKBXRWGO4qvJpGl3LZkhAJHapJeGBWiM/NnPSt9i1ZlZvCttuDWs7RnsN1Rz2WqaaA8RE0Y/unkVoG5GQCelSRXbdVbA9DT5gdNvqZlt4lVvkuhhhxz1q79rjlUmN1II6ZpzwWN3G6zwJ83VsVzuo6Ncae7TaZKZYuvlk80+ZMlqUSe/TqcEqa5S+A+fcvToa3LbVUuIWEzBZBwU7596z9QjGxjnAPP0pxlZ2JbTOJ1HCPvXgrWl4SusW3zHkE1ma1ujR+cg9Ki0CZYrWR8nuayqO0jVSvGxu6VNENYuJpSNitSeNNSiuXt7eH7oO5jWPbzpDazXMh++eB6mjQtMm1K5MtyDtJzj2rBJvQ5JNJ3Oj8N6fLqckZJZoFPI9a9b0u1SKAZToOMjoK5vwnYi2XaqbVAxkV2NvMqoVI4ArRaaiSuZ93P5U0DAclv0qa6nJiGBwOTWZrzhIoSOG3jHNFxcHZt6YFZydzQqTTruGfpU0l0NpCcvgDJ7Vhm48y52A8IMnND3JXo4+lZ30FIvSXBaQAkHuTVC7uVZiAcDoAKp3t6QCVwB0FZ7XbEHOMmk2ZvuXfOyzAmqss+W4OBVaWXjGeTWZquorZ2+cZc8KB1JppPYaJNTv5GZLO1BaeQ4AHb3r0/wB4fXTLFCwzK3zMT1Jrkfhz4ceR/7Qvl3XD84I+6PSvWYSIogMYxWqVtR2uW/9WowPpUcbj5snnNQG4JPzMAB0pq3KLkDB571JonYxYQoJySeTVkNz+tZKTEuy9881oq4ZAG/DFQUWAc4POPzp6lcAgEYpEOAMjinBTjHQn2oLQB1x1OeuTSqzAAZ460jxhcAAZ+tI52lcnnHSlYY4uWUfMOvSp41CjtVWP73zDBqdcrKo6g04ksu4xHn9RTR84xJ0xgn1p7MoTH6URbSmPXnBrUcX7p57q0MthqEsSHKZyAfQ9KcsoMQ3YIPp1roPF+nCe0F1GD5kbcgd1rjlLkdPlHpQZp6mhFgBnVmRSOdp5pLSVWkwD074xUJeNYmQErhc/Mf0qGDZHtkD/Me1UnqEtUdECpXIPPfNIWUrgVlfaypqT7SNvJFbIUZFh+WOOKhkZgCAcD2qB58Agmq8s2ScNwO1S0bKpYtm6Ea7WY5xwarrqRiJ5z9apSybuCPxNZ15KE/iyKQe0WzIfEVruf7fp6/vOsqj+L3qjFqy3lsVPDDgjvmrC6j5ZIU5zXL6xILLVFuIDtSbJI7A0r21MZaDfEEiKoBOSetYsdwEg8lDjP3qj8RXpuHjSM5PVsVL4d0x7mcM+ce9OV5K7MvaPZG3oemy6rLGpBES9Ae5r0rSdMSNokRAHHByKh8M6elskR2AZrp5AEnDIByADikkoojWTLdpELduQFIHPpUrN+/Yo3ylecdKieYqAGweORVGWYxTqqsCrdvSs5ysdEVZFLWpN06kONquMA1Hf3m2BuQDt5rK1i5Z9Q8teEzkn0qlqtwfJfBzxgVi5XuDFt5d8ssznI69e9RPcAsT39qzllMdsqdzzUF1dCGLOcE8AUm1YzerJby73HBPPSo43JGM59MVQtt0rFnOBU09wIlIHAFONhWHXt6ltC0jtyB61H4N0qbxDqy310D9nQ/u1Pf3rFtrabXtTWBc+Qp+YjvXuHhbSorGyjRUxgAYFbRiBu6dAlrbqqKAcY4qxLMoQliagZguACcj06VXklV32Ht1ptlJDzKGUkkcVXF2gyAM8+tQX0qrCxJ2+9cLd+IWjuHSEjapxz61m2k9Snqddbv+/Jzgc1qRMSMjpWPYsC7njrxWtar8wJPfvUopGhCp+UsflHWp+ANw6H9aagBXA4FJIMDO7pyKBp3EVgzMX4I6A004LqzDnpUDMexz70iOfuuPxoNEi2XQzAEcgdacrAzLnnNUDMpkIYkH+dWINrOCOce/emiS+zg5XPPrRDk7cEZ9zULkhuMc0+JgFXd1Hf1q0x7IdeZZMNgr0NcFqdtHZ3zBmcQynKsOg9jXdzsChOR7Vi6lbxzwFCBjqM9jQnZmLOeeVMbF2nj061EbdSMuAB3HSmLmCV4SmNp5B649qkLmUMPuqv8AKquNeRR1CYQxkx/Ngda5iHXXOpJG7FUY4/Guiv2BjYDp6VyN5pqmYSowYA59waqLuyUkjsVvFxnPI9aoz3hDNzyayVn3wgqw3D3qvMXYHJ49avczcrbmrJfnnc2Bisy7vxJwKpsflwSao3EgjUsWAHrQ07XEpp7FhpyGyGNY3iaVZLOIbvn3ZFRXN7K422wOOm40W9i9w4MxJPvUXsy220Q6PpjTuCRmvRfDelrbbCyYBHJ96o6BZpCwVhjuDXYWQVV29c0dbvczfZGlp4WBlLD5f5VouyI5LMdpPpWRExQhW5Aq0lyoj+b5gO9Ju+hoo21J55cndGcrisa7u2Eh3j7o61ZkuUCk5wh/IVzep3RUtgnGM1hNmiZWuLrzLiVtwAB71Qu5y8uC3HX61C0y7CzjNVZJsuWOAT+gqHorCbJ2uBkvJ90Vmsz3Uxc8L2X0pZ33napJFSxLtGentQld2JJ1YRpgdqzbnzb2ZYYQTuOKsyeZcSBE6d8V2HhTQgjLJIuXPt0rZKyJNTwRoMdjboSg3kZJxXcqQkXynHaqloiQoBjB7VMxYBiSMfSqvbQaXUYH3jB+99arzTCDcTkg8c96l4WNmGBmqN/OsdsS5AHXFJsq5z/irUWhtGAIDEcYNV/DXhtJtMWa7QGWVi/zDnHFUILdtX1je7M0EbcLnvXoFmuyAKAOOOtZR953FLXQo2YKKRzgGte0zxms+EbWIIySeK2LZdsQHpTRoloWFYADnFNkIVe/NOUqOpGajnk+YgYOKCkiGZ9inriqfmHGc/lUzFZDjn6Cq8q+WSFPHoaZqh0lxgAlQWPtVq0f5AQMEmscysG254bpmtfTSPIVSSTnjPemiZIuzpv53YqSNiwGMbRULuF3Eqck9qW3XEe5eM0yW9CVmDsVPb2qhOuHOPu+lWWUiNjn5iOeKrvGWj3KSKZlJGFfwiRt/AK55rDlk/gPY810t5GcN2Pr2Nc/dQh87gQR0x2pX6CXkZ97gjCjg/e+lc5qbby0UJ5xnOelb80cmCA24Dj0rIvIgs5IBDYAAx2p30BM5ySNoMlWJI6kGqU95dqEVJGyT+FbF3E8rMi/dY81TmiCkcE7R1qYzaY2k9ye2YzxfvMrIOo9aZNaKwBPJPrV+1QuFYDDdxSyqdwBGD6Vs5aamajroZaWaA8cYPArQs4FJwT93260hjAO4D/61WrUPtyTwKSKaNS2AWLPANalvdZjBPUHFZcbJIu00rSiJtueM/nQ3clI3obnZli2SeCDTLi7CKyrgbuSO1Ykl5GeV4Ze9QyXQkQ72GB3zWd+hZYl1AhSpJ2k9Kx9QumZvLVvlbrmq89wAOGJXPHvVSVi3zhsZ9azeqBvUfLMpJA7VC8hbCgcdzVdmB4FTwqe4qN2IkjTpxx61YjQyfKAeKWGIuQMAE1v6bpoZV3AY+vWt4xSRDYvh/SQ7B2X5e1d5YRrDFlc8DFZthAUQBFGBWxCNsZ3dKdxpXLMP3uB+lE8wDBO/pURl2RALy3pSeWdu5+p4NSXYbMW2ly3PpXL63czzSCGPBzwPrWtq1x5UWErO0yzeaQTzHAByM1L10G9EXdHsEsbaPcR5o6kCuhtFHlduves7YfMAcfL1+tX7dyEIGcZq0TbQr2+dzEBjk9TWlDvVcqP0qCIEliB8uat7v3fPU+tSbIaFLE5qNm25ByKeWbHHNRMS+Ac/ShF3InOW+9jHao5ArAnIB6H3pzYI/wqqFLSFcHngUCFjjR7hQo6c5rRgUrhOQahtLPyY94IPPSr6lVw2Mt/Ki9igbaqYxyeeadCTlueO1Qu2z/bz+lSHEYUYwcZzQiGtBxfPBIziqzMdwAIIqR/nY8kHGagJG05HI9adzNrQq3G4s2eR15rDvUPmHA/CugumHy+4rNu1U5YYBFDJWhzdwrAn1HIxWfKxYHcN2B3HIrcu0AOR96sueMEZx+dQrpjdmY0lsAvA4PrVaW2CowMbcjOBWuy+h/Co3YqOOhGM4quYmxmWpXywM7W9DxVp4lOCeSeMjmmeaom2NGD/tCp/LjPKsUB684rRSTJd0ymsR2beG5596dGhwwU9OuTirRt94Iz0HBzgioCsqHGFfvk9TVpBzXG7gmAcg4z1qtLcYBIcHH506UyMW3J0HX0qsRx90E9Oaiw1Kww3DAYbnPpUfm43Bi2D0FMdG3ZY5I6bRTSkrt8o249azbQ7jHYDlxgVBlpj0IFXBaHOW59anS3CjjpUJN6i5irDb5IJFaNtalyMdDRFGWYBR0rdsLXABOPatVGxEmNsLJRgbePpXQ2kK8YGFFV4IhjIUHmtO2QgHtRJ9Airly3BZcDgVdUDaAv5DtWVNcCFgp6mtG0O6PJIz2qTdRsWUhEhXgD6UXBEakFgcVLFnyxVS/cshSPBPp6UXsgW5z1wDd3eCSVzWtDEQFAHy+lMgs9oBPGecnrVx5I1XAHBODxQloJ6i/ebHUgVPbMDGcDvVe3HLOrZB/Srlsg8vjGM1SJbQsDsCTwc9qsGQHHOD71nwtkHB/iNWQR+XekXFk24lSMjB9KryEgnbmpApx160whhnnI60FXIlJbI4Bp8URzu2/QiiOMs5z8taMSqIzxj0pDRHGhCc04kYzk9Pzpzr8q9Qe9RNj5V5pWuU2QoW3FwMj0p7kkqxOGpm5kyCCcelI02cZIx1FANkiuAWLEkgVDK69jj8KhmPzZU4zwTimnBCc9upoRDXUVymxcEZHOSetUpSDkAAn1qWRmDjHzIPaqzqMsQcAflTbIaRVuFypAzkelZUsLEHdnAPYVpzA7CEbHvVKYjJAB+ucVIrdjJuFWM56iqzhSrByAOtXyhZyD3/OqF1AA+0gY/u1MtiolNIgAWJyc8HFSBcduKmijAGcZp0q98fj6U07KwpFZhwRngnqKjYD0/I1OVz0xkelRsBx3/CqMyHntnHcHpUZQM/IA+lT7cdzTdgLBlHzdKS1AjMa44HTjpR5QD/4VPgbeRzTWAAz3NNElaQYGMcU6GPeevJp/llj2FXraEADjNUg2Fs7XGCoyK1oY2A7DFRwKEUA1bjO7Cj8aq4WbZPaIeM+ta8KbYfWqUMZVB6Vftum01BaRWezWWVXYE4PArTtowmBnFJFywOKnCEtwcA0jS5IjFBx0PrTfJT72eW7elMmdxgL93vSxkABm5x0FMOgy7XYu7JH0qm4QgnljjOBVqZvMJ3HgmqoiYKzA8D9aYIsJjZ2HqKfAzMpx0BwKrqMEgnOeasQHKnGOtBBl2N6kkhKvyCeK1YpQw5Nce1tLZzNvBA3cN6Vfs70qdrHj1ronRa1Ry066ekjqldQMZBpdpIO3vVKzlWUD5hWnEMIdp4rn2OpMI0AXJ61KrfKVNQM2D15pS4P/AOqg1THsxAPzcVA+Aw3Nk+tPyN3HTFML5H3eKTRSZHJlUJGSSelQFWLblGM+tStuJ+fOT70wb4/mySPeiwNjZM7AN45/z0qISpGBuycH8DSzEMgBYZzniowoJGQM+1FiehG7jzCQDjqO1QuxbOR9M1NKCUBPX0qvJjYQ2c0WM2yGdgPpWVeSjLEjGO9XLqbC8dfeuf1i+jt4Hd2UYHepYIhutTitDvlYBAPqRVWPVI7+UPb7k8w9XX7tcuDNrF5k58lW4HrXZ6bpYSNMLz2ptK1ivQvG0eNdu4HHcd6geIhiHGf6VuQwMI1BGcVHNag5x1FQ12EYTRjsCKiYYOOBWw9ueQKpyW2AcUEWM0jDYxxQBk1ZktzwetNMJOcce9F+4NELLkCoxGS5JJ47VaEGTkn6U4RgNyODVXJ2I0hzt44rRt4eMY70WsYzk9B2q4YyoyhznqKfmSQlSgGVH0q9axYwTj8O9RJE0mcjAHer1pHjkD6Cm9C4l5QPKB6YqWLgA461EMhQAMc81bhwPpQUKmcncCOelW48befxqJOSWPT+VBbcCuSB60Ie5JIAw7/h3qoZVUZY+wA7VJNtRDhjnsAetVnKyDGMY7etBa2HPIqjjrjrTEZWiIHrioXOVyOD3ppIJUJgHv70XEXJGVQBxnHWnW6uUOSetU3ION341at3IQ4cYz3pmTOuvdEt78MGjHmZOGTH8q5HUvDrxSFYgSvY46VdubW/sblpYJHwCSAD0rU0rxHdIyLMzOOhr2fZR3izxFXe0kcFMLvTpPusVHarlnr8bHa7fN78GvUY/EtmhUXUEGP9uEcn8Ksy2ujatas0mi2MxfOXiUZx6cVjPCuWqN6WM5dDzqC/hmAw43elWVlHJBOa1p/AujSFtkl7aHOQUOSPzpsXguKPBttdlyDjbNEMZ/Cud4Oquh1xx1LuZmSVyGHrgUo+7wDnvWo/hvU4mIjlsbgD+65Rv1FUptP1SEOJNNuBt6soDg/TFYyoyjujphiIS2ZUcgcZNROQTtDdu/amyTKn+sDxE8jepH86jS4jPQqajkZrzpjyG28nJphHJOOvGKeJU4ywOKZNNHkkYC+9KwmyGQbSpJPWqs7YDDj1pt1qEMOTI4A9M1xfiPxrY2O5I282bsic/nRZvREOSWrNbWL6K0hkllcKi85PavMdQ1KXXr4RxbhbBv8AvqsbXNcu9YmLXDbY85WNTwP8a6TwnarsRgOozmrdP2au9zJVed2Wx1Xh3TVjjX5RXbWFkPLHy1R0a0BiGR3rqLSHZH0Gay3OlGf5IC5Hao5IwSSAOncdK1Jk9AKhaNcZHWiwNGO8GGJ9aqXEQAOF56cVtMmcjAqrNEMDH5VJNjHa3yDn9KhMA9eK1dgDVGY+GIH/ANalYTVjO8gL0GaFg3OOOKvBCOMU5lHbg5p7E2K6x7ZByOKnPqOvXFNVCCc9al6duMU7j5RbVXYMrDaDzWjEAoAHWqtsowMc565q3t+UGqYWHMcjDcelTwltoAqm2T64qWGTaQT9KRVtDQJ8s4OfoKTeACw9O9VvO2sSTzUM0hP3KCUhsrsxOBg0isQMMfqaYJc9Rtpnm/LhutJmpLKwUZByPamA/KGxg01+QV6UKdoAHpQRJ6DAwzjJyDVu2J2Hr1qgxy24EA+lS20hMZ5PX1oJZ7NJo6zFl29axb/wtGJC0QKyeorudOHmnaeo71f+wjb2NespWPIdJSPHrnTJoH2TjdH60ttHdaa3mWrsqnnaOlerT6Xbu2JkyT6Csm90CIqxtieOxq1JM55UZRd0ctZ+Jh5oi1CP5um9O31FdDA0NygeLypFPoKxbvQlIzjY+eR2NVVtJrJx5JZWPYdDUuThr0LhNT92W50LWFvJMpkQ+3epGsphg29wwYcYbp+FVLXUGUAToQe5rQhkWTBRsj1q1Xk+pUqMe1jMuNKvJpCJkimQLgZ9f8/zrA1LwYWlUi0UDccmMdRzjj8q9BSQAKH6eo71ehdVI/iGOopuonvFAqTXwyZ4XqHhiSMy7FnjK9AM5+nGfauG8S6RrsEe7SpEuBjO2Zipx7ev6V9XtbWsu7zgp3dsVj6j4Wt7hw4hXaBxjis5RpS3VjVOvHaVz4M1+/1tJ2g1JpYD/cA2gj2PcfjWFX2v4l+GlrqNs0ckKSLj5VcZA/rXhPjb4NX1gzS6QCygcxtyPwP+NL2cV8Avay/5eI8druPBNyHhEZ+8hx/hXHXlpPZXL291E0UyHDKw5q94avvsOpxlj+7c7W/pWFaHNGx0UpJO59DeHOYhkZGK6WJAEBAGO1cd4UuVaMHOQa7qIDyxg8elcCPTi9ClKm7I79armM59q0pl9BgVWdODxTGZ00ZAPr9KqSJ8xB7cdK05V55yagZNwzzgUrEmYycc4z9Kay8Yq5NH8+APyqORducdKLEMpbdp571Gch+nSrL8jmmInOTSKRHGvJZgKVyCcYA5qQKBnAxj3pGK4JYfjmmiWWYgNgXHUUrq6gDnHtTY3wRg5q1lTHzyRTepKdiFUBHJwfek2gNnjinM64IyxPr6VGWAznvSKQkrMy4XtSB1zgmk39j3qnLLySPlI/WqBFiZ0yMYx2qISneQw+XtioY2D8kEfWlZgCCDjHX6VJSLDP8AMNvUnrRLL5Zz69agD88Elajm+ZmPY0iJFiXACsvQ063kAQjpzVHz9qhWHI4pYHO0855oJPpFAIJP3ZYc9a1rKcPHtJ+YUUV6p5yLAIJ4xmlwPQZoopFFG/tllU7o+vcVjG2aIFZo90fZgORRRWkJdDCrBWuOhtoGcJInyHvipDoqbWNs3IPBBoorOtFR1Q6M3exFJbXcGNy7wPTqKWOcP94EMPwNFFZ05uS1OicEtUXrcB3U+aygVoQzyDIBDBRzRRWxCLCrsJBj3DGM1n32kRTbjs4PXIzRRSGebeOPhbpPiGF/OtlEh6OFw35183+O/g/rvh6SWewhkvbIHI2DLqPp3ooqr30ZnJcq5kSfDrWpVItbsOsseF+YHOOxr2zTZi8ScHkcGiiuCrBJ6HpYablFXLcyMRnBx9KgcEnocfSiisjpK8iMW6HA9qgeNv7rA/SiiiwrkDQkE/KSfpVeSNj1Vh+FFFLyIZC8bAj5SR9KYyE/wt+VFFIY1kZR9xifTFQyq3Qq2PpRRTRG5LGCI1O0/gDUyM5ByGGfaiiglakZVieAfyqKYMBtCn8qKKCk9SMllYDYx49KjkDqMlSD2oooGRHexwFbPbikaOT+NTj6UUVKBvUcPMxtMbLx6Ux9wkIw2B14oooM76lacEE/KT9BT7beEI8snmiiiwz/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Partial glans injury without surgical repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_13_27871=[""].join("\n");
var outline_f27_13_27871=null;
